10590585.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

 NEWS 1   Web Page for STN Seminar Schedule - N. America
 NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
                  minutes
 NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
                  (CS) field
 NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
 NEWS 5 AUG 24 CA/CAplus enhanced with legal status information for
                  U.S. patents
 NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
                  CAS REGISTRY
 NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
                  thesaurus
 NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
                  Taiwanese Content Expanded
 NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
                  translated claims for Chinese Applications and
                  Utility Models
 NEWS 10 OCT 27 Free display of legal status information in CA/CAplus,
                  USPATFULL, and USPAT2 in the month of November.
 NEWS 11 NOV 23 Addition of SCAN format to selected STN databases
 NEWS 12 NOV 23 Annual Reload of IFI Databases

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS   STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN   Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement. This agreement limits use to scientific research. Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:40:11 ON 23 NOV 2009

=> file reg
FILE 'REGISTRY' ENTERED AT 11:40:27 ON 23 NOV 2009

10590585.trn

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 NOV 2009 HIGHEST RN 1193309-59-9
DICTIONARY FILE UPDATES: 22 NOV 2009 HIGHEST RN 1193309-59-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10590585-coresearch.str

10590585.trn





chain nodes :
14 15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 16 17 18 19 20 21
chain bonds :
14-15 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 10-11 16-17 16-21 17-18
18-19 19-20 20-21
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 10-11 14-15 15-16 16-17
16-21 17-18 18-19 19-20 20-21

G1:C,O,S,N

G2:C,N

10590585.trn

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
26:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N
G2 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:40:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2184605 TO ITERATE

0.1% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 43622645 TO 43761555
PROJECTED ANSWERS: 19864 TO 23828

L2 1 SEA SSS SAM L1

=>
Connecting via Winsock to STN

Welcome to STN International! Enter x:X

10590585.trn

LOGINID:SSPTADKO1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 10  Time limit for inactive STN sessions doubles to 40
                  minutes
 NEWS  3  AUG 18  COMPENDEX indexing changed for the Corporate Source
                  (CS) field
 NEWS  4  AUG 24  ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
 NEWS  5  AUG 24  CA/CAplus enhanced with legal status information for
                  U.S. patents
 NEWS  6  SEP 09  50 Millionth Unique Chemical Substance Recorded in
                  CAS REGISTRY
 NEWS  7  SEP 11  WPIDS, WPINDEX, and WPIX now include Japanese FTERM
                  thesaurus
 NEWS  8  OCT 21  Derwent World Patents Index Coverage of Indian and
                  Taiwanese Content Expanded
 NEWS  9  OCT 21  Derwent World Patents Index enhanced with human
                  translated claims for Chinese Applications and
                  Utility Models
 NEWS 10  NOV 23  Addition of SCAN format to selected STN databases
 NEWS 11  NOV 23  Annual Reload of IFI Databases
 NEWS 12  DEC 01  FRFULL Content and Search Enhancements
 NEWS 13  DEC 01  DGENE, USGENE, and PCTGEN: new percent identity
                  feature for sorting BLAST answer sets
 NEWS 14  DEC 02  Derwent World Patent Index: Japanese FI-TERM
                  thesaurus added
 NEWS 15  DEC 02  PCTGEN enhanced with patent family and legal status
                  display data from INPADOCDB
 NEWS 16  DEC 02  USGENE: Enhanced coverage of bibliographic and
                  sequence information
 NEWS 17  DEC 21  New Indicator Identifies Multiple Basic Patent
                  Records Containing Equivalent Chemical Indexing
                  in CA/CAplus
 NEWS 18  JAN 12  Match STN Content and Features to Your Information
                  Needs, Quickly and Conveniently
 NEWS 19  JAN 25  Annual Reload of MEDLINE database
 NEWS 20  FEB 16  STN Express Maintenance Release, Version 8.4.2, Is
                  Now Available for Download
 NEWS 21  FEB 16  Derwent World Patents Index (DWPI) Revises Indexing
                  of Author Abstracts
 NEWS 22  FEB 16  New FASTA Display Formats Added to USGENE and PCTGEN
 NEWS 23  FEB 16  INPADOCDB and INPAFAMDB Enriched with New Content
                  and Features
 NEWS 24  FEB 16  INSPEC Adding Its Own IPC codes and Author's E-mail
                  Addresses

 NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
              AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.
```

10590585.trn

  All use of STN is subject to the provisions of the STN customer
  agreement. This agreement limits use to scientific research. Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:13:41 ON 23 FEB 2010

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND
command can only be used to look at the index in a file which has an
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 11:14:17 ON 23 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 FEB 2010 HIGHEST RN 1206966-88-2
DICTIONARY FILE UPDATES: 21 FEB 2010 HIGHEST RN 1206966-88-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10590585-9.str

10590585.trn





chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 14 15 16 17 19 20 21 22 23 24 26 27
chain bonds :
13-14 17-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17
17-20 19-20 21-22 21-23 22-27 23-24 24-26 26-27
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 9-10 13-14 14-15 14-19 15-16 16-17
17-20 17-21 19-20 21-22 21-23 22-27 23-24 24-26 26-27
exact bonds :
7-8 8-9

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 26:Atom 27:Atom 28:CLASS

10590585.trn

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:14:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 536104 TO ITERATE

0.4% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 10680258 TO 10763902
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1841 AND 1992

L3 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10590585-8.str

10590585.trn





chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 14 15 16 17 19 20 21 22 23 24 26 27
chain bonds :
13-14 17-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17
17-20 19-20 21-22 21-23 22-27 23-24 24-26 26-27
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 9-10 13-14 14-15 14-19 15-16 16-17
17-20 17-21 19-20 21-22 21-23 22-27 23-24 24-26 26-27
exact bonds :
7-8 8-9

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 26:Atom 27:Atom 28:CLASS

10590585.trn

L4 STRUCTURE UPLOADED

=> que L4 AND L3

L5 QUE L4 AND L3

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840 AND 1992

L6 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10590585-5.str





chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 14 15 16 17 19 20 21 22 23 24 26 27
chain bonds :
13-14 17-21

10590585.trn

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17
 17-20 19-20 21-22 21-23 22-27 23-24 24-26 26-27
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 9-10 13-14 14-15 16-17 17-20 17-21
21-22 21-23 22-27 23-24 24-26 26-27
exact bonds :
7-8 8-9 14-19 15-16 19-20

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 26:Atom 27:Atom 28:CLASS

L7   STRUCTURE UPLOADED

=> que L7 AND L6

L8   QUE L7 AND L6

=> s l8
SAMPLE SEARCH INITIATED 11:16:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   419348 TO ITERATE

  0.5% PROCESSED   2000 ITERATIONS   0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS: 8349557 TO 8424363
PROJECTED ANSWERS: 0 TO   0

L9   0 SEA SSS SAM L7 AND L6

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1992 AND 1840

L10   SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10590585-999.str

10590585.trn





chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 14 15 16 17 19 20 21 22 23 24 26 27
chain bonds :
13-14 17-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17
17-20 19-20 21-22 21-23 22-27 23-24 24-26 26-27
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 9-10 13-14 16-17 17-20 17-21 21-22
21-23 22-27 23-24 24-26 26-27
exact bonds :
7-8 8-9 14-15 14-19 15-16 19-20

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 26:Atom 27:Atom 28:CLASS

L11 STRUCTURE UPLOADED

=> que L11 AND L10

10590585.trn

L12 QUE L11 AND L10

=> d l12
L12 HAS NO ANSWERS
L10   SCR 1992 AND 1840
L11   STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.
L12   QUE ABB=ON PLU=ON L11 AND L10

=> s l12
SAMPLE SEARCH INITIATED 11:18:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   312257 TO ITERATE

  0.6% PROCESSED   2000 ITERATIONS   1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS: 6212540 TO 6277740
PROJECTED ANSWERS: 2373 TO   3871

L13   1 SEA SSS SAM L11 AND L10

=> d scan

10590585.trn

L13 1 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Quinoline,
2-[4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-1-
piperazinyl]-, hydrochloride (1:2)
MF C27 H33 N3 O . 2 Cl H



●2 HCl

ALL ANSWERS HAVE BEEN SCANNED

10590585.trn

```
=> s piperidine/cn
L14          1 PIPERIDINE/CN

=> d rsd
```

10590585.trn

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN

Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C5N	NC5	6	C5N	46.156.1	1

10590585.trn

```
=> s 46.156.1/rid
L15    2737850 46.156.1/RID

=> s piperazine
L16     547740 PIPERAZINE

=> s piperazine/cn
L17          1 PIPERAZINE/CN

=> d rsd
```

10590585.trn

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN

Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C4N2	NC2NC2	6	C4N2	46.383.1	1

10590585.trn

```
=> s 46.383.1/rid
L18    1597508 46.383.1/RID

=> d his

     (FILE 'HOME' ENTERED AT 11:13:41 ON 23 FEB 2010)

     FILE 'REGISTRY' ENTERED AT 11:14:17 ON 23 FEB 2010
L1               STRUCTURE UPLOADED
L2             0 S L1
L3               SCREEN 1841 AND 1992
L4               STRUCTURE UPLOADED
L5               QUE L4 AND L3
L6               SCREEN 1840 AND 1992
L7               STRUCTURE UPLOADED
L8               QUE L7 AND L6
L9             0 S L8
L10              SCREEN 1992 AND 1840
L11              STRUCTURE UPLOADED
L12              QUE L11 AND L10
L13            1 S L12
L14            1 S PIPERIDINE/CN
L15      2737850 S 46.156.1/RID
L16       547740 S PIPERAZINE
L17            1 S PIPERAZINE/CN
L18      1597508 S 46.383.1/RID

=> s l18 and l15
L19       90686 L18 AND L15

=> s l18 or l15
SYSTEM LIMITS EXCEEDED - SEARCH ENDED
The search profile you entered was too complex or gave too many
answers.  Simplify or subdivide the query and try again.  If you have
exceeded the answer limit, enter DELETE HISTORY at an arrow prompt
(=>) to remove all previous answers sets and begin at L1.  Use the
SAVE command to store any important profiles or answer sets before
using DELETE HISTORY.

=> d his

     (FILE 'HOME' ENTERED AT 11:13:41 ON 23 FEB 2010)

     FILE 'REGISTRY' ENTERED AT 11:14:17 ON 23 FEB 2010
L1               STRUCTURE UPLOADED
L2             0 S L1
L3               SCREEN 1841 AND 1992
L4               STRUCTURE UPLOADED
L5               QUE L4 AND L3
L6               SCREEN 1840 AND 1992
L7               STRUCTURE UPLOADED
L8               QUE L7 AND L6
L9             0 S L8
L10              SCREEN 1992 AND 1840
L11              STRUCTURE UPLOADED
```

10590585.trn

```
L12             QUE L11 AND L10
L13           1 S L12
L14           1 S PIPERIDINE/CN
L15     2737850 S 46.156.1/RID
L16      547740 S PIPERAZINE
L17           1 S PIPERAZINE/CN
L18     1597508 S 46.383.1/RID
L19       90686 S L18 AND L15

=> s sub=l15 sam l12
SAMPLE SUBSET SEARCH INITIATED 11:21:21 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -    45000 TO ITERATE

  4.4% PROCESSED     2000 ITERATIONS                              0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):       887323 TO   912677
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):               0 TO        0

L20           0 SEA SUB=L15 SSS SAM L11 AND L10

=> s sub=l15 full l12
FULL SUBSET SEARCH INITIATED 11:21:30 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   905986 TO ITERATE

 98.7% PROCESSED   893804 ITERATIONS                            394 ANSWERS

100.0% PROCESSED   905986 ITERATIONS                            394 ANSWERS
SEARCH TIME: 00.00.18

L21         394 SEA SUB=L15 SSS FUL L11 AND L10

=> s sub=l19 full l12
FULL SUBSET SEARCH INITIATED 11:22:02 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -    23135 TO ITERATE

100.0% PROCESSED    23135 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

L22           0 SEA SUB=L19 SSS FUL L11 AND L10

=> s sub=l18 full l12
FULL SUBSET SEARCH INITIATED 11:22:20 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   281857 TO ITERATE

100.0% PROCESSED   281857 ITERATIONS                            372 ANSWERS
SEARCH TIME: 00.00.06

L23         372 SEA SUB=L18 SSS FUL L11 AND L10

=> s l21 or l23
L24         766 L21 OR L23
```

10590585.trn

```
=> file caplus
FILE 'CAPLUS' ENTERED AT 11:22:38 ON 23 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 23 Feb 2010  VOL 152 ISS 9
FILE LAST UPDATED: 22 Feb 2010  (20100222/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Dec 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l24
L25         96 L24

=> file reg
FILE 'REGISTRY' ENTERED AT 11:22:47 ON 23 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 FEB 2010  HIGHEST RN 1206966-88-2
DICTIONARY FILE UPDATES:  21 FEB 2010  HIGHEST RN 1206966-88-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
```

predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> rea rn l25
READ COMMAND IS VALID ONLY IN THE MAIL FILE
Mail functions are available only in the mail file.  For an
explanation of how to use the electronic mail service, enter "HELP
MAIL".  For more information, enter "HELP READ".

=> tra rn l25
L26         TRANSFER L25 1- RN :   21131 TERMS
SEARCH OF L26 IS APPROXIMATELY 43% COMPLETE
SEARCH OF L26 IS APPROXIMATELY 86% COMPLETE
L27      21131 L26

=> d his

     (FILE 'HOME' ENTERED AT 11:13:41 ON 23 FEB 2010)

     FILE 'REGISTRY' ENTERED AT 11:14:17 ON 23 FEB 2010
L1              STRUCTURE UPLOADED
L2            0 S L1
L3              SCREEN 1841 AND 1992
L4              STRUCTURE UPLOADED
L5              QUE L4 AND L3
L6              SCREEN 1840 AND 1992
L7              STRUCTURE UPLOADED
L8              QUE L7 AND L6
L9            0 S L8
L10             SCREEN 1992 AND 1840
L11             STRUCTURE UPLOADED
L12             QUE L11 AND L10
L13           1 S L12
L14           1 S PIPERIDINE/CN
L15     2737850 S 46.156.1/RID
L16      547740 S PIPERAZINE
L17           1 S PIPERAZINE/CN
L18     1597508 S 46.383.1/RID
L19       90686 S L18 AND L15
L20           0 S SAM L12 SUB=L15
L21         394 S FULL L12 SUB=L15
L22           0 S FULL L12 SUB=L19
L23         372 S FULL L12 SUB=L18
L24         766 S L21 OR L23

     FILE 'CAPLUS' ENTERED AT 11:22:38 ON 23 FEB 2010
L25          96 S L24

     FILE 'REGISTRY' ENTERED AT 11:22:47 ON 23 FEB 2010

     FILE 'CAPLUS' ENTERED AT 11:22:56 ON 23 FEB 2010
L26             TRA L25 1- RN :    21131 TERMS
```

10590585.trn

```
     FILE 'REGISTRY' ENTERED AT 11:23:05 ON 23 FEB 2010
L27       21131 SEA L26

=> s l24 not l27
L28        160 L24 NOT L27

=> help dfields

 The display fields that you may use to display REGISTRY File records
 are listed below.  You may use any of the SUBSTANCE INFORMATION FIELD
 CODES or PROPERTY FIELD CODES with the DISPLAY and PRINT commands.
 You may also use any of the CA DOCUMENT REFERENCE FIELD CODES OR
 PREDEFINED FORMATS, but these must always be combined with one of the
 Substance Information fields or formats.  The fields appear in the
 order you request them.

 The Component Number (CM) field code appears in records for
 multicomponent substances but is not a custom display field.

 Substance Information Display Field Codes

 AF             Alternate Molecular Formula
 AR             Alternate CAS Registry Number
 CCI            Component Class Identifier
 CCN            Condensed Chemical Name (all names)
 CI             Class Identifier
 CIL            Component Isotope at Unknown Location
 CMF            Component Molecular Formula
 CN             Chemical Name (up to 50)
 COMP           Composition
 CRN            Component CAS Registry Number
 DEF            Definition
 DR             Deleted CAS Registry Number
 ED             Entry Date
 ENTE           Editor Note
 FCN            All Chemical Names
 FS             File Segment
 IL             Isotope at Unknown Location
 IN             CA Index Name
 LC             CAS Registry Number Locator
 MF             Molecular Formula
 PCT            Polymer Class Term
 PR             Preferred CAS Registry Number
 REF            Number of References in CAplus and CA
                files and the number of references in CA for the
                non-specific derivatives
 RN             CAS Registry Number
 RR             Replacing Registry Number
 RSD            Ring System Data
 SCN            Short Chemical Name (IN and OTHER NAMES)
 SR             Source of Registration
 SRSD           Short Ring System Data
 STR            Structure Diagram with stereo bond and R/S/Z/E
                designations, if available
```

STF	Flat Structure Diagram (no stereo bonds)
STS	Structure Diagram with stereo bonds, if available

Biosequence Field Codes

NA	Nucleic Acid
NTE	Note
PNTE	Patent Annotation
SEQ	Sequence (1-letter amino acid codes)
SEQ3	Sequence (3-letter amino acid codes)
SQL	Sequence Length

Property Field Codes

BCF	Bioconcentration Factor
BP	Boiling Point
DEN	Density
ECND	Electric Conductivity
ECON	Electric Conductance
ERES	Electric Resistance
EREST	Electric Resistivity
ETAG	Experimental Property Tags
FP	Flash Point
FRB	Freely Rotable Bonds
HAC	H acceptors
HD	H donors
HDAS	H Donor/Acceptor Sum
HVAP	Enthalpy of Vaporization
ISLB.MASS	Mass Intrinsic Solubility
KOC	Organic Carbon Adsorption Coefficient
LD50	Median Lethal Dose
LOGD	logD
LOGP	logP
MM	Magnetic Moment
MP	Melting Point
MW	Molecular Weight
ORP	Optical Rotatory Power
PKA	pKa
PSA	Polar Surface Area
RI	Refractive Index
SLB.MASS	Mass Solubility
SLB.MOL	Molar Solubility
SPEC	Spectra
SPEC.C13NMR	Carbon-13 NMR Spectra
SPEC.IR	IR Absorption Spectra
SPEC.MASS	Mass Spectra
SPEC.H1NMR	Proton NMR Spectra
TG	Glass Transition Temperature
TS	Tensile Strength
VP	Vapor Pressure

CAplus Super Roles and Document Type Display Field codes

DT.CA	Caplus document type

10590585.trn

```
 RL           CAplus super roles
 RL.NP        CAplus super roles from non-patents
 RL.P         CAplus super roles from patents
 RLD (RL.D)   CAplus super roles for non-specific derivatives
 RLD. NP      CAplus super roles for non-specific derivatives
                from non-patents
 RLD.P        CAplus super roles for non-specific derivatives
                from patents
 RLS          CAplus super roles for the specific substance
                and its non-specific derivatives

 For more information on display options, enter HELP FORMAT at an
 arrow prompt (=>).  To find out about extracting search terms from
 display fields, enter HELP SELECT and HELP ANALYZE.  For a list of
 fields that may be used with the ANALYZE and SELECT commands, enter
 HELP EFIELDS.


=> d his

     (FILE 'HOME' ENTERED AT 11:13:41 ON 23 FEB 2010)

     FILE 'REGISTRY' ENTERED AT 11:14:17 ON 23 FEB 2010
L1             STRUCTURE UPLOADED
L2           0 S L1
L3             SCREEN 1841 AND 1992
L4             STRUCTURE UPLOADED
L5             QUE L4 AND L3
L6             SCREEN 1840 AND 1992
L7             STRUCTURE UPLOADED
L8             QUE L7 AND L6
L9           0 S L8
L10            SCREEN 1992 AND 1840
L11            STRUCTURE UPLOADED
L12            QUE L11 AND L10
L13          1 S L12
L14          1 S PIPERIDINE/CN
L15    2737850 S 46.156.1/RID
L16     547740 S PIPERAZINE
L17          1 S PIPERAZINE/CN
L18    1597508 S 46.383.1/RID
L19      90686 S L18 AND L15
L20          0 S SAM L12 SUB=L15
L21        394 S FULL L12 SUB=L15
L22          0 S FULL L12 SUB=L19
L23        372 S FULL L12 SUB=L18
L24        766 S L21 OR L23

     FILE 'CAPLUS' ENTERED AT 11:22:38 ON 23 FEB 2010
L25         96 S L24

     FILE 'REGISTRY' ENTERED AT 11:22:47 ON 23 FEB 2010

     FILE 'CAPLUS' ENTERED AT 11:22:56 ON 23 FEB 2010
L26            TRA L25 1- RN :    21131 TERMS
```

10590585.trn

```
     FILE 'REGISTRY' ENTERED AT 11:23:05 ON 23 FEB 2010
L27       21131 SEA L26
L28         160 S L24 NOT L27

=> analyze l28
ENTER ANSWER NUMBER OR RANGE (1-):1-
ENTER DISPLAY CODE (CHEM) OR ?:lc
L29         ANALYZE L28 1- LC :       2 TERMS

=> d l29
L29         ANALYZE L28 1- LC :       2 TERMS

TERM #   # OCC  # DOC  % DOC LC
------ ------- ------ ------ ---------------
     1      40     40  25.00 CHEMCATS
     2       1      1   0.62 BEILSTEIN
*********  END OF L29***


=> s l28 and chemcats/lc
      10783402 CHEMCATS/LC
L30         40 L28 AND CHEMCATS/LC

=> s l28 and beilstein/lc
       4362486 BEILSTEIN/LC
L31          1 L28 AND BEILSTEIN/LC

=> s l30 or l31
L32         41 L30 OR L31

=> s l32 and ed<=2005
      84720038 ED<=2005
                  (ED<=20059999)
L33         26 L32 AND ED<=2005

=> d l33 str rn cn ed lc so 1-
YOU HAVE REQUESTED DATA FROM 26 ANSWERS - CONTINUE? Y/(N):y
```

10590585.trn

L33 ANSWER 1 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 862262-01-9 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
ED Entered STN: 01 Sep 2005
LC STN Files: CHEMCATS

L33 ANSWER 2 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 862261-90-3 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
ED Entered STN: 01 Sep 2005
LC STN Files: CHEMCATS

L33 ANSWER 3 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 862257-84-9 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
ED Entered STN: 01 Sep 2005
LC STN Files: CHEMCATS

L33 ANSWER 4 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 862257-82-7 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
ED Entered STN: 01 Sep 2005
LC STN Files: CHEMCATS

L33 ANSWER 5 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 862257-81-6 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
ED Entered STN: 01 Sep 2005
LC STN Files: CHEMCATS

L33 ANSWER 6 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 862257-80-5 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
ED Entered STN: 01 Sep 2005
LC STN Files: CHEMCATS

L33 ANSWER 7 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 821812-46-8 REGISTRY
CN Methanone, (8,9-dihydro-9,12,12-trimethyl-6,9-methano-1,3-dioxolo[4,5-b]phenazin-6(7H)-yl)[4-(2-pyrimidinyl)-1-piperazinyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(8,9-dihydro-9,12,12-trimethyl-6,9-methano-1,3-dioxolo[4,5-b]phenazin-6(7H)-yl)carbonyl]-4-(2-pyrimidinyl)- (9CI)
ED Entered STN: 28 Jan 2005
LC STN Files: CHEMCATS

L33 ANSWER 8 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 821811-34-1 REGISTRY
CN Methanone, [4-(3-chlorophenyl)-1-piperazinyl](8,9-dihydro-9,12,12-trimethyl-6,9-methano-1,3-dioxolo[4,5-b]phenazin-6(7H)-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-(3-chlorophenyl)-4-[(8,9-dihydro-9,12,12-trimethyl-6,9-methano-1,3-dioxolo[4,5-b]phenazin-6(7H)-yl)carbonyl]- (9CI)
ED Entered STN: 28 Jan 2005
LC STN Files: CHEMCATS

L33 ANSWER 9 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 821811-31-8 REGISTRY
CN Methanone, (8,9-dihydro-9,12,12-trimethyl-6,9-methano-1,3-dioxolo[4,5-b]phenazin-6(7H)-yl)(4-phenyl-1-piperazinyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine,
1-[(8,9-dihydro-9,12,12-trimethyl-6,9-methano-1,3-dioxolo[4,5-b]phenazin-6(7H)-yl)carbonyl]-4-phenyl- (9CI)
ED Entered STN: 28 Jan 2005
LC STN Files: CHEMCATS

L33 ANSWER 10 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 821810-20-2 REGISTRY
CN Methanone, [4-(2-pyrimidinyl)-1-piperazinyl](1,2,3,4-tetrahydro-4,7,8,11,11-pentamethyl-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(3,4-dihydro-4,7,8,11,11-pentamethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-(2-pyrimidinyl)- (9CI)
ED Entered STN: 28 Jan 2005
LC STN Files: CHEMCATS

L33 ANSWER 11 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 821016-63-1 REGISTRY
CN Methanone, [4-(3-chlorophenyl)-1-piperazinyl](1,2,3,4-tetrahydro-4,7,8,11,11-pentamethyl-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine,
1-(3-chlorophenyl)-4-[(3,4-dihydro-4,7,8,11,11-pentamethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]- (9CI)
ED Entered STN: 27 Jan 2005
LC STN Files: CHEMCATS

L33 ANSWER 12 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 821016-61-9 REGISTRY
CN Methanone, [4-(4-methoxyphenyl)-1-piperazinyl](1,2,3,4-tetrahydro-4,7,8,11,11-pentamethyl-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(3,4-dihydro-4,7,8,11,11-pentamethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-(4-methoxyphenyl)- (9CI)
ED Entered STN: 27 Jan 2005
LC STN Files: CHEMCATS

L33 ANSWER 13 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 821016-55-1 REGISTRY
CN Methanone, (4-phenyl-1-piperazinyl)(1,2,3,4-tetrahydro-4,7,8,11,11-pentamethyl-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(3,4-dihydro-4,7,8,11,11-pentamethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-phenyl- (9CI)
ED Entered STN: 27 Jan 2005
LC STN Files: CHEMCATS

L33 ANSWER 14 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622824-47-9 REGISTRY
CN Methanone, [4-(3-chlorophenyl)-1-piperazinyl](1,2,3,4-tetrahydro-4,11,11-trimethyl-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-(3-chlorophenyl)-4-[(3,4-dihydro-4,11,11-trimethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 15 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622824-43-5 REGISTRY
CN Methanone, [4-(4-methoxyphenyl)-1-piperazinyl](1,2,3,4-tetrahydro-4,11,11-trimethyl-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(3,4-dihydro-4,11,11-trimethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-(4-methoxyphenyl)- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 16 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622824-31-1 REGISTRY
CN Methanone, (4-phenyl-1-piperazinyl)(1,2,3,4-tetrahydro-4,11,11-trimethyl-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(3,4-dihydro-4,11,11-trimethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-phenyl- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 17 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622823-97-6 REGISTRY
CN Methanone, (7,8-dichloro-1,2,3,4-tetrahydro-4,11,11-trimethyl-1,4-methanophenazin-1-yl)[4-(2-pyrimidinyl)-1-piperazinyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(7,8-dichloro-3,4-dihydro-4,11,11-trimethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-(2-pyrimidinyl)- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 18 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622820-38-6 REGISTRY
CN Methanone, [4-(3-chlorophenyl)-1-piperazinyl](7,8-dichloro-1,2,3,4-tetrahydro-4,11,11-trimethyl-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-(3-chlorophenyl)-4-[(7,8-dichloro-3,4-dihydro-4,11,11-trimethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 19 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622820-33-1 REGISTRY
CN Methanone, (7,8-dichloro-1,2,3,4-tetrahydro-4,11,11-trimethyl-1,4-methanophenazin-1-yl)[4-(4-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(7,8-dichloro-3,4-dihydro-4,11,11-trimethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-(4-methoxyphenyl)- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 20 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622820-18-2 REGISTRY
CN Methanone, (7,8-dichloro-1,2,3,4-tetrahydro-4,11,11-trimethyl-1,4-methanophenazin-1-yl)(4-phenyl-1-piperazinyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(7,8-dichloro-3,4-dihydro-4,11,11-trimethyl-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-phenyl- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 21 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622814-21-5 REGISTRY
CN Methanone, [4-(2-pyrimidinyl)-1-piperazinyl](1,2,3,4-tetrahydro-4,11,11-trimethyl-8-nitro-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(3,4-dihydro-4,11,11-trimethyl-8-nitro-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-(2-pyrimidinyl)- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 22 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622808-33-7 REGISTRY
CN Methanone, [4-(3-chlorophenyl)-1-piperazinyl](1,2,3,4-tetrahydro-4,11,11-trimethyl-8-nitro-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-(3-chlorophenyl)-4-[(3,4-dihydro-4,11,11-trimethyl-8-nitro-1,4-methanophenazin-1(2H)-yl)carbonyl]- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 23 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622808-26-8 REGISTRY
CN Methanone, [4-(4-methoxyphenyl)-1-piperazinyl](1,2,3,4-tetrahydro-4,11,11-trimethyl-8-nitro-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(3,4-dihydro-4,11,11-trimethyl-8-nitro-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-(4-methoxyphenyl)- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

L33 ANSWER 24 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 622808-05-3 REGISTRY
CN Methanone, (4-phenyl-1-piperazinyl)(1,2,3,4-tetrahydro-4,11,11-trimethyl-8-nitro-1,4-methanophenazin-1-yl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, 1-[(3,4-dihydro-4,11,11-trimethyl-8-nitro-1,4-methanophenazin-1(2H)-yl)carbonyl]-4-phenyl- (9CI)
ED Entered STN: 02 Dec 2003
LC STN Files: CHEMCATS

10590585.trn

L33 ANSWER 25 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 332025-17-9 REGISTRY
CN 9,10-Ethanoanthracene-11-carboxylic acid, 9,10-dihydro-12-[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]- (CA INDEX NAME)
ED Entered STN: 23 Apr 2001
LC STN Files: CHEMCATS

L33 ANSWER 26 OF 26 REGISTRY COPYRIGHT 2010 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

RN 7773-25-3 REGISTRY
CN 2(1H)-Naphthalenone, 3,4-dihydro-1,1-dimethyl-3-[(4-phenyl-1-piperazinyl)methyl]- (CA INDEX NAME)
ED Entered STN: 16 Nov 1984
LC STN Files: BEILSTEIN*
(*File contains numerically searchable property data)

10590585.trn

```
=> file caplus
FILE 'CAPLUS' ENTERED AT 11:28:31 ON 23 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 23 Feb 2010  VOL 152 ISS 9
FILE LAST UPDATED: 22 Feb 2010  (20100222/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Dec 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 11:13:41 ON 23 FEB 2010)

     FILE 'REGISTRY' ENTERED AT 11:14:17 ON 23 FEB 2010
L1             STRUCTURE UPLOADED
L2           0 S L1
L3             SCREEN 1841 AND 1992
L4             STRUCTURE UPLOADED
L5             QUE L4 AND L3
L6             SCREEN 1840 AND 1992
L7             STRUCTURE UPLOADED
L8             QUE L7 AND L6
L9           0 S L8
L10            SCREEN 1992 AND 1840
L11            STRUCTURE UPLOADED
L12            QUE L11 AND L10
L13          1 S L12
L14          1 S PIPERIDINE/CN
L15    2737850 S 46.156.1/RID
L16     547740 S PIPERAZINE
L17          1 S PIPERAZINE/CN
L18    1597508 S 46.383.1/RID
```

10590585.trn

```
L19       90686 S L18 AND L15
L20           0 S SAM L12 SUB=L15
L21         394 S FULL L12 SUB=L15
L22           0 S FULL L12 SUB=L19
L23         372 S FULL L12 SUB=L18
L24         766 S L21 OR L23

     FILE 'CAPLUS' ENTERED AT 11:22:38 ON 23 FEB 2010
L25          96 S L24

     FILE 'REGISTRY' ENTERED AT 11:22:47 ON 23 FEB 2010

     FILE 'CAPLUS' ENTERED AT 11:22:56 ON 23 FEB 2010
L26             TRA L25 1- RN :    21131 TERMS

     FILE 'REGISTRY' ENTERED AT 11:23:05 ON 23 FEB 2010
L27       21131 SEA L26
L28         160 S L24 NOT L27
L29         ANALYZE L28 1- LC :       2 TERMS
L30          40 S L28 AND CHEMCATS/LC
L31           1 S L28 AND BEILSTEIN/LC
L32          41 S L30 OR L31
L33          26 S L32 AND ED<=2005

     FILE 'CAPLUS' ENTERED AT 11:28:31 ON 23 FEB 2010

=> d l25 cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 96 ANSWERS - CONTINUE? Y/(N):y
```

10590585.trn

L25 ANSWER 1 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2009:846112 Document No. 151:92849 Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds. Goldfarb, David Scott (University of Rochester, USA). U.S. Pat. Appl. Publ. US 20090163545 A1 20090625, 57pp. (English). CODEN: USXXCO. APPLICATION: US 2008-XN341615 20081222. PRIORITY: US 2007-16362P
20071221; US 2008-23801P 20080125.
AB The invention discloses a method for altering the lifespan of a eukaryotic
organism. The method comprises the steps of providing a lifespan-altering
compound, and administering an effective amount of the compound to a eukaryotic
organism, such that the lifespan of the organism is altered. In one embodiment, the compound is identified using the DeaD assay. [This abstract
record is one of 20 records for this document necessitated by the large number of index entries required to fully index the document and publication
system constraints.]
IT 622365-06-4
RL: PAC (Pharmacological activity); BIOL (Biological study)
(method using lifespan-altering compds. for altering lifespan of eukaryotic organisms, and screening for such compds.)
RN 622365-06-4 CAPLUS
CN Methanone, [4-(2-pyrimidinyl)-1-piperazinyl](1,2,3,4-tetrahydro-4,11,11-trimethyl-1,4-methanophenazin-1-yl)- (CA INDEX NAME)



L25 ANSWER 2 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2009:753543 Document No. 151:1632230 Identification of an Orally Active Opioid Receptor-like 1 (ORL1) Receptor Antagonist

4-{3-[(2R)-2,3-Dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as Clinical Candidate. Satoh, Atsushi; Sagara, Takeshi; Sakoh, Hiroki; Hashimoto, Masaya; Nakashima, Hiroshi; Kato, Tetsuya; Goto, Yasuhiro; Mizutani, Sayaka; Azuma-Kanoh, Tomoko; Tani, Takeshi; Okuda, Shoki; Okamoto, Osamu; Ozaki, Satoshi; Iwasawa, Yoshikazu;
Ohta, Hisashi; Kawamoto, Hiroshi (Tsukuba Research Institute, Banyu Pharmaceutical Co. Ltd., Okubo-3, Tsukuba 300-2611, Ibaraki, 300-2611, Japan). Journal of Medicinal Chemistry, 52(14), 4091-4094 (English) 2009.
CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 151:163223. Publisher: American Chemical Society.
AB Our efforts to optimize prototype opioid receptor-like 1 (ORL1) antagonist
1 led to the discovery of 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine 10. 10 Showed potent ORL1 antagonistic activity, excellent selectivity over other opioid receptors, and in vivo efficacy after oral dosing. Currently clin. trials of 10 are underway.
IT 864830-99-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally active ORL1 antagonists preparation)
RN 864830-99-9 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 3 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2008:1417101 Document No. 149:5482830 Novel 4-(4-Aryl)cyclohexyl-1-(2-pyridyl)piperazines as Δ8-Δ7 Sterol Isomerase (Emopamil Binding Protein) Selective Ligands with Antiproliferative Activity. Berardi, Francesco; Abate, Carmen; Ferorelli,
Savina; de Robertis, Anna F.; Leopoldo, Marcello; Colabufo, Nicola A.; Niso, Mauro; Perrone, Roberto (Dipartimento Farmacochimico, Universita degli Studi di Bari, Bari, I-70125, Italy). Journal of Medicinal Chemistry, 51(23), 7523-7531 (English) 2008. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 149:548283. Publisher: American Chemical Society.
AB To find Δ8-Δ7 sterol isomerase (EBP) selective ligands, various arylpiperazines previously studied and structurally related to some σ receptors ligands were preliminarily screened. Consequently, a novel series of 2- or 2,6-disubstituted (CH3, CH3O, Cl, F) cis- and trans-4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines was developed. Radioreceptor binding assays evidenced cis-19, cis-30 and cis-33 as new ligands with nanomolar affinity toward EBP site and a good selectivity relative to EBP-related σ receptors. The most selective 2,6-dimethoxy derivative (cis-33) demonstrated the highest potency (EC50 =
12.9 μM) and efficacy (70%) in inhibiting proliferation of human prostate cancer PC-3 cell line. Among the reference compds., σ2 agonist 36 (PB28) reached the maximum efficacy (100%), suggesting the contribution of
the σ2 receptor to the antiproliferative activity. This novel class of EBP inhibitors represents a valuable tool for investigating the last steps of cholesterol biosynthesis and related pathologies, as well as a starting point for developing new anticancer drugs.
IT 385811-17-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclohexyl pyridylpiperazines as Δ8-Δ7 sterol isomerase ligands with antiproliferative activity)
RN 385811-17-6 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]- (CA INDEX NAME)



L25 ANSWER 4 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2008:1398511 Document No. 149:5765880 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound. Kwak, Byong Sung; Moon, Hong Sik; Yi, Han-Ju;
Kang, Young Soon; Im, Dae Joong; Chae, Eun Hee; Chae, Sang Mi; Lee, Ki Ho (SK Holdings Co., Ltd., S. Korea). PCT Int. Appl. WO 2008140198 A1 20081120, 62pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2008-KR2470 20080430. PRIORITY: KR 2007-46708 20070514.
GI



I



II

AB There is provided a novel carbamoyloxy arylalkanoyl arylpiperazine derivative
compound having abundant racemic or enantiomeric characteristics, represented by the Formula I (wherein R1 and R2 are independently H, C1-C6
alkyl, and phenethyl, or together form part of a ring; Ar1 is furanyl, thionyl, methylenedioxyphenyl, and Ph that may be substituted; Z is H or F, or together with Ar1 forms a bicyclic ring; Ar2 is Ph, methylenedioxyphenyl, etc.; n is 1 or 2; and m is 0-2), and pharmaceutically available salts or hydrates thereof. Also, there are provided a pharmaceutical composition for treating pain, anxiety or depression
including an effective amount of the compound, and a method for treating pain,
anxiety or depression in mammals by administering an effective amount of the

L25 ANSWER 4 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
compd. to the mammals in need of treatment thereof. Synthetic procedures for prepg. I are exemplified. Example compd. II was prepd. via a multi-step synthesis starting with the reaction between Et benzoylacetate and 4-fluorophenylpiperazine. In an acetic acid-induced writhing test in mice, II (10 mg/kg, p.o.) inhibited pain by 73.5 %.
IT 1082831-66-0P, Carbamic acid
2-[(4-phenylpiperazin-1-yl)carbonyl]-1,2,3,4-tetrahydronaphthalen-1-yl ester 1082834-07-8P 1082834-09-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of carbamoyloxy arylalkanoyl arylpiperazine
compds. for treating pain, anxiety and depression)
RN 1082831-66-0 CAPLUS
CN Methanone, [1-[(aminocarbonyl)oxy]-1,2,3,4-tetrahydro-2-naphthalenyl](4-phenyl-1-piperazinyl)- (CA INDEX NAME)



RN 1082834-07-8 CAPLUS
CN Methanone, [1-[(aminocarbonyl)oxy]-1,2,3,4-tetrahydro-2-naphthalenyl](4-phenyl-1-piperazinyl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 1082834-09-0 CAPLUS
CN Methanone, [1-[(aminocarbonyl)oxy]-1,2,3,4-tetrahydro-2-naphthalenyl](4-phenyl-1-piperazinyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 1082831-66-0

L25 ANSWER 4 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CMF C22 H25 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S

L25 ANSWER 5 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2008:1398510 Document No. 149:5765870 Preparation of carbamoyloxy arylalkan arylpiperazine compounds for treating pain, anxiety and depression. Lee, Ki Ho; Yi, Han Ju; Cho, Hyeon; Im, Dae Joong; Chae, Eun Hee; Choi, Yeon Jung (SK Holdings Co., Ltd., S. Korea). PCT Int. Appl. WO 2008140197 A1 20081120, 73pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2008-KR2466 20080430. PRIORITY: KR 2007-46708 20070514.
GI



I



II

AB There is provided a novel carbamoyloxy arylalkan arylpiperazine derivative
compound having abundant racemic or enantiomeric characteristics, represented by the formula I (wherein --- may selectively form a cyclic ring; R1 and R2 are H or together with X1 form a bicyclic ring; the ring labeled X1 may be (un)substituted Ph or a bicyclic ring; Z is H or F or together with X1 forms a bicyclic ring; Ar is (un)substituted Ph, pyridine, pyrimidine, etc.; Y1 and Y2 are independently H or Me; Y3 is H, Ph, or CO; Y4 is H or Me; n is 1 or 2; and m is 0 or 1) , and pharmaceutically available salts or hydrates thereof. Also, there are provided a pharmaceutical composition for treating pain (i.e., acute or chronic
pain, neuropathic pain, inflammatory pain, diabetic pain, postherpetic neuralgia, etc.), anxiety or depression including an effective amount of the
compound, and a method for treating pain, anxiety or depression in mammals
by administering an effective amount of the compound to the mammals in need of
treatment thereof. Synthetic procedures for preparing I are exemplified. Example compound II was prepared in a multistep synthesis from an initial

L25 ANSWER 5 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
reaction between acetophenone and phenylpiperazine. In an acetic acid-induced writhing test in mice, II had an ED50 of 6.31 po in suppressing pain.
IT 1083076-22-5P, Carbamic acid

2-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-1,2,3,4-tetrahydronaphthalen-1-yl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of carbamoyloxy arylalkan arylpiperazine compds. for treating pain, anxiety and depression)
RN 1083076-22-5 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]-, 1-carbamate (CA INDEX NAME)



10590585.trn

L25 ANSWER 6 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2008:685859 Document No. 149:1761540 A Novel Class of Cycloalkano[b]pyridines as Potent and Orally Active Opioid Receptor-like 1
Antagonists with Minimal Binding Affinity to the hERG K+ Channel.
Yoshizumi, Takashi; Takahashi, Hirobumi; Miyazoe, Hiroshi; Sugimoto, Yuichi; Tsujita, Tomohiro; Kato, Tetsuya; Ito, Hirokatsu; Kawamoto, Hiroshi; Hirayama, Mioko; Ichikawa, Daisuke; Azuma-Kanoh, Tomoko; Ozaki, Satoshi; Shibata, Yoshihiro; Tani, Takeshi; Chiba, Masato; Ishii, Yasuyuki; Okuda, Shoki; Tadano, Kiyoshi; Fukuroda, Takahiro; Okamoto, Osamu; Ohta, Hisashi (Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd, Okubo-3, Tsukuba, Ibaraki, 300-2611, Japan). Journal of Medicinal Chemistry, 51(13), 4021-4029 (English) 2008. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 149:176154. Publisher: American Chemical Society.
GI


I


II

AB A series of compds. based on 7-{[4-(2-methylphenyl)piperidin-1-yl]methyl}-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol ((-)-I), a potent and selective opioid receptor-like 1 (ORL1) antagonist, was prepared and evaluated using structure-activity relationship studies with the aim of removing its affinity to human ether-a-go-go related gene (hERG) K+ channel. From these studies, II was identified as an optimized structure with respect to ORL1 antagonist activity, and affinity to the hERG K+channel. Furthermore, II showed good in vivo antagonism with a wide therapeutic index in regards to adverse cardiovascular effects.
IT 864828-68-2P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal structure; synthesis and biol. evaluation of arylpiperidinylmethyl-substituted cycloalkano[b]pyridines as orally active opioid receptor-like 1 antagonists with minimal binding affinity

L25 ANSWER 6 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT 1039359-51-7P 1039359-53-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(lipophilicity; synthesis and biol. evaluation of arylpiperidinylmethyl-substituted cycloalkano[b]pyridines as orally active opioid receptor-like 1 antagonists with minimal binding affinity
to the hERG K+ channel)
RN 1039359-51-7 CAPLUS
CN 8-Quinolinol, 5,6,7,8-tetrahydro-6-[[3-hydroxy-4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1039359-50-6
CMF C22 H28 N2 O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

L25 ANSWER 6 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
to the hERG K+ channel)
RN 864828-68-2 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, hydrochloride (1:1), (6R,8S)-(CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 1039359-49-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(lipophilicity and acidity; synthesis and biol. evaluation of arylpiperidinylmethyl-substituted cycloalkano[b]pyridines as orally active opioid receptor-like 1 antagonists with minimal binding affinity
to the hERG K+ channel)
RN 1039359-49-3 CAPLUS
CN 8-Quinolinol, 5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1039359-48-2
CMF C22 H28 N2 O

Absolute stereochemistry. Rotation (-).



CM 2

L25 ANSWER 6 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1039359-53-9 CAPLUS
CN 8-Quinolinol, 6-[[4-(4-fluoro-2-methylphenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1039359-52-8
CMF C22 H27 F N2 O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



10590585.trn

L25 ANSWER 7 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2008:670939 Document No. 149:100450 Synthesis of quinoline derivatives with antibacterial activity. Srivastava, Brijesh K.; Jain, Mukul R.; Patel, Pankaj R. (Cadila Healthcare Limited, India). Eur. Pat. Appl. EP 1927589 A1 20080604, 19pp. DESIGNATED STATES: R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS. (English). CODEN: EPXXDW. APPLICATION: EP 2007-254643 20071130. PRIORITY: IN 2006-MU1967 20061130.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to a process for preparing quinoline compds. I [R1 = H, (C1-C12)alkyl, (C3-C12)cycloalkyl; R2, R3 = H, OH, halo, alkoxy, NO2, cyano; R8, R9, R10, R11 = H, alkyl; R4, R5, R6, R7 = H, halo, haloalkyl, OH, alkoxy, thio NO2, cyano, amino, (C1-C12)alkyl, (C1-C12)alkoxy derivative of sulfenyl or sulfonyl group, sulfonic acid and derivs.; Z = O, S, NR, R = H, OH , (C1-C3)alkyl; X = absent or CH2, O, S, SO, SO2; Y = (CH2)n, n = 0-3], their tautomeric forms, their pharmaceutically acceptable salts and pharmaceutical compns. containing them. For example, reacting 6-methoxy-α-tetralone with quinolinecarboxylic acid II gave piperazinyl quinoline III in 75% yield. Compound III and analog IV were tested for antibacterial activity; their pharmacokinetic profile was also explored.

IT 1029844-02-7P, 1-Cyclopropyl-6-fluoro-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (oxoquinolinyl)piperazine derivs. and their antibacterial activity)

RN 1029844-02-7 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)

L25 ANSWER 7 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 1029844-04-9P, 1-Cyclopropyl-6-fluoro-8-methoxy-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 1029844-05-0P, 1-Cyclopropyl-5,6,8-trifluoro-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 1029844-06-1P, 1-Cyclopropyl-6-fluoro-8-methoxy-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]-3-methylpiperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 1029844-07-2P, 1-Ethyl-6-fluoro-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 1029844-18-5P, 1-Cyclopropyl-6-fluoro-7-[4-[(1-hydroxyimino-6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (oxoquinolinyl)piperazine derivs. and their antibacterial activity)

RN 1029844-04-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 1029844-05-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)

L25 ANSWER 7 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1029844-06-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-methyl-4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]-4-oxo- (CA INDEX NAME)



RN 1029844-07-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 1029844-18-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-[[1,2,3,4-tetrahydro-1-(hydroxyimino)-6-methoxy-2-naphthalenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)

L25 ANSWER 7 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



10590585.trn

L25 ANSWER 8 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2008:366390 Document No. 149:95648 Quantitative structure - activity relationship studies on membrane receptors inhibition by antipsychotic drugs. Application to schizophrenia treatment. Avram, Speranta; Berner, Heinz; Milac, Adina L.; Wolschann, Peter (Department of Physiology and Biophysics, Faculty of Biology, University of Bucharest, Bucharest, Rom.).
Monatshefte fuer Chemie, 139(4), 407-426 (English) 2008. CODEN: MOCMB7. ISSN: 0026-9247. Publisher: Springer Wien.
AB There are presented 6 new QSAR models, which are correlating antipsychotic activity (pK i values at dopamine D1-D4 and serotonine (5-HT2C, 5-HT2A) receptors) with physicochem. parameters. A large data set of typical and atypical antipsychotics already approved for clin. treatment including as well representatives with new chemical structures which are exhibiting antipsychotic activity (tetrahydrofuran-, benzamide-, 3-aminoethyl-1-tetralones-, piperazine-, benzothiazepine- and pyrrolobenzazepine-derivs.) were incorporated within this study. The appropriate 2D and internal-3D mol. descriptors could be generated by the computational software MOE (Mol. Operating Environment). Significant q2 (0.63-0.76) and r2 (0.70-0.78) correlation coeffs. were obtained, indicating that the established equations can be used within a wide range of binding consts. (pKi = 5 to 9.76). By use of these linear models an assembly of new aripiprazole structures could be established. Some of them are showing significantly improved antipsychotic activity in comparison with the parent compound
IT 861804-06-0 861804-07-1 861804-08-2
861804-09-3
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR studies on membrane receptors inhibition by antipsychotic drugs)
RN 861804-06-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 861804-07-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-7-methoxy-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

L25 ANSWER 8 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861804-08-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 861804-09-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-7-methoxy-3-[2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



L25 ANSWER 9 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2007:1028078 Document No. 147:5419990 Natural Products in Parallel Chemistry
- Novel 5-Lipoxygenase Inhibitors from BIOS-Based Libraries Starting from α-Santonin. Schwarz, Oliver; Jakupovic, Sven; Ambrosi, Horst-Dieter; Haustedt, Lars Ole; Mang, Christian; Mueller-Kuhrt, Lutz (Analyticon Discovery GmbH, Potsdam, 14473, Germany). Journal of Combinatorial Chemistry, 9(6), 1104-1113 (English) 2007. CODEN: JCCHFF. ISSN: 1520-4766. OTHER SOURCES: CASREACT 147:541999. Publisher: American Chemical Society.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Recently, we developed a concept known as biol.-oriented synthesis (BIOS), which targets the design and synthesis of small- to medium-sized compound libraries on the basis of genuine natural product templates to provide screening compds. with high biol. relevance. We herein describe the parallel solution phase synthesis of two BIOS-based libraries starting from α-santonin (I). Modification of the sesquiterpene lactone I by introduction of a thiazole moiety followed by a Lewis-acid-mediated lactone opening yielded a first library of natural product analogs, e.g. II. An acid-mediated dienone-phenol rearrangement of I and a subsequent etherification/amidation sequence led to a second natural product-based library, e.g. III. After application of a fingerprint-based virtual screening on these compds., the biol. screening of 23 selected library members against 5-lipoxygenase resulted in the discovery of four potent novel inhibitors of this enzyme.
IT 956601-08-4P 956601-18-6P 956601-45-9P
956601-46-0P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(BIOS-based library synthesis from α-santonin by introducing a thiazole moiety and lactone opening or rearrangement/etherification/amidation and their 5-lipoxygenase inhibitory activity)
RN 956601-08-4 CAPLUS
CN 1-Propanone, 1-[4-(4-fluorophenyl)-1-piperazinyl]-2-[(2R)-1,2,3,4-tetrahydro-7-methoxy-5,8-dimethyl-2-naphthalenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 9 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 956601-18-6 CAPLUS
CN 1-Propanone, 1-[4-(4-fluorophenyl)-1-piperazinyl]-2-[(2R)-1,2,3,4-tetrahydro-5,8-dimethyl-7-propoxy-2-naphthalenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 956601-45-9 CAPLUS
CN 1-Propanone, 1-[4-(4-fluorophenyl)-1-piperazinyl]-2-[(2R)-1,2,3,4-tetrahydro-7-(2-methoxyethoxy)-5,8-dimethyl-2-naphthalenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 9 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 956601-46-0 CAPLUS
CN 1-Propanone, 1-[4-(4-fluorophenyl)-1-piperazinyl]-2-[(2R)-1,2,3,4-tetrahydro-5,8-dimethyl-7-[2-(4-morpholinyl)ethoxy]-2-naphthalenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 10 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
independently 0 - 4; v is 0 and 1; Q is a bond, (un)branched (un)functionalized C1-6 alkylidene; Rq is (un)substituted C1-6 aliph., (un)substituted 3 to 8-membered (un)satd. mono(hetero)cycle, and (un)substituted 8- to 15-membered (un)satd. (bi/tri/spiro)(hetero)cycle; R11 is R2, halo, CN, NO2, CF3, OCF3, OH, etc.; R22 is R2, =O, =NNH2 and derivs., =N-OH and derivs., OH and derivs., O-acyl, OCO2H and derivs., etc.; R2 is H, (un)substituted C1-6 aliph.; ring A may be optionally fused with (un)substituted phenyl; and their pharmaceutically acceptable salts thereof, are claimed. The invention also provides pharmaceutically acceptable compns. comprising the compds. of the invention and methods of using the compns. in the treatment of various disorders. Compd. II was prepd. by acylation of 4-(piperazin-1-yl)-N-(thiazol-2-yl)benzenesulfonamide with (2R)-2-(fluoroindol-1-yl)propionic acid. All the invention compds. were evaluated for their sodium channel inhibitory activity.

IT 943651-27-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocyclic derivs. as inhibitors of ion channels useful in treatment of various disorders)

RN 943651-27-2 CAPLUS
CN Benzenesulfonamide, N-4-pyrimidinyl-4-[4-[(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)



L25 ANSWER 10 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2007:730896 Document No. 147:1434680 Heterocyclic derivatives as modulators of ion channels and their preparation, pharmaceutical compositions and use in the treatment of diseases. Wilson, Dean; Fanning, Lev T.D.; Sheth, Urvi; Martinborough, Esther; Termin, Andreas; Neubert, Timothy; Zimmermann, Nicole; Knoll, Tara; Whitney, Tara; Kawatkar, Aarti; Lehsten, Danielle; Stamos, Dean; Zhou, Jinglan; Arumugam, Vijayalaksmi; Gutierrez, Corey (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2007075895 A2 20070705, 369 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-US48802 20061221. PRIORITY: US 2005-752926P 20051221; US 2006-791181P 20060411; US 2006-799797P 20060512; US 2006-839444P 20060823.

GI



I



II

AB The invention relates to heterocyclic derivs. of formula I useful as inhibitors of ion channels. Compound of formula I wherein Z is (un)substituted 5- to 7-membered (un)saturated heterocycle; W and Y1 are independently CH and H, provided that at least one of W and Y1 is N; x and y are independently 0 - 3, provided that x + y is 2, 3 and 4; m and n are

L25 ANSWER 11 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2007:655407 Document No. 147:2498640 Multistructure 3D-QSAR Studies on a Series of Conformationally Constrained Butyrophenones Docked into a New Homology Model of the 5-HT2A Receptor. Dezi, Cristina; Brea, Jose; Alvarado, Mario; Ravina, Enrique; Masaguer, Christian F.; Loza, Maria Isabel; Sanz, Ferran; Pastor, Manuel (Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Barcelona, E-08003, Spain). Journal of Medicinal Chemistry, 50(14), 3242-3255 (English) 2007. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 147:249864. Publisher: American Chemical Society.

AB The present study is part of a long-term research project aiming to gain insight into the mechanism of action of atypical antipsychotics. Here we describe a 3D-QSAR study carried out on a series of butyrophenones with affinity for the serotonin-2A receptor, aligned by docking into the binding site of a receptor model. The series studied has two peculiarities: (i) all the compds. have a chiral center and can be represented by two enantiomeric structures, and (ii) many of the structures can bind the receptor in two alternative orientations, posing the problem of how to select a single representative structure for every compound We have used an original solution consisting of the simultaneous use of multiple structures, representing different configurations, binding conformations, and positions. The final model showed good statistical quality (n = 426, r2 = 0.84, q2LOO = 0.81) and its interpretation provided useful information, not obtainable from the simple inspection of the ligand-receptor complexes.

IT 149247-12-1 325489-07-4 676139-12-1
676139-13-2 861804-06-0 861804-07-1
861804-09-3
RL: PAC (Pharmacological activity); BIOL (Biological study)
(multistructure QSAR studies on conformationally constrained butyrophenones docked into homol. model of 5-HT2A receptor)

RN 149247-12-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 325489-07-4 CAPLUS
CN 5(6H)-Quinolinone, 7,8-dihydro-7-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



L25 ANSWER 11 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 676139-12-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 676139-13-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-3-[[4-(2-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 861804-06-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 861804-07-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-7-methoxy-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

L25 ANSWER 11 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861804-09-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-7-methoxy-3-[2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



L25 ANSWER 12 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

2007:61266 Document No. 146:1630230 Preparation of oxyacids and oxyacid esters as serotonin receptor modulators.. Klaveness, Jo; Brudeli, Bjame; Levy, Finn Olav (Bio-Medisinsk Innovasjon AS, Norway; Cockbain, Julian). PCT Int. Appl. WO 2007007072 A1 20070118, 107pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-GB2542 20060707. PRIORITY: US 2005-696780P 20050707.

AB Oxyacid and oxyacid ester serotonin modulators were prepared Thus, indole-3-carboxylic acid in CH2Cl2 was stirred 2 h with (COCl)2 and cat. DMF; the residue in THF/CH2Cl2 was added dropwise to 4-(4-hydroxymethylpiperidin-1-yl)butyric acid 2,2,2-trichloroethyl ester (preparation given) and Et3N in CH2Cl2 followed by stirring overnight to give 25.6% 1H-indole-3-carboxylic acid 1-[3-(2,2,2-trichloroethylethoxycarbonyl)propyl]piperidine-4-ylmethyl ester. The latter showed 5-HT4 antagonist activity with pKb = 9.13, vs. piboserod which showed pKb = 9.26.

IT 1057307-69-3
RL: PRPH (Prophetic)
(Preparation of oxyacids and oxyacid esters as serotonin receptor modulators.)

RN 1057307-69-3 CAPLUS
CN Benzoic acid, 4-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



L25 ANSWER 13 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

2006:941104 Document No. 145:335937 Preparation of A-form crystals of tetrahydroquinoline derivative and their medical compositions and pharmaceuticals. Sugimoto, Yuichi; Miyazoe, Hiroshi; Tsujita, Tomohiro (Banyu Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2006241096 A 20060914, 16pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2005-60632 20050304.

GI



AB A-form crystals of I.HCl are useful for prophylactic or therapeutic treatment of nociceptin receptor-associated diseases, e.g., pain, obesity, impaired learning, dementia, schizophrenia, depression, etc. Thus, trimethylsilylated I was deprotected, converted into HCl salt in MeOH, the solvent evaporated, dissolved in EtOH and treated with n-heptane to give A-form crystals of I.HCl, which inhibited the binding of [125I]-Tyr14-nociceptin to its receptor with IC50 value of 9.00 nM. The X ray powder diffraction pattern of the crystals is also described.

IT 864828-68-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of A-form crystals of tetrahydroquinoline derivative as nociceptin receptor antagonist)

RN 864828-68-2 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, hydrochloride (1:1), (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 13 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

IT 864830-99-9P 909781-64-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of A-form crystals of tetrahydroquinoline derivative as nociceptin
receptor antagonist)
RN 864830-99-9 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 909781-64-2 CAPLUS
CN 3-Piperidinol, 4-(2-chloro-4-fluorophenyl)-1-[[(6R,8S)-5,6,7,8-tetrahydro-8-[(triethylsilyl)oxy]-6-quinolinyl]methyl]-, (3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 13 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 14 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2006:729384 Document No. 145:3276470
1-Aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one Oximes as Potent Dopamine D4 Receptor Agonists for the Treatment of Erectile Dysfunction.
Kolasa, Teodozyj; Matulenko, Mark A.; Hakeem, Ahmed A.; Patel, Meena V.; Mortell, Kathleen; Bhatia, Pramila; Henry, Rodger; Nakane, Masaki; Hsieh, Gin C.; Terranova, Marc A.; Uchic, Marie E.; Miller, Loan N.; Chang, Renje; Donnelly-Roberts, Diana L.; Namovic, Marian T.; Hollingsworth, Peter R.; Martino, Brenda; El Kouhen, Odile; Marsh, Kennan C.; Wetter, Jill M.; Moreland, Robert B.; Brioni, Jorge D.; Stewart, Andrew O.
(Neuroscience Research, Abbott Laboratories, Abbott Park, IL, 60064-6101, USA). Journal of Medicinal Chemistry, 49(17), 5093-5109 (English) 2006.
CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 145:327647.
Publisher: American Chemical Society.
GI



I



II

AB A new series of dopamine D4 receptor agonists, 1-aryl-3-(4-pyridinepiperazin-1-yl)propanone oximes, was designed through the modification of known dopamine D4 receptor agonist PD 168077. Replacement of the amide group with a methylene-oxime moiety produced compds. with improved stability and efficacy. Structure-activity relationships (SAR) of the aromatic ring linked to the N-4-piperazine ring
confirmed the superiority of 2-pyridine as a core for D4 agonist activity.
A two-methylene linker between the oxime group and the N-1-piperazine ring
displayed the best profile. New dopamine D4 receptor agonists, exemplified by (E)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime(I) (59a) and (E)-1-(3-chloro-4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime (II) (64a), exhibited favorable pharmacokinetic profiles
and showed oral bioavailability in rat and dog. Subsequent evaluation of 59a in the rat penile erection model revealed in vivo activity, comparable

L25 ANSWER 14 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
in efficacy to apomorphine. Our results suggest that the oximes provide a
novel structural linker for 4-arylpiperazine-based D4 agonists, possessing
leadlike quality and with potential to develop a new class of potent and selective dopamine D4 receptor agonists.
IT 909414-28-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(1-Aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one Oximes as Potent Dopamine D4 Receptor Agonists for the Treatment of Erectile Dysfunction)
RN 909414-28-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-, O-ethyloxime (CA INDEX NAME)



L25 ANSWER 15 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2006:542524 Document No. 145:460880 Substituted piperazines as CB1 antagonists and their preparation, pharmaceutical compositions, and their use for treatment of metabolic disorders. Gilbert, Eric J.; Miller, Michael W.; Scott, Jack D.; Stamford, Andrew W.; Greenlee, William J.; Weinstein, Jay (Schering Corp., USA). PCT Int. Appl. WO 2006060461 A1 20060608, 383 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-US43281 20051201. PRIORITY: US 2004-633106P 20041203.
GI



I



II

AB Compds. of formula I or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions. Compds. of formula I wherein Ar1 and Ar2 are independently (un)substituted (hetero)aryl; n and m are independently 0 or 1; A is CO, SO2, C(=NOH) and derivs., or (un)substituted C1-3 alkyl; B is NH and derivs., CO or (un)substituted C1-2 alkyl; X is H, alkyl, S-alkyl, SO2-(cyclo)alkyl, SO2-(hetero)aryl, benzo(hetero)cycloalkyl, benzoheterocycloalkenyl, (un)substituted vinyl(hetero)aryl, etc.; R1 is alkyl, haloalkyl, alkenyl-NH2 and derivs., alkylene-OH and derivs., alkylene-N3, alkylene-CN, or alkylene-OSO2-alkyl; or two adjacent R1 on the same ring carbon atom for a carbonyl group; y is 0, 1, 2, 3, or 4; and their pharmaceutically acceptable salts, solvates and esters thereof are claimed. Example compd. II (R = Bn) was prepd. by regioselective ring cleavage of 4-chlorostyrene oxide with N-methylaminoethanol; the resulting N-(2-hydroxyethyl)-N-methyl-1-(4-chlorophenyl)-2-amino-1-ethanol underwent chlorination to give N-(2-chloroethyl)-N-methyl-2-(4-chlorophenyl)-2-chloroethylamine which underwent cyclization with 2,4-dichloroaniline to give compd. II (R = Me), which underwent demethylation to give II (R = H), which underwent reductive amination with benzaldehyde to give compd. II (R = Bn). All the invention compds. were evaluated for their cannabinoid antagonistic activity.

IT 890031-63-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted piperazines as CB1 antagonists useful for treatment of metabolic disorders)

RN 890031-63-7 CAPLUS
CN Methanone, [3-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-piperazinyl](1,2,3,4-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)



L25 ANSWER 16 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2006:493904 Document No. 145:80230 Preparation of heteroaroylaminotetralins and related compounds as glycogen phosphorylase inhibitors. Sher, Philip M.; Nirschl, Alexandra A.; Meng, Wei; Washburn, William N. (Bristol-Myers Squibb Company, USA). U.S. Pat. Appl. Publ. US 20060111338 A1 20060525, 42 pp. (English). CODEN: USXXCO. APPLICATION: US 2005-272845 20051114. PRIORITY: US 2004-628063P 20041115.
GI



I

II



Q1



Q2



Q3

AB Title compds. [I; W = Q1-Q3; X = CH2, CH2CH2, CH2o; Z = (substituted) 1,2-arylene, 1,2-heteroarylene; R1, R2 = H, (substituted) alkyl, aryl, aralkyl, heteroaralkyl, alkenyl, cyano, etc.; R3, R4 = H, halo, CF3, cyano, alkyl, alkoxy], were prepared Thus, title compound (II) was prepared in 9 steps from di-Et benzylmalonate, Et chloroacetate, acetonitrile, and 5-chloroindole-2-carboxylic acid. I deemed to posess activity as inhibitors of glycogen phosphorylase demonstrate IC50 of ≤10 μM.

IT 887752-74-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of heteroaroylaminotetralins and related compds. as glycogen phosphorylase inhibitors)

RN 887752-74-1 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(4S)-1,2,3,4-tetrahydro-4-hydroxy-4-[2-[4-hydroxy-4-[4-(trifluoromethyl)phenyl]-1-piperidinyl]-2-oxoethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 15 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

L25 ANSWER 16 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



10590585.trn

L25 ANSWER 17 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2006:228532 Document No. 144:4251110 Synthesis and appetite suppressant activity of 1-aryloxy-2-substituted aminomethyltetrahydronaphthalenes as conformationally rigid analogues of fluoxetine. Bhandari, Kalpana; Srivastava, Shipra; Shankar, Girija; Nath, Chandishwar (Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow, 226001, India). Bioorganic & Medicinal Chemistry, 14(8), 2535-2544 (English) 2006. CODEN: BMECEP. ISSN: 0968-0896. OTHER SOURCES: CASREACT
144:425111. Publisher: Elsevier B.V..
GI



I

AB Several 1-aryloxy-2-substituted aminomethyltetrahydronaphthalenes as conformationally rigid analogs of fluoxetine were synthesized and evaluated for their anorexigenic and antidepressant activities. For SAR studies the related acyclic analogs were also prepared Out of the 21 synthesized compds., 10 compds. exhibited significant anorexigenic activity (at 75 μmol/kg). Interestingly, all the compds. were devoid of antidepressant effect, except for 2 in which the antidepressant activity was retained. Compound I emerged as the most active compound of the
series with better anorexigenic activity (97.92%) compared to fluoxetine (76.25%) and even with a clin. used drug sibutramine, thus providing a new
structural lead for appetite suppressants.
IT 885100-79-8P 885100-81-2P 885100-83-4P
885100-85-6P 885100-97-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(appetite suppressant activity of 1-aryloxy-2-substituted aminomethyltetrahydronaphthalenes)
RN 885100-79-8 CAPLUS
CN Piperazine, 1-(4-methylphenyl)-4-[[(1R,2S)-1,2,3,4-tetrahydro-1-[4-(trifluoromethyl)phenoxy]-2-naphthalenyl]methyl]-, ethanedioate (1:2), rel- (CA INDEX NAME)

L25 ANSWER 17 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 885100-83-4 CAPLUS
CN Piperazine,
1-[[(1R,2S)-1,2,3,4-tetrahydro-1-[4-(trifluoromethyl)phenoxy]-2-naphthalenyl]methyl]-4-[4-(trifluoromethyl)phenyl]-, ethanedioate (1:2),
rel- (CA INDEX NAME)

CM 1

CRN 885100-82-3
CMF C29 H28 F6 N2 O

Relative stereochemistry.



L25 ANSWER 17 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 1

CRN 885100-78-7
CMF C29 H31 F3 N2 O

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 885100-81-2 CAPLUS
CN Ethanone, 1-[4-[[(1R,2S)-1,2,3,4-tetrahydro-2-[[4-(4-methylphenyl)-1-piperazinyl]methyl]-1-naphthalenyl]oxy]phenyl]-, ethanedioate (1:2), rel-
(CA INDEX NAME)

CM 1

CRN 885100-80-1
CMF C30 H34 N2 O2

Relative stereochemistry.

L25 ANSWER 17 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 885100-85-6 CAPLUS
CN Ethanone, 1-[4-[[(1R,2S)-1,2,3,4-tetrahydro-2-[[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-1-naphthalenyl]oxy]phenyl]-, ethanedioate (1:2), rel- (CA INDEX NAME)

CM 1

CRN 885100-84-5
CMF C30 H31 F3 N2 O2

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 885100-97-0 CAPLUS
CN Ethanone, 1-[4-[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-2-[[4-(4-methylphenyl)-1-piperazinyl]methyl]-1-naphthalenyl]oxy]phenyl]-, ethanedioate (1:2), rel- (CA INDEX NAME)

CM 1

L25 ANSWER 17 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CRN 885100-96-9
CMF C31 H36 N2 O3

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

IT 885101-13-3P 885101-14-4P 885101-15-5P
885101-17-7P 885101-18-8P 885101-21-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(appetite suppressant activity of 1-aryloxy-2-substituted aminomethyltetrahydronaphthalenes)

RN 885101-13-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(4-methylphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 885101-14-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-[4-(trifluoromethyl)phenyl]-1-

L25 ANSWER 17 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 885101-21-3 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-[[4-(4-methylphenyl)-1-piperazinyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 17 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
piperazinyl]methyl]- (CA INDEX NAME)



RN 885101-15-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[[4-(4-methylphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 885101-17-7 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(4-methylphenyl)-1-piperazinyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 885101-18-8 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 18 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2005:1143268 Document No. 144:638740 Design and synthesis of long-chain arylpiperazines with mixed affinity for serotonin transporter (SERT) and 5-HT1A receptor. Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Lacivita, Enza; Larizza, Carmela; Leopoldo, Marcello; Tortorella, Vincenzo (Dipartimento Farmaco-Chimico, Universita degli Studi di Bari, Bari, 70125, Italy). Journal of Pharmacy and Pharmacology, 57(10), 1319-1327 (English) 2005. CODEN: JPPMAB. ISSN: 0022-3573. OTHER SOURCES: CASREACT 144:63874. Publisher: Pharmaceutical Press.

AB A new generation of antidepressant agents could be represented by compds. with mixed activity as serotonin transporter (SERT) inhibitors and 5-HT1A receptor antagonists. We report here on the synthesis and evaluation of SERT and 5-HT1A receptor affinity of long-chain arylpiperazines obtained either by modifying 6-nitroquipazine into a long-chain arylpiperazine or by inserting a modified 6-nitroquipazine moiety or other structures endowed with SERT affinity into a long-chain arylpiperazine with 5-HT1A affinity. Among the compds. studied, 2-[4-(2-methoxyphenyl)piperazin-1-yl]-N-(6-nitro-2-quinolyl)ethylamine (21) and 1-(5-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)-3-[4-(2-methoxyphenyl)-piperazin-1-yl]-1-propanone (24) showed good affinity values for SERT and 5-HT1A receptors (SERT: Ki (inhibition constant) = 71.8 and 62.8 nM; 5-HT1A Ki = 14.2 and 0.82 nM, resp.).

IT 871739-13-8P 871739-14-9P 871739-15-0P
871739-16-1P 871739-24-1P 871739-25-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(arylpiperazines with mixed affinity for serotonin transporter and 5-HT1A receptor)

RN 871739-13-8 CAPLUS
CN Quinoline, 6-nitro-2-[4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 871739-14-9 CAPLUS
CN Piperazine, 1-(2-naphthalenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 18 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 871739-15-0 CAPLUS
CN Quinoline, 2-[4-[2-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)ethyl]-1-piperazinyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 871739-16-1 CAPLUS
CN Quinoline, 2-[4-[4-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)butyl]-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 18 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

IT 154744-88-4 763071-99-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arylpiperazines with mixed affinity for serotonin transporter and 5-HT1A receptor)

RN 154744-88-4 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 763071-99-4 CAPLUS
CN Quinoline, 2-[4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-1-piperazinyl]- (CA INDEX NAME)

L25 ANSWER 18 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 871739-24-1 CAPLUS
CN 1-Propanone, 1-(5-bromo-1,2,3,4-tetrahydro-1-naphthalenyl)-3-[4-(2-methoxyphenyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 871739-25-2 CAPLUS
CN 1-Propanone, 1-(7-bromo-1,2,3,4-tetrahydro-1-naphthalenyl)-3-[4-(2-methoxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 18 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



10590585.trn

L25 ANSWER 19 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2005:1004733 Document No. 143:3061610 Preparation of cycloalkanopyridine derivatives as antagonists of nociceptin receptor. Takahashi, Hirobumi; Sugimoto, Yuichi; Yoshizumi, Takashi; Kato, Tetsuya; Asai, Masanori; Miyazoe, Hiroshi (Banyu Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 2005085228 A1 20050915, 205 pp. DESIGNATED STATES: W: AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2005-JP4264 20050304. PRIORITY: JP 2004-62405 20040305.
GI



I



II

AB Cycloalkanopyridine derivs. represented by the general formula (I) [A1-A8 = (un)substituted CH or N, provided that at least one of A1-A4 is N; R1, R1' = H, halo, OH, cyano, C1-6 alkyloxy, C1-6 alkyloxyalkyloxy, C1-6 alkyloxycarbonyl, C1-6 alkyloxycarbonylamino, C1-6 alkylcarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, etc.; or R1
and R1' together form oxo or C1-3 alkylene ketal; R2, R2'= H, C1-6 alkyl, C1-6 hydroxyalkyl or R2 and R2' or R3' together form C1-3 alkylene or oxy-C1-3 alkylene; R2' and R2 or R3 together form C1-3 alkylene or oxy-C1-3 alkylene; R3, R3'= H, HO, halo, C1-6 alkyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylsulfonyl, C1-6 alkylsulfonylamino, C1-6 alkylsulfonylalkylamino, cyano, (un)substituted C1-6 alkyl; or R3 and R3' or R2' form C1-3 alkylene or oxy-C1-3 alkylene; or R3' and R3 or R2 together form C1-3 alkylene or oxy-C1-3 alkylene; R4 =
H, halo, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 alkyloxy-C1-6
alkyl, C1-6 alkylcarbonyl, cyano, CHO, C1-6 alkyloxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkyloxycarbonyl, etc.; X = CH2, CH(OH), (un)substituted NH, O, S, SO2; Y = CH2, (un)substituted NH; Z = (un)substituted CH, N; N = 0,1] or pharmaceutically acceptable salts thereof are prepd. These compds. are nociceptin receptor antagonists and useful for treatment or prevention of diseases in which a nociceptin receptor participates, e.g. (1) as drugs for overcoming resistance to narcotic analgesics, (2) as analgesic enhancers, antiobesity agents, and appetite regulators, (3) as drugs for improving or preventing learning or memory decline or dementia in aging, cerebral vascular disorders, or Alzheimer's disease, (4) as cognition enhancers in attention deficit hyperactivity disorder or learning disorder during developmental stage, (5) as drugs for treatment of schizophrenia, (6) as drugs for treatment of
regressive neurodegenerative diseases such as Parkinson's disease and chorea, (6) as antidepressants or mood regulators, (7) as preventives or remedies for diabetes insipidus or polyuria, and (8) as remedies for hypotension. Thus, a soln. of 70 mg toluene-4-sulfonic acid [(7R,9S)-9-(tert-butyldimethylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-7-yl]methyl ester and 33 mg spiro[8-azabicyclo[3.2.1]octane-3,1'-3'H-isobenzofuran] hydrochloride in 1.0 mL N-methylpyrrolidone were treated with 124 mg NaI and 0.21 mL Et3N and heated at 90° for 5 h with stirring, followed by treatment of the product with 1 M Bu4NF/THF at 50° for 4 h and sepn. of the resulting racemate using chiral column (CHRALPAC AD column), to give (7R,9S)- and (7S,9R)-7-[spiro[8-azabicyclo[3.2.1]octane-3,1'-3'H-
isobenzofuran]-8-ylmethyl]-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol (II) and its (7R,9S)-stereoisomer. II inhibited the binding of [125I]Tyr14-nociceptin to human nociceptin receptor by 50% at 0.39 nM.
IT 864828-63-7P 864828-68-2P 864828-72-8P
864829-28-7P 864829-30-1P 864829-31-2P
864830-99-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cycloalkanopyridine derivs. as antagonists of nociceptin
receptor for treating or preventing nociceptin receptor-associated diseases)
RN 864828-63-7 CAPLUS
CN 8-Quinolinol, 6-[[4-(2-chlorophenyl)-4-fluoro-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864828-62-6
CMF C21 H24 Cl F N2 O

Absolute stereochemistry.

L25 ANSWER 19 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864828-68-2 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, hydrochloride (1:1), (6R,8S)-(CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 864828-72-8 CAPLUS
CN 8-Quinolinol, 6-[[4-(2-chloro-4-fluorophenyl)-3-methoxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864828-71-7
CMF C22 H26 Cl F N2 O2

L25 ANSWER 19 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864829-28-7 CAPLUS
CN 8-Quinolinol, 2-chloro-5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 864829-30-1 CAPLUS
CN 8-Quinolinol, 3-chloro-5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-rel-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864829-29-8
CMF C22 H27 Cl N2 O

Relative stereochemistry.

L25 ANSWER 19 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864829-31-2 CAPLUS
CN 8-Quinolinol, 5,6,7,8-tetrahydro-2-methyl-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 864830-99-9 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 19 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 20 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2005:511376 Document No. 143:1937740 Synthesis and binding affinity of novel
3-aminoethyl-1-tetralones, potential atypical antipsychotics. Alvarado, Mario; Coelho, Alberto; Masaguer, Christian F.; Ravina, Enrique; Brea, Jose; Padin, J. Fernando; Loza, Maria I. (Facultad de Farmacia, Departamento de Quimica Organica, Laboratorio de Quimica Farmaceutica, Universidad de Santiago de Compostela, Santiago de Compostela, E-15782, Spain). Bioorganic & Medicinal Chemistry Letters, 15(12), 3063-3066 (English) 2005. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT
143:193774. Publisher: Elsevier B.V..
GI



I

AB A series of 3-aminoethyl-1-tetralones, e.g., I, conformationally constrained higher homologs of haloperidol (standard for typical antipsychotic
profile), have been obtained by a four-step route from valerolactone. Their binding affinities at dopamine D2 and serotonin 5-HT2A and 5-HT2C receptors were determined, showing in some cases an atypical antipsychotic
profile.
IT 861804-06-0P 861804-07-1P 861804-08-2P
861804-09-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, dopamine D2, serotonin 5-HT2A and 5HT2C binding affinities,
antipsychotic activity, and structure-activity relationship of aminoethyltetralones using amination and cyclization as the key steps)
RN 861804-06-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

L25 ANSWER 20 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861804-07-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-7-methoxy-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 861804-08-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 861804-09-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-7-methoxy-3-[2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



10590585.trn

L25 ANSWER 21 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2005:506114 Document No. 143:188544 Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. Du, Lue-Pei; Li, Min-Yong; Tsai, Keng-Chang; You, Qi-Dong; Xia, Lin (Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, Peop. Rep. China). Biochemical and Biophysical Research Communications, 332(3), 677-687 (English) 2005. CODEN: BBRCA9. ISSN: 0006-291X. Publisher: Elsevier.

AB This investigation was performed to assess the importance of interaction in the binding of blockers to KCNQ1 potassium using mol. modeling. This work could be considered made up by three main steps: (1) the construction of closed-state structure of KCNQ1 through homol. modeling; (2) the automated docking of three blockers: IKS-142, L-735821, and BMS-IKS, using DOCK program; (3) the generation and validation of pharmacophore for KCNQ1 ligands using Catalyst/HypoGen. The obtained results highlight the hydrophobic or aromatic residues involved in S6 transmembrane domain and the base of the pore helix of KCNQ1, confirming the mutagenesis data and pharmacophore model, and giving new suggestions for the rational design of novel KCNQ1 ligands.

IT 109132-88-9, SQ 23791
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(homol. modeling, mol. docking, and pharmacophore identification permit characterization of binding site of closed-state human KCNQ1 potassium channel)

RN 109132-88-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



L25 ANSWER 22 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2004:881223 Document No. 142:713960 Novel Mannich ketones of oxazolidinones as antibacterial agents. Srivastava, Brijesh Kumar; Kapadnis, Prashant B.; Pandya, Purvi; Lohray, Vidya Bhushan (Zydus Research Centre, Ahmedabad, Moraiya, 382210, India). European Journal of Medicinal Chemistry, 39(11), 989-992 (English) 2004. CODEN: EJMCA5. ISSN: 0223-5234. OTHER SOURCES: CASREACT 142:71396. Publisher: Elsevier Ltd..

GI



I

AB A few Mannich ketones of piperazinyl oxazolidinone derivs. were synthesized and their antibacterial activity in various Gram-pos. organisms, such as Bacillus subtilis, Staphylococcus aureus, Staphylococcus epidermidis, and Enterococcus faecalis were evaluated by MIC determination Compound I showed comparable activity to linezolid and superior to eperezolid.

IT 612055-27-3P 612055-28-4P 612055-32-0P
612056-68-5P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(novel Mannich ketones of oxazolidinones as antibacterial agents)

RN 612055-27-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 22 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 612055-28-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 612055-32-0 CAPLUS
CN Acetamide,
N-[[(5S)-3-[3-fluoro-4-[4-[(1,2,3,4-tetrahydro-4-methyl-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 612056-68-5 CAPLUS
CN Ethanethioamide,
N-[[(5S)-3-[3-fluoro-4-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 22 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



10590585.trn

L25 ANSWER 23 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2004:534173 Document No. 141:890160 Preparation of benzimidazolylazabicyclooctylethylpiperidines as Ccr5 antagonists for the treatment of HIV infection. Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph; Bifulco, Neil; Boros, Eric Eugene; Chauder, Brian Andrew; Chong, Pek Yoke; Duan, Maosheng; Deanda, Felix, Jr.; Koble, Cecilia Suarez; Mclean, Ed Williams; Peckham, Jennifer Poole; Perkins, Angilique C.; Thompson, James Benjamin; Vanderwall, Dana (Smithkline Beecham Corporation, USA; et al.; et al.). PCT Int. Appl. WO 2004054974 A2 20040701, 859 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US39644 20031212. PRIORITY: US 2002-433634P 20021213.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I [R1 = (optionally substituted) alkyl, aryl, heteroaryl, carbocyclyl; R2 = H, (optionally substituted) alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroarylalkyl, heteroarylcycloalkyl, aralkylcarbonyl, heteroarylsulfinyl; R3 = H, halo, cyano, trifluoromethyl, (optionally substituted) amino, acylamino, alkyl; X = C1-5 alkylene, optionally substituted with oxo or thioxo groups or halogen atoms, and optionally containing 1-3 oxygen, nitrogen, sulfur, or phosphorus atoms; Y = carbonyl, thiocarbonyl, 1,2-dioxoethylene, oxyalkylcarbonyl, sulfinyl, sulfonyl, oxycyanoimino, (optionally substituted) aminocarbonyl, carbonylamino, aminothiocarbonyl, oxyiminomethyl, thioiminomethyl, amino(cyanoimino)methyl, (cyanoimino)methyl, amino(acylimino)methyl, amino(sulfonylimino)methyl, amino(sulfinylimino)methyl, amino(alkoxyimino)methyl, amino(imino)methyl, (cyanoimino)methoxy, iminomethoxy, (cyanoimino)methanethiyl, alkylcarbonyloxy; A = saturated, partially saturated, or aromatic monocyclic ring with 5-6 atoms or a bicyclic ring with 8-10 members containing 0-5 nitrogen, oxygen, and/or sulfur atoms] such as II are prepared I are prepared as Ccr5 antagonists for the treatment of viral infections, (particularly HIV infection), related syndromes such as AIDS-related complex (ARC), progressive generalized lymphadenopathy, Kaposi's sarcoma, and neurol. conditions, and other diseases such as multiple sclerosis, rheumatoid arthritis, Crohn's disease, and immune-mediated disorders. The invention compds. have pIC50 values of ≥5 in assays for Ccr5 antagonism. Piperidineacetaldehyde III is prepared in four steps from 4-phenyl-4-piperidinecarbonitrile by protection of the piperidine with Boc

L25 ANSWER 23 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
anhydride, redn. of the nitrile with diisobutylaluminum hydride, Wittig olefination with methoxymethylphosphonium chloride, and hydrolysis of the enol ether with catalytic p-toluenesulfonic acid monohydrate. The hydrochloride of endo-(benzimidazolyl)azabicyclooctane IV is prepd. in five steps from tert-Bu endo-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate; reductive amination with benzylamine, reductive cleavage of the benzyl group by palladium-mediated hydrogenation, a nucleophilic aryl substitution reaction with 1-fluoro-2-nitrobenzene, redn. of the nitro group by hydrogenation over palladium on carbon, and treatment with tri-Et orthoacetate followed by treatment with hydrochloric acid in ethanol. Coupling of III and IV by reductive amination with sodium triacetoxyborohydride, cleavage of the Boc group with hydrochloric acid in dioxane, and acylation with pivaloyl chloride and triethylamine yields II.
IT 716354-57-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in treatment of bacterial and viral infections and other diseases)
RN 716354-57-3 CAPLUS
CN Methanone, [4-[2-[(3-endo)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-4-phenyl-1-piperidinyl](1,2,3,4-tetrahydro-6-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 24 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2004:263486 Document No. 140:417259 Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors. Leopoldo, Marcello; Berardi, Francesco; Colabufo, Nicola A.; Contino, Marialessandra; Lacivita, Enza; Perrone, Roberto; Tortorella, Vincenzo (Dipartimento Farmaco-Chimico, Universita degli Studi di Bari, Bari, 70125, Italy). Journal of Pharmacy and Pharmacology, 56(2), 247-255 (English) 2004. CODEN: JPPMAB. ISSN: 0022-3573. Publisher: Pharmaceutical Press.
AB Several 1-aryl-4-(2-arylethyl)piperazine derivs. were synthesized and tested in-vitro for their binding affinity for 5-HT7 and 5-HT1A receptors. These compds. displayed 5-HT7 receptor affinity ranging between Ki=474 nM and Ki=8.2 nM, besides high affinity for the 5-HT1A receptor. Intrinsic activity of the most potent compds. was assessed. 4-[2-(3-Methoxyphenyl)ethyl]-1-(2-methoxyphenyl)piperazine (16) and 1-(1,2-benzisoxazol-3-yl)-4-[2-(3-methoxyphenyl)ethyl]piperazine (20) (Ki=24.5 and 8.2 nM, resp.) behaved as partial agonist and full agonist, resp., when tested for 5-HT7 receptor-mediated relaxation of substance P-induced guinea-pig ileum contraction.
IT 201608-39-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arylpiperazine derivs. with affinity for rat 5-HT7 and 5-HT1A receptors)
RN 201608-39-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



L25 ANSWER 25 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2004:80449 Document No. 140:157927 Homology modeling of nuclear hormone receptor Site II and design of Site II ligands. Doweyko, Arthur; Nadler, Steven G. (Bristol-Myers Squibb Company, USA). PCT Int. Appl. WO 2004009016 A2 20040129, 276 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US22299 20030717. PRIORITY: US 2002-396907P 20020718.
AB A binding site in nuclear hormone receptors is described and its structural coordinates are provided. The invention provides machine-readable data storage media comprising structure coordinates of Site II and computer systems comprising the machine-readable data storage media. The invention provides methods used in the design and identification of ligands of Site II and of modulators of nuclear hormone receptors. The invention provides ligands of Site II, modulators of NHRs, pharmaceutical compns. comprising modulators of NHRs, methods of modulating NHRs, and methods of treating diseases by administering modulators of an NHR. Also provided are methods of designing mutants, mutant NHRs, Site II binding assays, and models of Site II.
IT 650625-50-6P
RL: CPS (Chemical process); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(homol. modeling of nuclear hormone receptor Site II in ligand binding domain and design of Site II ligands)
RN 650625-50-6 CAPLUS
CN Methanone, (9,10-dihydro-11-methyl-9,10-ethanoanthracen-11-yl)[4-(1-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)



10590585.trn

L25 ANSWER 26 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2004:51780 Document No. 140:2871550 Chemoenzymatic synthesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics. Caro, Yolanda; Torrado, Maria; Masaguer, Christian F.; Ravina, Enrique; Padin, Fernando; Brea, Jose; Loza, Maria I.
(Facultad de Farmacia, Laboratorio de Quimica Farmaceutica (Drug Research & Development Group), Departamento de Quimica Organica, Universidad de Santiago de Compostela, Santiago de Compostela, E-15782, Spain). Bioorganic & Medicinal Chemistry Letters, 14(3), 585-589 (English) 2004. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT 140:287155. Publisher: Elsevier Science B.V..
AB A series of (R)- and (S)-3-aminomethyl-1-tetralones, conformationally constrained analogs of haloperidol, have been obtained by enzymic resolution
of the corresponding racemic 3-hydroxymethyl-1-tetralones using Pseudomonas fluorescens lipase. Their binding affinities at dopamine D2 and serotonin 5-HT2A and 5-HT2C receptors were determined showing in some cases
an atypical antipsychotic profile with Meltzer's ratio higher than 1.30.
IT 133496-60-3P 676139-10-9P 676139-11-0P
676139-12-1P 676139-13-2P 676139-14-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(chemoenzymic synthesis of (R)- and (S)-3-aminomethyl-1-tetralones and their binding affinities at dopamine D2 and serotonin 5-HT2A and 5-HT2C
receptors)
RN 133496-60-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 676139-10-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



L25 ANSWER 26 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 676139-11-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6,7-dimethoxy-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 676139-12-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 676139-13-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-3-[[4-(2-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 676139-14-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6,7-dimethoxy-3-[[4-(2-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



L25 ANSWER 26 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

L25 ANSWER 27 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2003:981457 Document No. 140:2284530 Tetrahydronaphthalene-derived amino alcohols and amino ketones as potent and selective inhibitors of the delayed rectifier potassium current IKs. Ahmad, Saleem; Doweyko, Lidia; Ashfaq, Aaila; Ferrara, Francis N.; Bisaha, Sharon N.; Schmidt, Joan B.; DiMarco, John; Conder, Mary Lee; Jenkins-West, Tonya; Normandin, Diane E.;
Russell, Anita D.; Smith, Mark A.; Levesque, Paul C.; Lodge, Nicholas J.; Lloyd, John; Stein, Philip D.; Atwal, Karnail S. (Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543, USA). Bioorganic
& Medicinal Chemistry Letters, 14(1), 99-102 (English) 2004. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT 140:228453. Publisher:
Elsevier Science B.V..
AB Class III anti-arrhythmic drugs (e.g., dofetilide) prolong cardiac action potential duration (APD) by blocking the fast component of the delayed rectifier potassium current (IKr). The block of IKr can result in life threatening ventricular arrhythmias (i.e., torsades de pointes). Unlike IKr, the role of the slow component of the delayed rectifier potassium current (IKs) becomes significant only at faster heart rate. Therefore selective blockers of IKs could prolong APD with a reduced propensity to cause pro-arrhythmic side effects. This report describes structure-activity relationships (SARs) of a series of IKs inhibitors derived from 6-alkoxytetralones with good in vitro activity (IC50 ≥ 30 nM) and ≤40-fold IKs/IKr selectivity.
IT 667900-14-3P 667900-19-8P 667900-23-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(tetrahydronaphthalene-derived amino alcs. and amino ketones as potent and selective inhibitors of delayed rectifier potassium current IKs as class III antiarrhythmics)
RN 667900-14-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]-6-(phenylmethoxy)- (CA INDEX NAME)



RN 667900-19-8 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-(phenylmethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



L25 ANSWER 27 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 667900-23-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(phenylmethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



IT 212256-93-4P 212257-25-5P 212257-52-8P
212257-53-9P 212257-67-5P 667900-24-5P
667900-25-6P 667900-26-7P 667900-27-8P
667900-28-9P 667900-32-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetrahydronaphthalene-derived amino alcs. and amino ketones as potent and selective inhibitors of delayed rectifier potassium current IKs as class III antiarrhythmics)
RN 212256-93-4 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212257-25-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



L25 ANSWER 27 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-phenyl-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 667900-26-7 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 667900-27-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-(3-pyridinylmethoxy)- (CA INDEX NAME)



RN 667900-28-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-(4-pyridinylmethoxy)- (CA INDEX NAME)



RN 667900-32-5 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[2-(4-

L25 ANSWER 27 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212257-52-8 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-4-ylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-53-9 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-2-ylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-67-5 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-3-ylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 667900-24-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-phenoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 667900-25-6 CAPLUS

L25 ANSWER 27 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
phenyl-1-piperidinyl)ethyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 212256-71-8P 212259-30-8P 667900-15-4P
667900-16-5P 667900-17-6P 667900-18-7P
667900-20-1P 667900-21-2P 667900-22-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tetrahydronaphthalene-derived amino alcs. and amino ketones as potent and selective inhibitors of delayed rectifier potassium current IKs as class III antiarrhythmics)
RN 212256-71-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-30-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-hydroxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 667900-15-4 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-2-ylmethoxy)-3,4-dihydro-2-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 27 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 667900-16-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]-6-phenoxy- (CA INDEX NAME)



RN 667900-17-6 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]-6-phenyl- (CA INDEX NAME)



RN 667900-18-7 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 667900-20-1 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 28 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2003:876891 Document No. 139:3958940 Optimization of the Pharmacophore Model
for 5-HT7R Antagonism. Design and Synthesis of New Naphtholactam and Naphthosultam Derivatives. Lopez-Rodriguez, Maria L.; Porras, Esther; Morcillo, M. Jose; Benhamu, Bellinda; Soto, Luis J.; Lavandera, Jose L.; Ramos, Jose A.; Olivella, Mireia; Campillo, Mercedes; Pardo, Leonardo (Departamento de Quimica Organica I, Facultad de Ciencias Quimicas and Departamento de Bioquimica y Biologia Molecular III, Facultad de Medicina,
Universidad Complutense, Madrid, E-28040, Spain). Journal of Medicinal Chemistry, 46(26), 5638-5650 (English) 2003. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 139:395894. Publisher: American Chemical Society.
GI



I

AB An optimization of a preliminary pharmacophore model for 5-HT7R antagonism, with the incorporation of recently reported ligands and using an efficient procedure with the CATALYST program is reported. The model consists of five features: a pos. ionizable atom (PI), a H-bonding acceptor group (HBA), and three hydrophobic regions (HYD). This model has
been supported by the design, synthesis, and biol. evaluation of new naphtholactam and naphthosultam derivs. of general structure I (X = CO, SO2; Y = N, CH, C; n = 1, 3 - 6; R = H, Me, Me2CH, cyclohexyl, Ph, 2-MeOC6H4). A systematic structure-affinity relationship (SAFIR) study on
these analogs has allowed us to confirm that the model incorporates the essential structural features for 5-HT7R antagonism. In addition, computational simulation of the complex between I (X = CO; Y = N, n = 5; R
= Ph) and a rhodopsin-based 3D model of the 5-HT7R transmembrane domain has permitted us to define the mol. details of the ligand-receptor interaction and gives addnl. support to the proposed pharmacophore model for 5-HT7R antagonism: (i) the HBA feature of the pharmacophore model binds Ser5.42 and Thr5.43, (ii) the HYD1 feature interacts with Phe6.52, (iii) the PI feature forms an ionic interaction with Asp3.32, and (iv) the
HYD3 (AR) feature interacts with a set of aromatic residues (Phe3.28, Tyr7.43). These results provide the tools for the design and synthesis of
new ligands with predetd. affinities and pharmacol. properties.
IT 201608-39-1 201608-45-9 201608-78-8
201608-87-9 201608-88-0 201609-20-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(optimization of the pharmacophore model for serotoninergic 5-HT7

L25 ANSWER 27 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 667900-21-2 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-phenoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 667900-22-3 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-phenyl-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



L25 ANSWER 28 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
antagonists)
RN 201608-39-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-45-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 201608-78-8 CAPLUS
CN Benzonitrile, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



RN 201608-87-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



L25 ANSWER 28 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 201608-88-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[3-(4-phenyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 201609-20-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-pyridinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



L25 ANSWER 29 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2003:796700 Document No. 139:3077980 Preparation of 3-(4-piperazinophenyl) substituted oxazolidinones as novel antiinfective compounds and pharmaceutical compositions containing them. Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Srivastava, Brijesh Kumar (Cadila Healthcare Limited, India). PCT Int. Appl. WO 2003082864 A2 20031009, 78 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-IN81 20030326.
PRIORITY:
IN 2002-MU310 20020401.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Ar = (un)substituted Ph, 5-6 membered heteroaryl; R1, R2 = H, halo, alkyl, etc.; Y = II-IV (wherein R3, R4 = H, alkyl, halo, etc.; X = O, S, NR5; R5 = H, alkyl, aryl; A = (un)substituted (un)saturated single or fused ring optionally containing one or more heteroatoms selected from N, S, O; Z = H, alkyl, CN, etc.); W = OH, N3, NH2, NCS, etc.], useful for treating bacterial infections, psoriasis, arthritis, were prepared Thus, amidation of (S)-N-({3-[3-fluoro-4-(N-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl)acetamide with 3-(2-thienyl)acrylic acid afforded 53% (S)-V. The compds. I inhibited the growth of bacteria such as Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecalis with MIC's in a range of about 0.25 μg/mL to about 64 μg/mL. Pharmaceutical composition comprising the compound I is claimed.
IT 612055-27-3P 612055-28-4P 612055-31-9P
612055-32-0P 612056-68-5P 612056-70-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-piperazinophenyl) substituted oxazolidinones as novel antiinfective compds. and pharmaceutical compns. containing them)
RN 612055-27-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 29 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 612055-28-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 612055-31-9 CAPLUS
CN Acetamide,
N-[[(5S)-3-[3-fluoro-4-[4-[[1,2,3,4-tetrahydro-1-(hydroxyimino)-6-methoxy-2-naphthalenyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L25 ANSWER 29 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 612055-32-0 CAPLUS
CN Acetamide,
N-[[(5S)-3-[3-fluoro-4-[4-[(1,2,3,4-tetrahydro-4-methyl-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 612056-68-5 CAPLUS
CN Ethanethioamide,
N-[[(5S)-3-[3-fluoro-4-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 29 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 612056-70-9 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(1,2,3,4-tetrahydro-4-methyl-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 30 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2003:796468 Document No. 139:3076080 Preparation of sodium sulfamic acid salts as inhibitors of human cytoplasmic protein tyrosine phosphatases for the treatment of wounds and of damaged tissues. Sankar, Sabita; Raheja, Raj K.; Newman, Michael J.; Bhat, Abhijit S.; Slee, Deborah H.; Lee, Kyung Joo; Lee, Younghee N.; McConnell, Stephen J.; Coats, Eugene A.; Nguyen, Truc; Soll, Richard; Smith, Mark; Short, Kevin M.; Ligsay, Kathleen J. (Ontogen Corporation, USA; et al.). PCT Int. Appl. WO 2003082263 A1 20031009, 110 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US9750 20030328. PRIORITY: US 2002-368901P 20020329; US 2002-431950P 20021209.
GI



II

AB Sodium sulfamates (RY1)(R1Y1)(R2Y2)X-T-NHSO3-Na+ I [R, R1, R2 = H, (un)substituted alkyl, cycloalkyl, aralkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkylcarboxyalkyl, alkoxyalkyl, arylalkoxyalkyl, heteroarylalkoxyalkyl; R3, R7 = (un)substituted aralkyl, heteroaralkyl, alkyl; R4, R5, R6 = alkyl, aralkyl, heteroaralkyl, R7Y1; T = single bond, NH; X = (un)substituted Ph, pyridyl, pyrimidinyl, furyl, thienyl, indolyl, thiazolyl, imidazolyl, oxazolyl, isoxazolyl; Y1 = single bond, (un)substituted NHC(:O), NHC(:S), O(C:O), NHC(:O)NH, NHC(:S)NH, NHSO2, NHSO, O, NH; Y2 = (un)substituted NHC(:O), NHC(:S), O(C:O), NHC(:O)NH, NHC(:S)NH, NHSO2, NHSO, O, NH, O2CCH:CHY1, NHCOCH:CHY1, A(CH2)mY1] such as II are prepared as inhibitors of human cytoplasmic protein tyrosine phosphatase, an enzyme that impedes angiogenesis, for the treatment of wounds and diseased tissue by the acceleration of wound and injury repair; Et N- [4-(4-morpholinyl)phenyl]sulfamate is also claimed as a compound of the invention. Pharmaceutical compns. containing I are also claimed (no data). II is prepared by alkylation of 4-nitrophenylpiperazine with 3-fluorobenzyl bromide followed by reduction of the nitro group to an amino group (procedures but no prep. data given); treatment of the aniline with chlorosulfonic acid followed by deprotonation of the sulfamic acid with sodium carbonate yields II. Seventy-six example compds. inhibit human cytoplasmic protein tyrosine phosphatase (EC 3.1.3.2) with IC50 values between 0.06 μM and 61 μM. E.g., II inhibits human cytoplasmic protein tyrosine phosphatase with an IC50 value of 0.06 μM.

IT 611399-62-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediates; preparation of sodium sulfamates and a sulfamic acid ester as human cytoplasmic protein tyrosine phosphatase inhibitors for the treatment of wounds and tissue damage by accelerating wound and tissue repair)
RN 611399-62-3 CAPLUS
CN Methanone, [4-(4-aminophenyl)-1-piperazinyl](1,2,3,4-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)



IT 611397-82-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compds.; preparation of sodium sulfamates and a sulfamic acid ester as human cytoplasmic protein tyrosine phosphatase inhibitors for the treatment of wounds and tissue damage by accelerating wound and tissue repair)
RN 611397-82-1 CAPLUS
CN Sulfamic acid, N-[4-[4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)



IT 611401-03-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting materials; preparation of sodium sulfamates and a sulfamic acid ester as human cytoplasmic protein tyrosine phosphatase inhibitors for the treatment of wounds and tissue damage by accelerating wound and tissue repair)
RN 611401-03-7 CAPLUS
CN Methanone, [4-(4-nitrophenyl)-1-piperazinyl](1,2,3,4-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)

L25 ANSWER 30 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



10590585.trn

L25 ANSWER 31 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2003:511098 Document No. 139:853660 Preparation of N-(pyrimidin-4-yl)acetamides as A2b adenosine receptor selective antagonists. Castelhano, Arlindo; McKibben, Bryan; Steinig, Arno; Collington, Eric William (OSI Pharmaceuticals, Inc., USA). PCT Int. Appl.
WO 2003053366 A2 20030703, 150 pp. DESIGNATED STATES: W: AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.
APPLICATION: WO 2002-US41273 20021220. PRIORITY: US 2001-342595P 20011220.

GI



I



II

AB Title compds. I [wherein R1 = (un)substituted Ph, heterocyclyl, or heteroaryl; R2 and R3 = independently H or (un)substituted (cyclo)alkyl, alkanoyl, alkoxy(carbonyl), alkenyl, monocyclic or bicyclic aryl, heteroaryl, or heterocyclyl; or R2 and R3 are joined to form a heterocyclic ring; wherein the dashed line = a double bond which may be present or absent, and when present R3 = O; R4 and R5 = independently (un)substituted (cyclo)alkyl, alkanoyl, alkoxy(carbonyl), alkenyl, monocyclic or bicyclic aryl, heteroaryl, or heterocyclyl; or NR4R5 = (un)substituted monocyclic or bicyclyl, heterocyclyl, or heteroaryl; R12 =

L25 ANSWER 31 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
H, alkyl, halo, or cyano; n = 0-4; or enantiomers, tautomers, or pharmaceutically acceptable salts thereof] were prepd. as A2b adenosine receptor antagonists. For example, cycloaddn. of benzamidine•HCl and di-Et malonate using DBU in DMF gave 2-phenylpyrimidine-4,6-diol (73%). Chlorination (95%), amination (93%), substitution with N-(2-aminoethyl)acetamide (57%), and amidation with chloroacetyl chloride (91%) provided N-[6-(2-acetylaminoethylamino)-2-phenylpyrimidin-4-yl]-2-chloroacetamide. Coupling of the chloroacetamide with 4-(2-chlorophenoxy)piperidine in the presence of NaI and DIPEA in 3:1 acetonitrile:THF afforded II (86%). Compds. of the invention showed greater than tenfold selectivity for the human A2b adenosine receptor (Ki values <100 nM) over the A1, A2a, and A3 receptors in radioligand binding assays. Thus, I and pharmaceutical compns. comprising I are useful for the treatment of diseases assocd. with the A2b adenosine receptor, such as
asthma, diabetes, or proliferating tumors assocd. with mast cell degranulation (no data).

IT 552871-19-9P, N-[2-[[2-Phenyl-6-[4-[(1,2,3,4-tetrahydronaphthalen-2-yl)carbonyl]piperazin-1-yl]pyrimidin-4-yl]amino]ethyl]acetamide 552873-05-9P, N-[2-[[2-(4-Chlorophenyl)-6-[4-[(1,2,3,4-tetrahydronaphthalen-2-yl)carbonyl]piperazin-1-yl]pyrimidin-4-yl]amino]ethyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(A2b antagonist; preparation of N-(pyrimidinyl)acetamides as A2b adenosine
receptor selective antagonists for treatment of asthma, diabetes, tumors, and other A2b associated diseases)

RN 552871-19-9 CAPLUS
CN Acetamide, N-[2-[[2-phenyl-6-[4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1-piperazinyl]-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)



RN 552873-05-9 CAPLUS
CN Acetamide, N-[2-[[2-(4-chlorophenyl)-6-[4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1-piperazinyl]-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)

L25 ANSWER 31 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 32 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2003:362816 Document No. 139:301686 In vivo and in vitro pharmacological studies of a new hypotensive compound (QF0301B) in rat: Comparison with prazosin, a known α1-adrenoceptor antagonist. Orallo, Francisco; Garcia-Ferreiro, Tomas; Enguix, Maria Jose; Tristan, Helena; Masaguer, Cristian; Ravina, Enrique; Cadavid, Isabel; Loza, Maria Isabel (Department
of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain). Vascular Pharmacology,
40(2), 97-108 (English) 2003. CODEN: VPAHAJ. ISSN: 1537-1891.
Publisher: Elsevier Science Inc..

AB In this work, the authors studied the in vivo and in vitro pharmacol. effects of the novel compound QF0301B (2-[2-(N-4-o-methoxyphenyl-N-1-piperazinyl)ethyl]-1-tetralone) and compared with those of prazosin. In anesthetized normotensive rats, both QF0301B and prazosin (0.1-0.2 mg/kg i.v.) caused a pronounced and prolonged fall in mean arterial blood pressure accompanied by bradycardia.
Neither QF0301B nor prazosin (0.2 mg/kg iv) significantly modified the cardiovascular effects of either 5-hydroxytryptamine (serotonin, 5-HT, 75 μg/kg i.v.) or the selective α2-adrenoceptor agonist B-HT 920 (0.2 mg/kg i.v.), but both markedly inhibited the hypertensive effect of noradrenaline (5 μg/kg i.v.), a nonselective α-adrenergic receptor agonist. In isolated rubbed rat aorta rings, QF0301B and prazosin showed marked α1-adrenoceptor blocking activity, with pA2 values of 9.00±0.12 and 9.75±0.14, resp. In addition, QF0301B reversed and competitively antagonized the inhibitory action produced by clonidine in elec. stimulated rat vas deferens and inhibited the force and rate of contraction in rat isolated atria (pA2=5.91±0.43), competitively antagonized the contractile effect of 5-HT in rat aorta (pA2=6.75±0.06) and in rat stomach fundus (pA2=7.13±0.48) and the contractions induced by histamine in isolated guinea pig longitudinal ileal muscle (pA2=7.40±0.40). QF0301B showed noncompetitive low action in 5-HT3, muscarinic, and nicotinic receptors, or as Ca2+ antagonist. These results
indicate that a α1-adrenoceptor blocking lead was obtained with a new chemical structure and interesting pharmacol. properties, which only α1-adrenoceptor blocking activity seems to be responsible for its cardiovascular effects.

IT 149247-12-1
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new hypotensive compound QF0301B in comparison with prazosin in rats)

RN 149247-12-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



L25 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2003:173387 Document No. 138:2213680 Preparation of aryl tetrahydronaphthalene derivatives as inhibitors of P-glycoprotein-mediated transport. Melikian-Badalian, Anita (Avlan Limited, UK). PCT Int. Appl. WO 2003017948 A2 20030306, 48 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US27932 20020828. PRIORITY: US 2001-315880P 20010829.

GI



I

AB A new family of compds., particularly aryl 1,2,3,4-tetrahydronaphthalene derivs. of formula I [R1, R2 = alkoxy, heterocyclyl, etc.; R3-R8 = H, alkyl, alkoxy, Ph, OPh, benzyl, cycloalkyl, etc.], are prepared The compds. may be used as inhibitors of P-glycoprotein-mediated transport. Use of the compds. to enhance bioavailability and to modulate multi-drug resistance to chemotherapeutic agents is disclosed.

IT 500614-55-1P 500614-56-2P 500614-57-3P
500614-64-2P 500614-65-3P 500614-66-4P
500614-67-5P 500614-74-4P 500614-75-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl tetrahydronaphthalene derivs. as inhibitors of P-glycoprotein-mediated transport)

RN 500614-55-1 CAPLUS
CN Piperazine, 1,1'-[[1-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2,3-naphthalenediyl]dicarbonyl]bis[4-(2-ethoxyphenyl)- (9CI) (CA INDEX NAME)

L25 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 500614-56-2 CAPLUS
CN Piperazine, 1,1'-[[(1R,2R)-1-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2,3-naphthalenediyl]dicarbonyl]bis[4-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 500614-57-3 CAPLUS
CN Piperazine, 1,1'-[[(1R,2R)-1-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2,3-naphthalenediyl]dicarbonyl]bis[4-(2-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 500614-64-2 CAPLUS
CN Piperazine, 1,1'-[[(1R,2R)-1-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2,3-naphthalenediyl]dicarbonyl]bis[4-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 500614-65-3 CAPLUS
CN Piperazine, 1,1'-[[(1R,2R)-1-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2,3-naphthalenediyl]dicarbonyl]bis[4-(2-pyridinyl)-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 500614-66-4 CAPLUS
CN Piperazine,
1,1'-[[(1R,2S)-1-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2,3-naphthalenediyl]dicarbonyl]bis[4-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 500614-67-5 CAPLUS
CN Piperazine,
1,1'-[[(1R,2S)-1-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2,3-naphthalenediyl]dicarbonyl]bis[4-(2-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 500614-74-4 CAPLUS
CN Piperazine,
1,1'-[[(1R,2S)-1-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2,3-naphthalenediyl]dicarbonyl]bis[4-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 500614-75-5 CAPLUS
CN Piperazine,
1,1'-[[(1R,2S)-1-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2,3-naphthalenediyl]dicarbonyl]bis[4-(2-pyridinyl)-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L25 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

2002:335088 Document No. 137:631500

2a-[4-(Tetrahydropyridoindol-2-yl)butyl]tetrahydrobenzindole Derivatives: New Selective Antagonists of the 5-Hydroxytryptamine7 Receptor. Kikuchi, Chika; Ando, Takashi; Watanabe, Takashi; Nagaso, Hiroshi; Okuno, Masayo; Hiranuma, Toyokazu; Koyama, Masao (Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., Kohoku-ku, Yokohama, 222-8567, Japan). Journal of Medicinal Chemistry, 45(11), 2197-2206 (English) 2002. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 137:63150. Publisher: American Chemical Society.

GI



I

AB Tetrahydrobenzindoles were prepared and their affinity for the 5-hydroxytryptamine7 (5-HT7) receptor and other receptors was evaluated. Most of the compds. showed high affinity for the 5-HT7 receptor, and the [(tetrahydropyridoindolyl)butyl]tetrahydrobenzindoles I (R = H, MeO; R1 = H, Me, MeOCH2, Ac, allyl, Me2NCO, H2NCOCH2, Me2NCOCH2, MeNHCOCH2) exhibited high selectivity for this receptor. The nature of the substituent at C-9 of the tetrahydropyridindole ring affected the affinity for the 5-HT7 receptor and the C-9 carbamoyl substituent afforded increased selectivity. I (R = H; R1 = MeNHCOCH2) exhibited high affinity for the 5-HT7 receptor, with at least 280-fold selectivity over the 5-HT2 receptor. In a functional model of 5-HT7 receptor activation, this compound was confirmed to have 5-HT7 receptor antagonist activity. It should be a useful tool for clarifying the biol. role of the 5-HT7 receptor.

IT 201608-39-1P 201608-45-9P 201608-47-1P
201608-49-3P 201608-51-7P 201608-53-9P
201608-57-3P 201608-69-7P 201608-78-8P
201608-79-9P 201608-91-5P 201608-95-9P
201609-01-0P 201609-20-3P 201609-21-4P
439815-19-7P 439815-21-1P 439815-23-3P
439815-31-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of piperazinyl-, phenylpiperidinyl-, tetrahydropyridinyl-, and tetrahydropyridoindolylbutylbenzindoles with 5-hydroxytryptamine receptor antagonist activity)

RN 201608-39-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

L25 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 201608-45-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 201608-47-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-piperidinyl)butyl]- (CA INDEX NAME)



RN 201608-49-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(4-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-51-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methylphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

L25 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 201608-53-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(3-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-57-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2-chlorophenyl)-1-piperazinyl]butyl]-2a,3,4,5-tetrahydro- (CA INDEX NAME)



RN 201608-69-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2,6-dimethylphenyl)-1-piperazinyl]butyl]-2a,3,4,5-tetrahydro- (CA INDEX NAME)



RN 201608-78-8 CAPLUS
CN Benzonitrile, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



RN 201608-79-9 CAPLUS
CN Benzamide, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



RN 201608-91-5 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-hydroxy-4-phenyl-1-piperidinyl)butyl]- (CA INDEX NAME)



RN 201608-95-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-methoxy-4-phenyl-1-piperidinyl)butyl]- (CA INDEX NAME)



RN 439815-21-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-[2-(trifluoromethyl)phenyl]-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 439815-23-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-nitrophenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 439815-31-3 CAPLUS
CN 4-Piperidinecarboxamide, 4-phenyl-1-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]- (CA INDEX NAME)



IT 201608-44-8P 201608-46-0P 201608-68-6P
201608-77-7P 201608-80-2P 201608-94-8P
439815-14-2P 439815-15-3P 439815-16-4P



RN 201609-01-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-(4-acetyl-4-phenyl-1-piperidinyl)butyl]-2a,3,4,5-tetrahydro- (CA INDEX NAME)



RN 201609-20-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-pyridinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201609-21-4 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 439815-19-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2-acetylphenyl)-1-piperazinyl]butyl]-2a,3,4,5-tetrahydro- (CA INDEX NAME)

439815-17-5P 439815-20-0P 439815-22-2P
439815-24-4P 439815-25-5P 439815-27-7P
439815-28-8P 439815-30-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of piperazinyl-, phenylpiperidinyl-, tetrahydropyridinyl-, and tetrahydropyridoindolylbutylbenzindoles with 5-hydroxytryptamine receptor antagonist activity)

RN 201608-44-8 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-piperazinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 201608-46-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-piperidinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 201608-68-6 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2,6-dimethylphenyl)-1-piperazinyl]butyl]-2a,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 201608-77-7 CAPLUS
CN Benzonitrile, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-80-2 CAPLUS
CN Benzamide, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L25 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● 2 HCl

RN 439815-16-4 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(4-methoxyphenyl)-1-piperazinyl]butyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 439815-17-5 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2-chlorophenyl)-1-piperazinyl]butyl]-2a,3,4,5-tetrahydro-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 439815-20-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2-acetylphenyl)-1-piperazinyl]butyl]-2a,3,4,5-tetrahydro-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 201608-94-8 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-methoxy-4-phenyl-1-piperidinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 439815-14-2 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 439815-15-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(3-methoxyphenyl)-1-piperazinyl]butyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● 2 HCl

RN 439815-22-2 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-[2-(trifluoromethyl)phenyl]-1-piperazinyl]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 439815-24-4 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-nitrophenyl)-1-piperazinyl]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 439815-25-5 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methylphenyl)-1-piperazinyl]butyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 439815-27-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-pyridinyl)-1-piperazinyl]butyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 439815-28-8 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 439815-30-2 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-hydroxy-4-phenyl-1-piperidinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

L25 ANSWER 35 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

2001:886939 Document No. 136:1608570 New Serotonin 5-HT2A, 5-HT2B, and 5-HT2C Receptor Antagonists: Synthesis, Pharmacology, 3D-QSAR, and Molecular Modeling of (Aminoalkyl)benzo and Heterocycloalkanones. Brea, Jose; Rodrigo, Jordi; Carrieri, Antonio; Sanz, Ferran; Cadavid, M. Isabel; Enguix, Maria J.; Villazon, Maria; Mengod, Guadalupe; Caro, Yolanda; Masaguer, Christian F.; Ravina, Enrique; Centeno, Nuria B.; Carotti, Angelo; Loza, M. Isabel (Departamento de Farmacologia Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, E-15782, Spain). Journal of Medicinal Chemistry, 45(1), 54-71 (English) 2002. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 136:160857. Publisher: American Chemical Society.

AB A series of 52 conformationally constrained butyrophenones have been synthesized and pharmacol. tested as antagonists at 5-HT2A, 5-HT2B, and 5-HT2C serotonin receptors, useful for dissecting the role of each 5-HT2 subtype in pathophysiol. These compds. were also a consistent set for the identification of structural features relevant to receptor recognition and subtype discrimination. Six compds. were found highly active (pKi > 8.76) and selective at the 5-HT2A receptor vs. 5-HT2B and/or 5-HT2C receptors. Piperidine fragments confer high affinity at the 5-HT2A receptor subtype, with benzofuranone- and thiotetralonepiperidine as the most selective derivs. over 5-HT2C and 5-HT2B receptors, resp.; Ki 2A/2C and/or KB 2A/2B ratios greater than 100 were obtained. Compds. showing a more pronounced selectivity at 5-HT2A/5-HT2C than at 5-HT2A/5-HT2B bear 6-fluorobenzisoxazolyl- and p-fluorobenzoylpiperidine moieties containing one methylene bridging the basic piperidine to the alkanone moiety. An ethylene bridge between the alkanone and the amino moieties led to ligands with higher affinities for the 5-HT2B receptor. Significant selectivity at the 5-HT2B receptor vs. 5-HT2C was observed with 1-1[(1-oxo-1,2,3,4-tetrahydro-3-naphthyl)methyl]-4-[3-(p-fluorobenzoyl)propyl]piperazine (more than 100-fold higher). Although piperidine fragments also confer higher affinity at 5-HT2C receptors, only piperazine-containing ligands were selective over 5-HT2A. Moderate selectivity was observed at 5-HT2C vs. 5-HT2B (10-fold) with some compds. bearing a 4-[3-(6-fluorobenzisoxazolyl)]piperidine moiety in its structure. Mol. determinants for antagonists acting at 5-HT2A receptors were identified by 3D-QSAR (GRID-GOLPE) studies. Docking simulations at 5-HT2A and 5-HT2C receptors suggest a binding site for the studied type of antagonists (between transmembrane helixes 2, 3, and 7) different to that of the natural agonist serotonin (between 3, 5, and 6).

IT 133496-60-3 149247-12-1
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation, QSAR and mol. modeling of (aminoalkyl)benzo and heterocycloalkanones as serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonists)

RN 133496-60-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)

L25 ANSWER 35 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 149247-12-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



10590585.trn

L25 ANSWER 36 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2001:868447 Document No. 136:59170 Preparation of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors.
Astles, Peter C.; Eastwood, Paul R.; Houille, Olivier; Levell, Julian; Pauls, Heinz; Czekaj, Mark; Liang, Guyan; Gong, Yong; Pribish, James; Neuenschwander, Kent (Aventis Pharmaceuticals Products Inc., USA). PCT Int. Appl. WO 2001090101 A1 20011129, 267 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US13811 20010427. PRIORITY: GB 2000-12362 20000522; US 2001-843126 20010426.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Ar = (hetero)aryl, where the two groups on the Ar ring are β to each other; R1-2 = H, alkyl; R3 = (un)substituted(hetero)aryl, arylalkenyl, cycloalkenyl, cycloalkyl, etc.; R4 = H, acyl, alkoxy, alkyloxycarbonyl, carboxy, CN, halo, etc.; n = 0 - 4] were prepared Over 300 synthetic examples were disclosed. For instance, 3-bromobenzylbromide was converted in two steps to boronate II. II was coupled to the triflate ester derivative of the enol of 4-oxo-N-benzyloxycarbonylpiperidine (DMF, K2CO3, PdCl2(dppf)•CH2Cl2, 80°C, 18 h) to give the corresponding bicyclic intermediate. This intermediate was deprotected and reduced to the piperidine (EtOH, 10% Pd-C/H2, room temperature, 5 h) and coupled to 5-phenethylthiophene-2-carboxylic acid (DMF, HAPyU, iPr2NEt, room temperature, 18 h) to give III. III had Ki = 50 nM for tryptase. I are useful in the treatment of e.g., asthma and inflammatory diseases.
IT 375852-09-8P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
RN 375852-09-8 CAPLUS
CN Methanone, [4-[3-(aminomethyl)phenyl]-1-piperidinyl](1,2,3,4-tetrahydro-2-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 375852-08-7
CMF C23 H28 N2 O

L25 ANSWER 36 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L25 ANSWER 37 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2001:809680 Document No. 136:857980 trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: A New Class of Potent and Selective 5-HT1A Receptor Ligands as Conformationally Constrained Analogues of 4-[3-(5-Methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines. Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Leopoldo, Marcello; Lacivita, Enza; Tortorella, Vincenzo; Leonardi, Amedeo; Poggesi, Elena; Testa, Rodolfo (Dipartimento Farmaco-Chimico, Bari, 70126, Italy). Journal of Medicinal Chemistry, 44(25), 4431-4442 (English) 2001. CODEN: JMCMAR. ISSN: 0022-2623.
OTHER SOURCES: CASREACT 136:85798. Publisher: American Chemical Society.
AB The influence of conformational parameters on the recognition by rat 5-HT1A receptors of derivs. of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-(2-pyridinyl)piperazine (I) and 3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-N-[2-(2-pyridyloxy)ethyl]propanamine (II), two highly potent and selective 5-HT1A receptor ligands, is addressed. Fifteen flexible and rigid analogs were prepared following several synthetic routes and were tested in binding assays with radioligands at 5-HT1A, D2, and α1 receptors from rat brain membranes. Among the new derivs. trans-4-[4-(3-methoxyphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine (III) and trans-N-[4-(3-methoxyphenyl)cyclohexyl]-2-(2-pyridyloxy)ethylamine (IV) emerged as active compds. These compds. can be considered as conformationally constrained analogs of I and II, resp. In fact, III and IV showed a marked enhancement in 5-HT1A receptor affinity when compared to their cis isomers. Because III was a potent and selective 5-HT1A ligand (Ki, nM: 5-HT1A = 0.028, D2 = 2194, α1 = 767), it was chosen as a lead to prepare other analogs that were tested at 5-HT1A, D2, and α1 receptors from rat brain membranes, showing high affinity at the 5-HT1A and selectivity vs D2 and α1 receptors. Selected compds. were tested for their affinity at the human cloned 5-HT1A, α1a, α1b, α1d receptor subtypes. They were also submitted to the [35S]GTPγS binding assay stimulating the 5-HT1A receptor-mediated G-protein activation, therefore behaving as full or as partial agonists. Finally, the ability of iv administration of III to induce fore-paw treading in rats was evaluated in comparison with 8-OH-DPAT. Although the affinity (Ki) and in vitro activity (pD'2) of III at the 5-HT1A receptor were higher than those of 8-OH-DPAT, the compound was less potent than the reference standard in inducing the symptom.
IT 385811-17-6P 385811-22-3P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(trans-4-[4-(methoxyphenyl)cyclohexyl]-1-arylpiperazines as potent and selective 5-HT1A receptor agonists)
RN 385811-17-6 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]- (CA INDEX NAME)



L25 ANSWER 37 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 385811-22-3 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[2-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)ethyl]- (CA INDEX NAME)



10590585.trn

L25 ANSWER 38 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2001:521906 Document No. 135:1072590 Lactam derivatives as antiarrhythmic agents. Atwal, Karnail S.; Ahmad, Saleem; Ferrara, Francis N. (Bristol-Myers Squibb Co., USA). U.S. US 6262068 B1 20010717, 17 pp., Cont.-in-part of U.S. Ser. No. 8,948, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1999-231678 19990114. PRIORITY: US 1997-PV38895 19970221; US 1998-8948 19980120.
GI



I

AB Lactam derivs. I [X is C(O)NR3'; R1 = halo, alkyl, cycloalkyl, alkyl(cycloalkyl), aryl, (aryl)alkyl, (aryl)alkenyl, (aryl)alkynyl, O-alkyl, O-alkenyl, O-aryl, O-alky(aryl), O-alkyl(heterocyclo), etc.; R2 = H, alkyl, halo, aryl, (aryl)alkyl, O-alkyl, amino, substituted amino; R3 and R3' are the same or different and are independently selected from H, alkyl or alkyl(aryl); R4 which can be bonded to a ring carbon or nitrogen, is selected from hydrogen, alkyl, alkenyl, alky(aryl), alkyl(heterocyclo), cycloalkyl, alkyl(cycloalkyl), alkyl(amino), etc.; n is an integer of 0 to 2], useful in the treatment of arrhythmia (no data), were prepared. E.g., a multistep synthesis of 3,4-dihydro-6-methoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]-1(2H)-isoquinolinone monohydrochloride is described. The starting compound for the synthesis was 3,4-dihydro-6-methoxy-1(2H)-isoquinolinone.
IT 212256-36-5P 212256-47-8P 212257-79-9P
212257-80-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of lactam derivs. as antiarrhythmic agents)
RN 212256-36-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 38 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212256-47-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212257-79-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, oxime, (1Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 212257-80-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, oxime, (1E)- (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 38 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 39 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2001:29942 Document No. 134:231507 N-aryl- or N-alkylpiperazine derivatives: the role of N-substituent on σ1, σ2, 5-HT1A and D2 receptor affinity. Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Leopoldo, Marcello; Abate, Carmen; Tortorella, Vincenzo (Dipartimento Farmaco-Chimico, Bari, 70126, Italy). Medicinal Chemistry Research, 10(4), 201-207 (English) 2000. CODEN: MCREEB. ISSN: 1054-2523. Publisher: Birkhaeuser Boston.
AB The binding profile at σ1, σ2, 5-HT1A and D2 receptors of eight N-substituted-N'-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazines is reported. Results indicated that a suitable substitution can lead to potent 5-HT1A or σ1, or σ2 ligands.
IT 154744-86-2 330568-39-3
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(role of N-substituent of N-aryl- or N-alkylpiperazine derivs. on σ1, σ2, 5-HT1A and D2 receptor affinity)
RN 154744-86-2 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 330568-39-3 CAPLUS
CN Piperazine, 1-(1-naphthalenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 39 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 330568-38-2P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(role of N-substituent of N-aryl- or N-alkylpiperazine derivs. on σ1, σ2, 5-HT1A and D2 receptor affinity)
RN 330568-38-2 CAPLUS
CN Piperazine, 1-(3-chlorophenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



L25 ANSWER 40 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2000:855012 Document No. 134:162904 A simple, efficient method for regioselective synthesis of 7-aminomethyl-7,8-dihydro-6H-quinolin-5-ones, new potential CNS agents. Pita, B.; Masaguer, C. F.; Ravina, E. (Facultad de Farmacia, Laboratorio de Quimica Farmaceutica, Departamento de Quimica Organica, Universidad de Santiago de Compostela, Santiago de Compostela, 15706, Spain). Tetrahedron Letters, 41(50), 9829-9833 (English) 2000. CODEN: TELEAY. ISSN: 0040-4039. OTHER SOURCES: CASREACT 134:162904. Publisher: Elsevier Science Ltd..
AB An efficient and convenient strategy for the regioselective synthesis of new conformationally restricted butyrophenones of the quinoline series is presented. 7-(Aminomethyl)-7,8-dihydro-6H-quinolin-5-ones were obtained from 7-(methoxymethyl)-7,8-dihydro-6H-quinolin-5-one via the tosylate, and also in a 1-pot reaction via 7-(bromomethyl)-7,8-dihydro-6H-quinolin-5-one, with moderate-to-good overall yields in both cases.
IT 325489-07-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (aminomethyl)dihydroquinolinones)
RN 325489-07-4 CAPLUS
CN 5(6H)-Quinolinone, 7,8-dihydro-7-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



L25 ANSWER 41 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2000:608722 Document No. 133:1930790 Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix metalloprotease inhibitors. Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffery N.; De Crescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Hanson, Gunnar J.; Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Steve A.; Li, Hui; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.; Vernier, William F.; Villamil, Clara I.; Rao, Shashidahar N. (G.D. Searle and Co., USA). PCT Int. Appl. WO 2000050396 A1 20000831, 851 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US2518 20000222. PRIORITY: US 1999-256948 19990224.
GI



I

AB A process for treating conditions associated with pathol. matrix metalloproteinase (MMP) activity comprises administration of compds. having inhibitory activity against >1 of MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition of MMP-1. The compds. are of the form HONHCOCR1R2SO2R3 [R1, R2 = H; R1R2 = atoms to form a 5-8 membered ring containing 1-3 heteroatoms; R3 = (substituted) aryl, heteroaryl]. Thus, 4-PhOC6H4SH was heated in Me2SO to give the disulfide dimer, which in THF was added to a mixture of Et N-tert-butoxycarbonylisonipecotate (preparation given) and LDA in THF at -60° to room temperature to give 40% sulfide, which was oxidized with m-ClC6H4CO(OOH) to give 59% sulfone. The Et ester was saponified with NaOH in EtOH/H2O to give 100% acid, which in DMF was treated with hydroxybenzotriazole, EDC, 4-methylmorpholine, and aqueous NH2OH to give title compound I. I inhibited MMP-2 with IC50 = 0.2 nM. Pharmacol., pharmacokinetic, and toxicol. data are given for selected compds.
IT 226393-08-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonylheterocyclylhydroxamic acids and related compds.

L25 ANSWER 41 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
as matrix metalloprotease inhibitors)
RN 226393-08-4 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1-piperazinyl]phenyl]sulfonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 226393-07-3
CMF C27 H33 N3 O6 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L25 ANSWER 42 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2000:537881 Document No. 133:246811 GRid-INdependent Descriptors (GRIND): A Novel Class of Alignment-Independent Three-Dimensional Molecular Descriptors. Pastor, Manuel; Cruciani, Gabriele; McLay, Iain; Pickett, Stephen; Clementi, Sergio (Laboratory on Chemometrics Department of Chemistry, University of Perugia, Perugia, 06123, Italy). Journal of Medicinal Chemistry, 43(17), 3233-3243 (English) 2000. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

AB Traditional methods for performing 3D-QSAR rely upon an alignment step that is often time-consuming and can introduce user bias, the resultant model being dependent upon and sensitive to the alignment used. There are several methods which overcome this problem, but in general the necessary transformations prevent a simple interpretation of the resultant models in the original descriptor space (i.e. 3D mol. coordinates). Here we present a novel class of mol. descriptors which we have termed GRid-INdependent Descriptors (GRIND). They are derived in such a way as to be highly relevant for describing biol. properties of compds. while being alignment-independent, chemical interpretable, and easy to compute. GRIND are obtained starting from a set of mol. interaction fields, computed by the program GRID or by other programs. The procedure for computing the descriptors involves a first step, in which the fields are simplified, and a second step, in which the results are encoded into alignment-independent variables using a particular type of autocorrelation transform. The mol. descriptors so obtained can be used to obtain graphical diagrams called "correlograms" and can be used in different chemometric analyses, such as principal component anal. or partial least-squares. An important feature of GRIND is that, with the use of appropriate software, the original descriptors (mol. interaction fields) can be regenerated from the autocorrelation transform and, thus, the results of the anal. represented graphically, together with the original mol. structures, in 3D plots. In this respect, the article introduces the program ALMOND, a software package developed in our group for the computation, anal., and interpretation of GRIND. The use of the methodol. is illustrated using some examples from the field of 3D-QSAR. Highly predictive and interpretable models are obtained showing the promising potential of the novel descriptors in drug design.

IT 133496-60-3 149247-12-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GRid-Independent Descriptors (GRIND): novel class of alignment-independent three-dimensional mol. descriptors)

RN 133496-60-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)

L25 ANSWER 42 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 149247-12-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



L25 ANSWER 43 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2000:395917 Document No. 133:202604
1-Substituted-4-[3-(1,2,3,4-tetrahydro-5- or 7-methoxynaphthalen-1-yl)propyl]piperazines: influence of the N-1 piperazine substituent on 5-HT1A receptor affinity and selectivity versus D2 and α1 receptors. Part 6. Perrone, R.; Berardi, F.; Colabufo, N. A.; Leopoldo, M.; Tortorella, V. (Dipartimento Farmaco-Chimico, Universita degli Studi di Bari, Bari, 70126, Italy). Bioorganic & Medicinal Chemistry, 8(5), 873-881 (English) 2000. CODEN: BMECEP. ISSN: 0968-0896. Publisher: Elsevier Science Ltd..

AB In the present paper, we report the synthesis and the binding profiles on 5-HT1A, D2, and α1 receptors of 1-substituted-4-[3-(5- or 7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine derivs. and some related heteroalkyl derivs. The results obtained are compared to those previously reported for the 1-Ph, 1-(2-methoxyphenyl), 1-(2-pyridyl) analogs. The results pointed out the critical role of the group linked in the N-1 position of the piperazine in terms of 5-HT1A binding affinity. In fact, 1-cyclohexyl, 1-(3-benzisoxazolyl), 1-(benzothiazole-2-carbonyl), 1-(2-benzothiazolyl), 1-(2-quinolyl) substituted piperazines displayed moderate or low 5-HT1A receptor affinity; on the contrary, 1-(3-benzisothiazolyl) and 1-(1-naphthalenyl) substituted piperazines displayed high 5-HT1A receptor affinity, the Ki values being in the subnanomolar range. Furthermore, three compds. demonstrated better selectivity over α1 receptors than the reference compds.

IT 154744-84-0P 154744-86-2P 154744-87-3P
154744-88-4P 154744-89-5P 184346-64-3P
290370-34-2P 290370-35-3P 290370-37-5P
290370-38-6P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(substituent on 5-HT1A receptor affinity and selectivity vs. D2 and α1 receptors of arylpiperazine deriv)

RN 154744-84-0 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 43 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 154744-86-2 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 154744-87-3 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 43 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 154744-88-4 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 154744-89-5 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 43 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 184346-64-3 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 290370-34-2 CAPLUS
CN Quinoline, 2-[4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 43 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● 2 HCl

RN 290370-35-3 CAPLUS
CN Quinoline, 2-[4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-1-piperazinyl]-, hydrochloride, hydrate (1:2:1) (CA INDEX NAME)



● 2 HCl

● H_2O

RN 290370-37-5 CAPLUS
CN Piperazine, 1-(1-naphthalenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 43 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 290370-38-6 CAPLUS
CN Piperazine, 1-(1-naphthalenyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

10590585.trn

L25 ANSWER 44 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2000:379675 Document No. 133:159635 First pharmacophoric hypothesis for 5-HT7 antagonism. Lopez-Rodriguez, Maria L.; Porras, Esther; Benhamu, Bellinda; Ramos, Jose A.; Morcillo, M. Jose; Lavandera, Jose L. (Departamento de Quimica Organica I, Facultad de Ciencias Quimicas, Universidad Complutense, Madrid, E-28040, Spain). Bioorganic & Medicinal Chemistry Letters, 10(10), 1097-1100 (English) 2000. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier Science Ltd..

AB In order to make the first contribution to the elucidation of essential structural features for 5-HT7 antagonism, a set of 30 5-HT7 antagonists were selected from the literature. A pharmacophore model was built using mol. modeling studies with Catalyst program. The information contained in this model was validated with newly synthesized compds.

IT 201608-39-1 201608-45-9 201608-78-8
201608-87-9 201608-88-0 201609-20-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (pharmacophoric hypothesis for 5-HT7 antagonism)

RN 201608-39-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-45-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 201608-78-8 CAPLUS
CN Benzonitrile, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)

L25 ANSWER 44 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 201608-87-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 201608-88-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[3-(4-phenyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 201609-20-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-pyridinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



L25 ANSWER 45 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
2000:335384 Document No. 132:3474900 Preparation of piperidines as ORL-1 receptor ligands.. Barlocco, Daniela; Cignarella, Giorgio; Giardina, Guiseppe Arnaldo Maria; Grugni, Mario; Ronzoni, Silvano (Smithkline Beecham Spa, Italy). PCT Int. Appl. WO 2000027815 A2 20000518, 75 pp. DESIGNATED STATES: W: CA, JP, US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP8706 19991110. PRIORITY: IT 1998-MI2442 19981111.

GI

AB Title compds. [I; X, Y = H, (substituted) aryl; m, n = 0-3, provided that m and n are not both 0; A = bond, (CR1R2)p; p = 1-3; R1, R2 = H, halo, (substituted) alkyl, alkoxy; B = C4-8 (unsatd.) (substituted) ring], were prepared Thus, 2,3-dihydro-2-[(4-phenylpiperidin-1-yl)carbonyl]-1H-indene was stirred with LiAlH4 in THF to give 2,3-dihydro-2-[(4-phenylpiperidin-1-yl)methyl]-1H-indene. The most potent I showed ORL-1 binding with Ki = 1-1000 nM.

IT 69797-43-9P 109132-90-3P 126684-43-3P
269084-27-7P 269084-28-8P 269084-29-9P
269084-30-2P 269084-87-9P 269084-88-0P
269084-89-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of piperidines as ORL-1 receptor ligands)

RN 69797-43-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 109132-90-3 CAPLUS
CN Piperidine, 4-phenyl-1-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (CA INDEX NAME)

L25 ANSWER 45 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 126684-43-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



RN 269084-27-7 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-3-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



RN 269084-28-8 CAPLUS
CN Piperidine, 4-phenyl-1-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 269084-29-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 45 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 269084-30-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 269084-87-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 269084-88-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 45 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 269084-15-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)carbonyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 269084-16-4 CAPLUS
CN Methanone, (4-phenyl-1-piperidinyl)(1,2,3,4-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)



RN 269084-17-5 CAPLUS
CN 4(1H)-Phenanthrenone, 2,3-dihydro-2-[(4-phenyl-1-piperidinyl)carbonyl]- (CA INDEX NAME)



L25 ANSWER 45 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 269084-89-1 CAPLUS
CN 4(1H)-Phenanthrenone, 2,3-dihydro-2-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



IT 269084-13-1P 269084-14-2P 269084-15-3P
269084-16-4P 269084-17-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidines as ORL-1 receptor ligands)

RN 269084-13-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)carbonyl]- (CA INDEX NAME)



RN 269084-14-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)carbonyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 46 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

2000:210150 Document No. 132:2510670 Novel amidine derivatives, their preparation and application as inhibitors of NO synthase and lipid peroxidation, and pharmaceutical compositions containing them. Auvin, Serge; Chabrier de Lassauniere, Pierre-Etienne; Harnett, Jeremiah; Pons, Dominique; Ulibarri, Gerard (Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.). PCT Int. Appl. WO 2000017190 A2 20000330, 119 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (French). CODEN: PIXXD2. APPLICATION: WO 1999-FR2250 19990922. PRIORITY: FR 1998-11868 19980923.

GI



I



II

AB The invention concerns novel amidine derivs., including compds. I [R = H, alkyl, alkoxy; A = certain substituted aryl or (un)substituted heteroaryl groups; B = alkyl, (un)substituted aryl or heteroaryl, (un)substituted or heterocyclic amino; X = bond, (CH2)m, O(CH2)m, (CH2)mO, S(CH2)m, O(CH2)mCO, CH:CH, etc.; Y = bond, (CH2)n, (CH2)rQ(CH2)s; Q = piperazine, homopiperazine, piperidine, pyrrolidine, azetidine, thiazolidine, saturated C3-7 carbocycles, etc; Z = bond, (CH2)pO(CH2)q, (CH2)pS(CH2)q, (CH2)pNH(CH2)q, etc; m, n, p, q, r, s = 0-6], as well as addnl. specific compds. In particular, 2-hydroxy-5-methoxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide (II) and 2,5-dihydroxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide are disclosed. Also disclosed are the use of I as medicines, and pharmaceutical compns. containing them. For instance, amidation of 5-methoxysalicylic acid with 4-nitrophenethylamine-HCl, followed by hydrogenation of the nitro group to amino, condensation of the amine with

L25 ANSWER 46 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
S-methyl-2-thiophenethiocarboximide-HI, and acidification in acetone, gave
II.HCl. The IC50 of selected I, including II.HCl, against rat neuronal NO
synthase in vitro, was < 3.5 μM.
IT 262613-20-7P 262614-14-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of amidine derivs. as inhibitors of NO synthase
and/or lipid peroxidn.)
RN 262613-20-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1-piperazinyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 262614-14-2 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)



L25 ANSWER 47 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1999:815373 Document No. 132:165762 A structure-affinity relationship study on derivatives of N-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a high-affinity and selective D4 receptor ligand.
Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Leopoldo, Marcello; Tortorella, Vincenzo (Dipartimento Farmaco-Chimico, Universita di Bari, Bari, 70126, Italy). Journal of Medicinal Chemistry, 43(2), 270-277 (English) 2000. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.
AB N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a high-affinity and selective dopamine D4 receptor ligand, was chosen as a lead, and structural modifications were done on its amide bond and on its alkyl chain linking the benzamide moiety to the piperazine ring and by preparing some semirigid analogs. The binding profile at dopamine D4 and dopamine D2, serotonin 5-HT1A, and adrenergic α1 receptors of 16 new compds. was determined From the results emerged that the modification of the
amide bond and the elongation of the intermediate alkyl chain caused a decrease in dopamine D4 receptor affinity. All prepared semirigid analogs
displayed D4 receptor affinity values in the same range of the opened counterparts.
IT 258882-67-6P 258882-68-7P 258882-79-0P
258882-80-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of derivs. of [[(chlorophenyl)piperazinyl]ethyl]methoxybenzamid
e as selective D4 receptor ligand)
RN 258882-67-6 CAPLUS
CN Piperazine, 1-(4-chlorophenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 47 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 258882-68-7 CAPLUS
CN Piperazine, 1-(4-chlorophenyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 258882-79-0 CAPLUS
CN Piperazine, 1-(4-chlorophenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 47 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● 2 HCl

RN 258882-80-3 CAPLUS
CN Piperazine, 1-(4-chlorophenyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

10590585.trn

L25 ANSWER 48 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1999:691080 Document No. 131:2994660 Preparation of optically active tetrahydrobenzindole derivatives having affinity to 5-HT7 receptor.
Koyama, Masao; Ushiroda, Osamu; Kikuchi, Chika; Ando, Takashi; Sato, Eriko; Okuno, Masayo; Hiranuma, Toyokazu (Meiji Seika Kaisha, Ltd., Japan). PCT Int. Appl. WO 9954303 A1 19991028, 56 pp. DESIGNATED STATES:
W: CA, CN, JP, KR, NO, US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2.
APPLICATION:
WO 1999-JP2127 19990421. PRIORITY: JP 1998-111833 19980422.
GI


I





AB Title compds. I (R1, R3 = H, halo, alkyl, etc.; R2, R4 = H, alkyl, aralkyl; n = 2, 3, 4; D = Q1, Q2, etc; E1 = a group forming a benzene ring, etc.; A = N, CH, etc.; X = O, S, etc.; dotted line = optional double bond) and their pharmaceutically acceptable salts, useful in the treatment or prevention of mental diseases, are prepared Thus, reaction of (S)-2a-(4-bromobutyl)-2a,3,4,5-tetrahydro-1H-benz[cd]indol-2-one with 1,2,3,4-tetrahydroisoquinoline in DMF in the presence of K2CO3 gave 100% (S)-2a-[4-(1,2,3,4-tetrahydroisoquinolin-2-yl)butyl]-2a,3,4,5-tetrahydro-1H-benz[cd]indol-2-one (II). In tests for affinity for 5-HT7 receptor, II had a Ki value of 7.7 nM.
IT 247082-14-0P

L25 ANSWER 48 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of optically active tetrahydrobenzindole derivs. having affinity to 5-HT7 receptor)
RN 247082-14-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[5-[4-(2-methoxyphenyl)-1-piperazinyl]pentyl]-, (2aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 247082-15-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of optically active tetrahydrobenzindole derivs. having affinity to 5-HT7 receptor)
RN 247082-15-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[5-[4-(2-methoxyphenyl)-1-piperazinyl]pentyl]-, hydrochloride (1:1), (2aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L25 ANSWER 49 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1999:350651 Document No. 131:189290 Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix metalloprotease inhibitors. Barta, Thomas E.; Becker, Daniel P.; Boehm, Terri L.; De Crescenzo, Gary A.; Villamil, Clara I.; McDonald, Joseph J.; Freskos, John N.; Getman, Daniel P. (G.D. Searle and Co., USA). PCT Int. Appl. WO 9925687 A1 19990527, 840 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US23242 19981112. PRIORITY: US 1997-66007 19971114.
GI


I

AB A process for treating conditions associated with pathol. matrix metalloproteinase (MMP) activity comprises administration of compds. having inhibitory activity against >1 of MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition of MMP-1. The compds. are of the form HONHCOCR1R2SO2R3 [R1, R2 = H; R1R2 = atoms to form a 5-8 membered ring containing 1-3 heteroatoms; R3 = (substituted) aryl, heteroaryl]. Thus, 4-PhOC6H4SH was heated in Me2SO to give the disulfide dimer, which in THF was added to a mixture of Et N-tert-butoxycarbonylisonipecotate (preparation given) and LDA in THF at -60° to room temperature to give 405 sulfide, which was oxidized with m-ClC6H4CO(OOH) to give 59% sulfone. The Et ester was saponified with NaOH in EtOH/H2O to give 100% acid, which in DMF was treated with hydroxybenzotriazole, EDC, 4-methylmorpholine, and aqueous NH2OH to give title compound (I). I inhibited MMP-2 with IC50 = 0.2 nM.
IT 226393-08-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonylheterocyclylhydroxamic acids and related compds. as matrix metalloprotease inhibitors)
RN 226393-08-4 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1-piperazinyl]phenyl]sulfonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

L25 ANSWER 49 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 1

CRN 226393-07-3
CMF C27 H33 N3 O6 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

10590585.trn

L25 ANSWER 50 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1999:65930 Document No. 130:276228 Tetrahydrobenzindoles: Selective Antagonists of the 5-HT7 Receptor. Kikuchi, Chika; Nagaso, Hiroshi; Hiranuma, Toyokazu; Koyama, Masao (Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., Yokohama, 222-8567, Japan). Journal of Medicinal Chemistry, 42(4), 533-535 (English) 1999. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

AB A novel series of tetrahydrobenzindoles was synthesized and tested for affinity towards 5-HT7 and other receptors. Some of the compds. showed high affinity and high selectivity for the 5-HT7 receptor. 2A-[4-(4-Phenyl-1,2,3,6-tetrahydropyridyl)butyl]-2a,3,4,5-tetrahydrobenzo[cd]indol-2(1H)one (I) was a highly potent ligand for the 5-HT7 receptor, with at least 47-fold selectivity over the 5-HT2 receptor and other receptors. A limited structure-activity relationship study for these derivs. indicated that an aromatic ring is required for affinity for the 5-HT7 and 5-HT2 receptors. I was evaluated in a functional model of the 5-HT7 receptor activation and confirmed to be a 5-HT7 receptor antagonist.

IT 201608-39-1 201608-45-9 201608-78-8
201608-87-9 201608-88-0 201609-20-3
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation and structure activity of tetrahydrobenzindoles and towards 5-HT7 receptor antagonist activity)

RN 201608-39-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-45-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-piperazinyl)butyl]- (CA INDEX NAME)



L25 ANSWER 50 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 50 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 201608-78-8 CAPLUS
CN Benzonitrile, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



RN 201608-87-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 201608-88-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[3-(4-phenyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 201609-20-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-pyridinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

L25 ANSWER 51 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1999:59416 Document No. 130:196622
1-Aryl-4-[(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)alkyl]piperazines and Their Analogs: Influence of the Stereochemistry of the Tetrahydronaphthalen-1-yl Nucleus on 5-HT1A Receptor Affinity and Selectivity versus α1 and D2 Receptors. 5. Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Leopoldo, Marcello; Tortorella, Vincenzo (Dipartimento Farmaco-Chimico, Universita di Bari, Bari, 70126, Italy). Journal of Medicinal Chemistry, 42(3), 490-496 (English) 1999. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

AB Some 1-aryl-4-[(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazines and their alkylamino and alkylamido analogs, previously studied as 5-HT1A ligands, were prepared in enantiomerically pure form, and their absolute configuration was determined by chemical correlation or by chiroptical properties. They were evaluated for in vitro 5-HT1A, D2, and α1 receptor affinity by radioligand binding assays, to study the influence of the chiral carbon atom of the tetrahydronaphthalene nucleus on the 5-HT1A affinity and selectivity. Results indicated that, as regarding the 5-HT1A receptor affinity, there was no difference in affinity between (-)- and (+)-enantiomers as well as the racemate of each compound The stereochem., instead, influenced the selectivity: all (-)-enantiomers displayed affinity values higher than those of (+)-isomers at D2 receptors, and conversely, all (+)-enantiomers displayed affinity values higher than those of (-)-isomers at α1 receptors. As a result of this trend, it is not possible to predict the isomer with the better selectivity profile. However, (+)-isomers displayed high affinity for the 5-HT1A receptor (IC50 2,3-7.0 nM) and good selectivity (≥250-fold) vs. both D2 and α1 receptors. Furthermore, (S)-(+)- and (R)-(-)-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]1-1(2-pyridyl)piperazine were submitted to the [35S]GTPγS binding assay for a preliminary evaluation of their intrinsic activity on the 5-HT1A receptor.

IT 220832-25-7P 220832-26-8P 220832-27-9P
220832-28-0P 220832-29-1P 220832-30-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(aryl(methoxytetrahydronaphthyl)alkylpiperazines and their 5-HT1A receptor affinity and selectivity vs. α1 and D2 receptors)

RN 220832-25-7 CAPLUS
CN Piperazine, 1-phenyl-4-[3-[(1R)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L25 ANSWER 51 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 220832-26-8 CAPLUS
CN Piperazine, 1-phenyl-4-[3-[(1S)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

RN 220832-27-9 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-[(1R)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L25 ANSWER 51 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

Absolute stereochemistry. Rotation (-).



●2 HCl

RN 220832-30-4 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-[(1S)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

IT 220831-82-3P 220831-84-5P 220831-86-7P
220831-88-9P 220831-90-3P 220831-92-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aryl(methoxytetrahydronaphthyl)alkylpiperazines and their 5-HT1A receptor affinity and selectivity vs. α1 and D2 receptors)

L25 ANSWER 51 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 220832-28-0 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-[(1S)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

RN 220832-29-1 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-[(1R)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 51 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 220831-82-3 CAPLUS
CN Piperazine, 1-phenyl-4-[3-[(1S)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 220831-84-5 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-[(1S)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 220831-86-7 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-[(1S)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L25 ANSWER 51 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 220831-88-9 CAPLUS
CN Piperazine, 1-phenyl-4-[3-[(1R)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220831-90-3 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-[(1R)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L25 ANSWER 51 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 220831-92-5 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-[(1R)-1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L25 ANSWER 52 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1998:703905 Document No. 130:90062
N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: A Potent and Selective Dopamine D4 Ligand. Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Leopoldo, Marcello; Tortorella, Vincenzo (Dipartimento Farmaco-Chimico, Universita di Bari, Bari, 70126, Italy). Journal of Medicinal Chemistry, 41(24), 4903-4909 (English) 1998. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

AB A series of new 1-aryl-4-alkylpiperazines containing a terminal benzamide fragment or a tetralin-1-yl nucleus on the alkyl chain were synthesized and tested for binding at cloned human dopamine D4 and D2 receptor subtypes. A SAFIR (structure-affinity relationship) study on this series is herein discussed. The most relevant D4 receptor affinities were displayed by N-[ω-[4-arylpiperazin-1-yl]alkyl]-methoxybenzamides, their IC50 values ranging between 0.057 and 7.8 nM. Among these, N-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide (I) emerged since it exhibited very high affinity for dopamine D4 receptor (IC50 = 0.057 nM) with selectivity of >10 000 for the D4 vs. the D2 receptor; compound I was also selective vs. serotonin 5-HT1A and adrenergic α1 receptors.

IT 154744-84-0 154744-87-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(preparation of piperazinyl benzamides as dopamine D4 ligands and potential antipsychotics)

RN 154744-84-0 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 154744-87-3 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 52 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



10590585.trn

L25 ANSWER 53 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1998:608594 Document No. 129:2164280 Original Reference No. 129:43999a,44002a Preparation of 2-aminoalkylteralines as amyloid-β production inhibitors. Kato, Kaneyoshi; Terauchi, Jun; Fukumoto, Hiroaki;
Kakihana, Mitsuru (Takeda Chemical Industries, Ltd., Japan). PCT Int. Appl. WO 9838156 A1 19980903, 238 pp. DESIGNATED STATES: W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-JP780 19980226. PRIORITY: JP 1997-43940 19970227; JP 1997-193497 19970718.
GI



I



II

AB The title compds. [I; Ar = (un)substituted aromatic ring, fused aromatic group;
X = a bond, S, SO, SO2, etc.; Y = (un)substituted divalent C1-6 aliphatic hydrocarbon group optionally containing O or S; R1, R2 = H, lower alkyl; NR1R2
= (un)substituted N-containing heterocyclic ring; Ring A = (un)substituted
benzene; Ring B = (un)substituted 4-8 membered ring] and their salts, which have the effect of inhibiting amyloid-β protein production and/or secretion and are useful for preventing and/or treating the neurodegenerative disease such as Alzheimer's disease, were prepared and formulated. Thus, treatment of [6-(4-biphenylyl)methoxy-2-tetralin]-N,N-dimethylacetamide with LiAlH4 in THF afforded II.HCl which showed 74% and 75% inhibition of the production and/or secretion of Aβ1-40 and Aβ1-42, resp.
IT 212571-19-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L25 ANSWER 53 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-aminoalkyltetralines as amyloid-β prodn. inhibitors)
RN 212571-19-2 CAPLUS
CN Piperidine, 4-phenyl-1-[2-[1,2,3,4-tetrahydro-6-(2-naphthalenylmethoxy)-2-naphthalenyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



L25 ANSWER 54 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1998:606943 Document No. 129:312907 Original Reference No. 129:63785a,63788a
Synthesis and biodistribution of (R,S)-[O-methyl-11C]-1-[3-(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-4-phenylpiperazine (PNU-157760),
a putative radioligand for 5-HT1A receptors. Matarrese, Mario; Soloviev, Dmitrij V.; Moresco, Rosa M.; Ferri, Valentino; Simonelli, Pasquale; Magni, Fulvio; Colombo, Diego; Todde, Sergio; Carpinelli, Assunta; Fazio, Ferruccio; Kienle, Marzia Galli (CNR INB, Institute H. S. Raffaele, University of Milan, Milan, Italy). Bioorganic Chemistry, 26(2), 91-102 (English) 1998. CODEN: BOCMBM. ISSN: 0045-2068. Publisher: Academic Press.
AB Racemic 1-[3-(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-4-phenylpiperazine (PNU-157760) was labeled with carbon-11 (t1/2 = 20.4 min)
as a putative radioligand for the noninvasive assessment of 5-HT1A receptors in vivo with positron emission tomog. (PET). The radiochem. synthesis consisted of O-methylation of desmethyl precursor with [11C]methyliodide in the presence of potassium tert-butoxide in DMF. The desmethyl precursor for the radiosynthesis of [11C]PNU-157760, was prepared
by a convenient one-step demethylation of PNU-157760 with boron tribromide. (R,S)-[O-Methyl-11C]-1-[3-(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-4-phenylpiperazine with >99% radiochem. purity was obtained in 30 min with a radiochem. yield of 10 ± 5% (EOS, nondecay corrected) and a specific radioactivity of 2.5 ± 1 Ci/μmol. Biodistribution studies in rats showed that [11C]PNU-157760 readily crosses the blood-brain barrier with a maximum of brain uptake at 30 min after injection; however, the low specific-to-nonspecific binding ratio in
vivo as evidenced by the low hippocampus/cerebellum uptake ratio (1.17 at 60 min postinjection) does not make [11C]PNU-157760 a promising radioligand for serotonin 5-HT1A receptors. (c) 1998 Academic Press.
IT 214957-40-1P
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC
(Process)
(synthesis and biodistribution of (R,S)-[O-methyl-11C]-1-[3-(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-4-phenylpiperazine, a putative radioligand for 5-HT1A receptors)
RN 214957-40-1 CAPLUS
CN Piperazine, 1-phenyl-4-[3-[1,2,3,4-tetrahydro-5-(methoxy-11C)-1-naphthalenyl]propyl]- (9CI) (CA INDEX NAME)

L25 ANSWER 54 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 161923-88-2, PNU 157760
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and biodistribution of (R,S)-[O-methyl-11C]-1-[3-(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-4-phenylpiperazine, a putative radioligand for 5-HT1A receptors)
RN 161923-88-2 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

IT 214957-39-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and biodistribution of (R,S)-[O-methyl-11C]-1-[3-(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-4-phenylpiperazine, a putative radioligand for 5-HT1A receptors)
RN 214957-39-8 CAPLUS
CN 1-Naphthalenol, 5,6,7,8-tetrahydro-5-[3-(4-phenyl-1-piperazinyl)propyl]-

L25 ANSWER 54 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
(CA INDEX NAME)



L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1998:603193 Document No. 129:2164200 Original Reference No. 129:43995a,43998a Preparation of tetralone derivatives as antiarrhythmic agents. Ahmad, Saleem; Stein, Philip D.; Ferrara, Francis N.; Atwal, Karnail S. (Bristol-Myers Squibb Co., USA). PCT Int. Appl. WO 9836749 A1 19980827, 204 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US2338 19980207.
PRIORITY: US 1997-38917 19970221.
GI



AB The title compds. [I; R1 = halo, alkyl, alkenyl, etc.; R2 = H, alkyl, halo, etc.; R3 = O, OH, alkoxy, etc.; R4 = H, alkyl, alkyl(COalkyl), alkyl(COOalkyl); R3R4 taken together with the atoms to which they are attached form a 5-7 membered ring containing up to three heteroatoms selected from O, N and S; R5 = H, alkyl, alkenyl, etc.; n = 0-2], useful in the treatment of arrhythmia, were prepared Thus, treatment of 6-methoxytetralone with paraformaldehyde and N-methylanilinium trifluoroacetate in THF followed by reaction of the resulting 2-methylene-6-methoxy-1-tetralone with 4-phenylpiperidine over alumina in PhMe afforded the title compound II. Compds. I are effective at 0.001-10 mg/kg/day.
IT 212256-47-8P 212256-71-8P 212256-91-2P
212257-97-1P 212257-98-2P 212258-02-1P
212258-21-4P 212258-22-5P 212258-76-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetralones as antiarrhythmic agents)
RN 212256-47-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212256-71-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212256-91-2 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212257-97-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, methyl ester (CA INDEX NAME)



L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212257-98-2 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-phenyl-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-02-1 CAPLUS
CN Glycine, N-[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 212258-21-4 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-22-5 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-methoxy-N-methyl-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-76-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[3-(4-phenyl-1-piperidinyl)propyl]- (CA INDEX NAME)



IT 109132-88-9P 212256-36-5P 212256-39-8P
212256-40-1P 212256-42-3P 212256-43-4P
212256-44-5P 212256-45-6P 212256-51-4P
212256-52-5P 212256-53-6P 212256-54-7P
212256-55-8P 212256-57-0P 212256-58-1P
212256-59-2P 212256-63-8P 212256-66-1P
212256-70-7P 212256-72-9P 212256-92-3P
212256-93-4P 212256-94-5P 212256-96-7P
212256-97-8P 212256-98-9P 212257-02-8P
212257-03-9P 212257-24-4P 212257-25-5P
212257-26-6P 212257-27-7P 212257-28-8P
212257-29-9P 212257-30-2P 212257-31-3P
212257-32-4P 212257-33-5P 212257-34-6P
212257-35-7P 212257-36-8P 212257-37-9P
212257-38-0P 212257-39-1P 212257-40-4P
212257-44-8P 212257-47-1P 212257-48-2P
212257-49-3P 212257-50-6P 212257-51-7P
212257-52-8P 212257-53-9P 212257-54-0P
212257-55-1P 212257-57-3P 212257-58-4P
212257-59-5P 212257-60-8P 212257-61-9P
212257-62-0P 212257-63-1P 212257-64-2P
212257-65-3P 212257-66-4P 212257-67-5P
212257-68-6P 212257-79-9P 212257-80-2P
212257-82-4P 212257-83-5P 212257-84-6P
212257-85-7P 212257-86-8P 212257-88-0P
212257-89-1P 212257-90-4P 212257-91-5P
212257-93-7P 212257-94-8P 212257-95-9P
212257-96-0P 212257-99-3P 212258-00-9P
212258-01-0P 212258-03-2P 212258-04-3P
212258-05-4P 212258-06-5P 212258-07-6P
212258-08-7P 212258-09-8P 212258-10-1P

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

212258-11-2P 212258-12-3P 212258-13-4P
212258-14-5P 212258-15-6P 212258-16-7P
212258-17-8P 212258-18-9P 212258-19-0P
212258-20-3P 212258-23-6P 212258-24-7P
212258-25-8P 212258-26-9P 212258-27-0P
212258-29-2P 212258-30-5P 212258-31-6P
212258-32-7P 212258-33-8P 212258-34-9P
212258-35-0P 212258-36-1P 212258-37-2P
212258-38-3P 212258-39-4P 212258-40-7P
212258-41-8P 212258-42-9P 212258-43-0P
212258-44-1P 212258-45-2P 212258-46-3P
212258-47-4P 212258-48-5P 212258-49-6P
212258-50-9P 212258-51-0P 212258-53-2P
212258-55-4P 212258-57-6P 212258-59-8P
212258-61-2P 212258-63-4P 212258-65-6P
212258-67-8P 212258-69-0P 212258-70-3P
212258-72-5P 212258-73-6P 212258-74-7P
212258-75-8P 212258-78-1P 212258-79-2P
212258-81-6P 212258-82-7P 212258-83-8P
212258-85-0P 212258-87-2P 212258-89-4P
212258-90-7P 212258-91-8P 212258-92-9P
212258-97-4P 212258-98-5P 212258-99-6P
212259-00-2P 212259-01-3P 212259-03-5P
212259-04-6P 212259-05-7P 212259-06-8P
212259-07-9P 212259-08-0P 212259-09-1P
212259-10-4P 212259-11-5P 212259-12-6P
212259-13-7P 212259-14-8P 212259-15-9P
212259-16-0P 212259-64-8P 212260-11-2P
212330-98-8P 212330-99-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetralones as antiarrhythmic agents)

RN 109132-88-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



RN 212256-36-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212256-39-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-5-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212256-40-1 CAPLUS
CN 1(2H)-Naphthalenone, 6-ethyl-3,4-dihydro-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212256-42-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(phenylmethoxy)-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212256-43-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(2-phenylethoxy)-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212256-44-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-phenoxy-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212256-45-6 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-phenyl-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212256-51-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-5-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212256-52-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-methyl-6-phenoxy-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212256-53-6 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-methyl-6-phenyl-2-[(4-phenyl-1-

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212256-57-0 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1), (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 212256-58-1 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



RN 212256-59-2 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212256-63-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(phenylmethoxy)-2-[(4-phenyl-1-piperidinyl)carbonyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212256-54-7 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212256-55-8 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1), (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212256-66-1 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-2-ylmethoxy)-3,4-dihydro-2-[(4-phenyl-1-piperidinyl)carbonyl]- (CA INDEX NAME)



RN 212256-70-7 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[(4-phenyl-1-piperidinyl)methyl]-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212256-72-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-6-(phenylmethoxy)- (CA INDEX NAME)



RN 212256-92-3 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1R,2R)-rel- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
Relative stereochemistry.



RN 212256-93-4 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212256-94-5 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1R,2S)-rel-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 212256-93-4
CMF C36 H39 N O2

Relative stereochemistry.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212256-98-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-phenoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212257-02-8 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-(phenylmethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1R,2R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 212257-03-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-(phenylmethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1R,2R)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 212256-96-7 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-(phenylmethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212256-97-8 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-phenyl-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 212257-24-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212257-25-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-26-6 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(phenylmethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212257-27-7 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-phenoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212257-28-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-phenyl-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212257-29-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-(4-pyridinylmethoxy)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212257-30-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(2-phenylethyl)-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 212257-34-6 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(3-methylphenyl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-35-7 CAPLUS
CN 1(2H)-Naphthalenone, 6-[(4-chlorophenyl)methoxy]-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-36-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(4-methoxyphenyl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-37-9 CAPLUS

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212257-31-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(2-methylpropoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-32-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-(2-pyridinylmethoxy)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212257-33-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-(3-pyridinylmethoxy)-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN 1(2H)-Naphthalenone, 6-[(2-chlorophenyl)methoxy]-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-38-0 CAPLUS
CN 1(2H)-Naphthalenone, 6-[(3-chlorophenyl)methoxy]-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-39-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[[4-(1-methylethyl)phenyl]methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-40-4 CAPLUS
CN Benzonitrile, 4-[[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]oxy]methyl]- (CA INDEX NAME)



L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 212257-44-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(phenylmethoxy)-2-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 212257-47-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1-phenyl-1H-imidazol-2-yl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-48-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-(2,2,2-trifluoroethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



RN 212257-49-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(3-nitrophenyl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212257-50-6 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(2-methoxyphenyl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-51-7 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(2-nitrophenyl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-52-8 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-4-ylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-53-9 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-2-ylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212257-54-0 CAPLUS
CN 1(2H)-Naphthalenone, 6-ethoxy-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-55-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(2-methylphenyl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-57-3 CAPLUS
CN Benzonitrile, 2-[[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]oxy]methyl]- (CA INDEX NAME)



RN 212257-58-4 CAPLUS
CN Benzoic acid, 4-[[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]oxy]methyl]-, methyl ester (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212257-59-5 CAPLUS
CN Benzonitrile, 3-[[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]oxy]methyl]- (CA INDEX NAME)



RN 212257-60-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(4-nitrophenyl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-61-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(4-methylphenyl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-62-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(3-methoxyphenyl)methoxy]-2-[2-(4-

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-63-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-propoxy- (CA INDEX NAME)



RN 212257-64-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(1-methylethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-65-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(1-phenylethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212257-80-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, oxime, (1E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 212257-82-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(phenylmethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, oxime, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212257-83-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, oxime (CA INDEX NAME)



RN 212257-84-6 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[2-(4-phenyl-1-

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212257-66-4 CAPLUS
CN 1(2H)-Naphthalenone, 6-(1H-benzimidazol-2-ylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212257-67-5 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-3-ylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-68-6 CAPLUS
CN 1(2H)-Naphthalenone, 6-(cyclopropylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-79-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, oxime, (1Z)- (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
piperidinyl)ethyl]-, hydrazone (CA INDEX NAME)



RN 212257-85-7 CAPLUS
CN Hydrazinecarboxamide, 2-[3,4-dihydro-6-methoxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]-1(2H)-naphthalenylidene]-N-methyl- (CA INDEX NAME)



RN 212257-86-8 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-2-ylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, oxime, (1E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 212257-88-0 CAPLUS
CN 1(2H)-Naphthalenone, 6-ethoxy-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, oxime, (1E)- (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212257-89-1 CAPLUS
CN 1(2H)-Naphthalenone,
3,4-dihydro-2-methyl-6-(phenylmethoxy)-2-[(4-phenyl-1-piperidinyl)methyl]-, oxime, (1E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 212257-90-4 CAPLUS
CN 1(2H)-Naphthalenone,
3,4-dihydro-2-methyl-6-(phenylmethoxy)-2-[(4-phenyl-1-piperidinyl)methyl]-, oxime, (1Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 212257-91-5 CAPLUS
CN Acetamide,
N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212257-93-7 CAPLUS
CN Acetamide,
N-[(1R,2R)-1,2,3,4-tetrahydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212257-94-8 CAPLUS
CN Spiro[imidazolidine-4,1'(2'H)-naphthalene]-2,5-dione,
3',4'-dihydro-6'-methoxy-2'-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212257-95-9 CAPLUS
CN Spiro[imidazolidine-4,1'(2'H)-naphthalene]-2,5-dione,
3',4'-dihydro-6'-(phenylmethoxy)-2'-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1'R,2'R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212257-96-0 CAPLUS
CN Spiro[imidazolidine-4,1'(2'H)-naphthalene]-2,5-dione,
3',4'-dihydro-6'-(phenylmethoxy)-2'-[2-(4-phenyl-1-piperidinyl)ethyl]-, (1'R,2'S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212257-99-3 CAPLUS
CN 2-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-5-oxo-N-pentyl-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-00-9 CAPLUS
CN 1(2H)-Naphthalenone,
3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-(1-piperidinylcarbonyl)- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-01-0 CAPLUS
CN 2-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-N-[2-(1H-imidazol-5-yl)ethyl]-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212258-03-2 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 212258-04-3 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-05-4 CAPLUS
CN 2-Naphthalenecarboxamide,
N-[1,1'-biphenyl]-2-yl-5,6,7,8-tetrahydro-5-oxo-
6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212258-06-5 CAPLUS
CN 2-Naphthalenecarboxamide,
N-[1,1'-biphenyl]-2-yl-5,6,7,8-tetrahydro-5-oxo-
6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-07-6 CAPLUS
CN 2-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-N-methyl-5-oxo-N-phenyl-6-[2-
(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-08-7 CAPLUS
CN 2-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-N-(1-methylethyl)-5-oxo-6-[2-
(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-09-8 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-(phenylmethyl)-6-[2-
(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-10-1 CAPLUS
CN 2-Naphthalenecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-5,6,7,8-
tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride
(1:1)
(CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212258-11-2 CAPLUS
CN 2-Naphthalenecarboxamide,
N-(3,3-dimethylbutyl)-5,6,7,8-tetrahydro-5-oxo-6-
[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212258-12-3 CAPLUS
CN Benzoic acid, 4-[[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-
piperidinyl)ethyl]-2-naphthalenyl]carbonyl]amino]-, methyl ester (CA
INDEX NAME)



RN 212258-13-4 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-(2-methoxyphenyl)-5-oxo-6-
[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212258-14-5 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-
piperidinyl)ethyl]-N-3-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212258-15-6 CAPLUS
CN 2-Naphthalenecarboxamide,
N-(3,4-dimethyl-5-isoxazolyl)-5,6,7,8-tetrahydro-
5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA
INDEX
NAME)



● HCl

RN 212258-16-7 CAPLUS
CN 2-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-N-[2-(1-methylethyl)phenyl]-5-
oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX
NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212258-17-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-(3-chlorophenyl)-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212258-18-9 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-N-4-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212258-19-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, 1-phenylhydrazide, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212258-25-8 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-(2-phenylethyl)-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-26-9 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-(2-phenoxyphenyl)-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212258-27-0 CAPLUS
CN 2-Naphthalenecarboxamide, N-(3,5-dimethoxyphenyl)-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 212258-20-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, 2-phenylhydrazide, hydrochloride (4:5) (CA INDEX NAME)



●5/4 HCl

RN 212258-23-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-[1,1'-biphenyl]-3-yl-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-24-7 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-N-1H-pyrrol-1-yl-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212258-29-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212258-30-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-([1,1'-biphenyl]-3-ylmethyl)-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1)
(CA INDEX NAME)



● HCl

RN 212258-31-6 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
piperidinyl)ethyl]-N-(3-phenylpropyl)- (CA INDEX NAME)



RN 212258-32-7 CAPLUS
CN 2-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-5-oxo-N-(4-phenylbutyl)-6-[2-
(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-33-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-[2-(1-cyclohexen-1-yl)ethyl]-5,6,7,8-
tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-34-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-5,6,7,8-
tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 212258-38-3 CAPLUS
CN 2-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-N-[2-(2-naphthalenyl)ethyl]-5-
oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-39-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-[(2,2-dimethylcyclopentyl)methyl]-5,6,7,8-
tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-40-7 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-[(1R,2S)-2-
phenylcyclopropyl]-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, rel- (CA INDEX
NAME)

Relative stereochemistry.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212258-35-0 CAPLUS
CN 2-Naphthalenecarboxamide,
N-(2,2-diphenylethyl)-5,6,7,8-tetrahydro-5-oxo-6-
[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-36-1 CAPLUS
CN 2-Naphthalenecarboxamide,
N-(2,3-dihydro-1H-inden-2-yl)-5,6,7,8-tetrahydro-
5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-37-2 CAPLUS
CN 2-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-N-[2-(1-naphthalenyl)ethyl]-5-
oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX
NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-41-8 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-(1-naphthalenylmethyl)-5-
oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-42-9 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-
piperidinyl)ethyl]-N-[(2S)-2-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 212258-43-0 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-
piperidinyl)ethyl]-N-[(2R)-2-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-44-1 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 212258-45-2 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 212258-46-3 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-N-[2-(2-thienyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-47-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-[[1-(4-chlorophenyl)cyclopropyl]methyl]-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-48-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-[2-(4-dibenzofuranyl)ethyl]-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-49-6 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-(3-hydroxy-2,3-diphenylpropyl)-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-50-9 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-[(1R,2R)-2-phenylcyclopropyl]-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212258-51-0 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-(2,2,3,3,3-pentafluoropropyl)-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-53-2 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-(2-methylbutyl)-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212258-52-1
CMF C29 H38 N2 O2

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 212258-55-4 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-(3-methylbutyl)-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212258-54-3
CMF C29 H38 N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212258-57-6 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-(1-methylbutyl)-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212258-56-5
CMF C29 H38 N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 212258-59-8 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-N-[(tetrahydro-2-furanyl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212258-58-7
CMF C29 H36 N2 O3

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212258-63-4 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-(2-hydroxy-2-phenylethyl)-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212258-62-3
CMF C32 H36 N2 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 212258-65-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-[2-(2-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212258-64-5
CMF C32 H35 F N2 O2

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 212258-61-2 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-N-(2-phenylpropyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212258-60-1
CMF C33 H38 N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 212258-67-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-[2-(4-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212258-66-7
CMF C32 H35 F N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212258-69-0 CAPLUS
CN 2-Naphthalenecarboxamide,
N-[2-(3-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-5-
oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 212258-68-9
CMF C32 H35 F N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 212258-70-3 CAPLUS
CN 2-Naphthalenecarboxamide,
N-[2-(4-chlorophenyl)ethyl]-5,6,7,8-tetrahydro-5-
oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-72-5 CAPLUS
CN 2-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-N-[2-(1H-indol-3-yl)ethyl]-5-
oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-73-6 CAPLUS
CN 2-Naphthalenecarboxamide,
N-(3,3-diphenylpropyl)-5,6,7,8-tetrahydro-5-oxo-
6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-74-7 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-[2-(4-
phenoxyphenyl)ethyl]-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX
NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-75-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[3-(4-phenyl-1-
piperidinyl)propyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 212258-78-1 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-(hydroxyimino)-N-phenyl-6-
[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-79-2 CAPLUS
CN 2-Naphthalenecarboxylic acid,
5,6,7,8-tetrahydro-5-(hydroxyimino)-6-[2-(4-
phenyl-1-piperidinyl)ethyl]-, methyl ester (CA INDEX NAME)



L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212258-81-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-(3,3-dimethylbutyl)-5,6,7,8-tetrahydro-5-
(hydroxyimino)-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-82-7 CAPLUS
CN Glycine,
N-[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-
2-naphthalenyl]carbonyl]- (CA INDEX NAME)



RN 212258-83-8 CAPLUS
CN 2-Naphthalenemethanol, 5,6,7,8-tetrahydro-5-hydroxy-6-[2-(4-phenyl-1-
piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-85-0 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-hydroxy-N-phenyl-6-[2-(4-
phenyl-1-piperidinyl)ethyl]-, (5R,6S)-rel-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 212258-84-9
CMF C30 H34 N2 O2

Relative stereochemistry.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 212258-87-2 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-hydroxy-N-phenyl-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, (5R,6R)-rel-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212258-86-1
CMF C30 H34 N2 O2

Relative stereochemistry.



CM 2

CRN 76-05-1

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CMF C2 H F3 O2

RN 212258-89-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(2-phenylacetyl)-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-90-7 CAPLUS
CN 2-Naphthaleneacetamide, 5,6,7,8-tetrahydro-5-oxo-N-(phenylmethyl)-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-91-8 CAPLUS
CN Benzeneacetamide, N-[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]methyl]- (CA INDEX NAME)



RN 212258-92-9 CAPLUS
CN Butanamide, 3,3-dimethyl-N-[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]methyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212258-97-4 CAPLUS
CN 1-Naphthalenecarboxamide, N-(3,3-dimethylbutyl)-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-98-5 CAPLUS
CN 1-Naphthalenecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212258-99-6 CAPLUS
CN 1-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-(phenylmethyl)-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212259-00-2 CAPLUS
CN 1-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-pentyl-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-01-3 CAPLUS
CN 1-Naphthalenecarboxamide, N-[1,1'-biphenyl]-2-yl-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-03-5 CAPLUS
CN Piperidine, 1-[[5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-1-naphthalenyl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CRN 212259-02-4
CMF C29 H36 N2 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 212259-04-6 CAPLUS
CN 1-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-5-oxo-N-(2-phenylethyl)-6-[2-
(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-05-7 CAPLUS
CN 1-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-5-oxo-N-[(1R)-1-phenylethyl]-
6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212259-08-0 CAPLUS
CN 1-Naphthalenecarboxamide,
N-(2,5-dimethoxyphenyl)-5,6,7,8-tetrahydro-5-oxo-
6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-09-1 CAPLUS
CN 1-Naphthalenecarboxamide, N-([1,1'-biphenyl]-2-ylmethyl)-5,6,7,8-
tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
Absolute stereochemistry.



RN 212259-06-8 CAPLUS
CN 1-Naphthalenecarboxamide,
5,6,7,8-tetrahydro-5-oxo-N-[(1S)-1-phenylethyl]-
6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 212259-07-9 CAPLUS
CN 1-Naphthalenecarboxamide,
N-(3,5-dimethoxyphenyl)-5,6,7,8-tetrahydro-5-oxo-
6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212259-10-4 CAPLUS
CN 1-Naphthalenecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-5,6,7,8-
tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-11-5 CAPLUS
CN 1-Naphthalenecarboxamide,
N-[1,1'-biphenyl]-3-yl-5,6,7,8-tetrahydro-5-oxo-
6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212259-12-6 CAPLUS
CN 1-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-methyl-5-oxo-N-phenyl-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-13-7 CAPLUS
CN 1-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-(2-phenoxyphenyl)-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212259-14-8 CAPLUS
CN 1-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-N-(3-phenylpropyl)- (CA INDEX NAME)



RN 212259-15-9 CAPLUS
CN 1-Naphthalenecarboxamide, N-[(2,2-dimethylcyclopentyl)methyl]-5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212259-16-0 CAPLUS
CN 1-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-oxo-N-phenyl-N-(phenylmethyl)-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-64-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-6-(2-propen-1-yloxy)- (CA INDEX NAME)



RN 212260-11-2 CAPLUS
CN 1-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-(hydroxyimino)-N-phenyl-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212330-98-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-5-(phenylmethoxy)-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 212330-97-7
CMF C30 H33 N O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 212330-99-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[3-(4-phenyl-1-piperidinyl)propyl]-, oxime, (1E)- (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 212259-30-8P 212259-31-9P 212259-32-0P
212259-33-1P 212259-34-2P 212259-40-0P
212259-45-5P 212259-46-6P 212259-47-7P
212259-48-8P 212259-49-9P 212259-50-2P
212259-51-3P 212259-57-9P 212259-58-0P
212259-59-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetralones as antiarrhythmic agents)

RN 212259-30-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-hydroxy-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-31-9 CAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl ester (CA INDEX NAME)



RN 212259-32-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-(2-phenylethynyl)-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212259-45-5 CAPLUS
CN Piperidine, 1-[3-[(1R,2R)-1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]propyl]-4-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212259-46-6 CAPLUS
CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-5-hydroxy-N-methoxy-N-methyl-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-47-7 CAPLUS
CN Ethanone, 2-phenyl-1-[5,6,7,8-tetrahydro-5-hydroxy-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)



L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212259-33-1 CAPLUS
CN 1-Naphthalenamine, 1,2,3,4-tetrahydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:2), (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212259-34-2 CAPLUS
CN 1-Naphthalenamine, 1,2,3,4-tetrahydro-6-methoxy-2-methyl-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1), (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 212259-40-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 212259-48-8 CAPLUS
CN 2-Naphthaleneacetic acid, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, methyl ester (CA INDEX NAME)



RN 212259-49-9 CAPLUS
CN 2-Naphthaleneacetic acid, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-50-2 CAPLUS
CN 1-Naphthalenol, 6-(aminomethyl)-1,2,3,4-tetrahydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-51-3 CAPLUS
CN Benzeneacetamide, N-[[5,6,7,8-tetrahydro-5-hydroxy-6-[2-(4-phenyl-1-piperidinyl)ethyl]-2-naphthalenyl]methyl]- (CA INDEX NAME)



RN 212259-57-9 CAPLUS
CN 1-Naphthalenecarboxylic acid, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]-, methyl ester (CA INDEX NAME)

L25 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 212259-58-0 CAPLUS
CN 1-Naphthalenecarboxylic acid, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 212259-59-1 CAPLUS
CN 1-Naphthalenecarbonyl chloride, 5,6,7,8-tetrahydro-5-oxo-6-[2-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)



L25 ANSWER 56 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1998:349268 Document No. 129:62433 Original Reference No. 129:12769a
Theoretical descriptors in quantitative structure-affinity and selectivity
relationship study of potent N4-substituted arylpiperazine 5-HT1A receptor
antagonists. Menziani, M. C.; De Benedetti, P. G.; Karelson, M. (Dipartimento di Chimica, Universita' di Modena, Modena, 41100, Italy). Bioorganic & Medicinal Chemistry, 6(5), 535-550 (English) 1998. CODEN: BMECEP. ISSN: 0968-0896. Publisher: Elsevier Science Ltd..
AB The ability of ad hoc defined size and shape descriptors and theor. descriptors derived on a single structure to give powerful interpretative and predictive QSAR models was compared and evaluated with respect to the quality of the pharmacol. data available for structurally diverse 5-HT1A receptor antagonists, displaying selectivity towards the α1-adrenergic receptor.
IT 143355-89-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); CAT (Catalyst use); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(theor. descriptors in QSAR study of arylpiperazine 5-HT1A receptor antagonists)
RN 143355-89-9 CAPLUS
CN Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]- (CA INDEX NAME)



L25 ANSWER 57 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1998:236274 Document No. 128:2827800 Original Reference No. 128:55978h,55979a Preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein. Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Sulsky, Richard B.; Tino, Joseph A. (Bristol-Myers Squibb Co., USA). U.S. US 5739135 A 19980414, 185 pp., Cont.-in-part of U.S. Ser. No. 391,901, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1995-472067 19950606. PRIORITY: US 1993-117362 19930903; US 1994-284808 19940805; US 1995-391901 19950221.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-V; Q = C(O), S(O)2; X = CHR8, C(O), CHR9CHR10, CR9:CR10 (wherein R8-R10 = H, alkyl, alkenyl, etc.); Y = (CH2)m, C(O) (m = 2-3); R1 = alkyl, alkenyl, alkynyl, etc.; R2-R4 = H, halo, alkyl, etc.; R5 = alkyl, alkenyl, alkynyl, etc.; R6 = H, C1-4 alkyl, C1-4 alkenyl] which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases such as hyperglycemia and obesity, were prepared Thus, reaction of 1-(3,3-diphenylpropyl)-4-piperidinamine.HCl (preparation described) with benzoyl chloride in the presence of Et3N in CH2Cl2 afforded 84% the title compound III.HCl [Q = C(O); R1 = 3,3-diphenylpropyl; R5 = Ph; R6 = H]. Compds. I-V are effective at 5-500 mg/day.
IT 133496-73-8P 163266-60-2P 205931-38-0P
205931-39-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic inhibitors of microsomal triglyceride transfer
protein)
RN 133496-73-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L25 ANSWER 57 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 163266-60-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 205931-38-0 CAPLUS
CN 1(2H)-Naphthalenone, 6-fluoro-3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 205931-39-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperazinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 163268-03-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic inhibitors of microsomal triglyceride transfer
protein)
RN 163268-03-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)

L25 ANSWER 57 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 58 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1998:71131 Document No. 128:1407290 Original Reference No. 128:27691a,27694a
Preparation of 3-[2-(4-arylazino)ethyl]-2-indolones and analogs as antiincontinence agents. Kato, Kaneyoshi; Doi, Takayuki; Sugiura, Yoshihiro; Kawada, Mitsuru (Takeda Chemical Industries, Ltd., Japan). PCT
Int. Appl. WO 9802432 A1 19980122, 185 pp. DESIGNATED STATES: W: AL, AM,
AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-JP2447 19970715. PRIORITY: JP 1996-186025 19960716; JP 1997-87980 19970407.
GI



AB Title compds. [(ring-substituted) I; R = (CH2)mZ1Z2R2; R1,R2 = (un)substituted aryl; Z = atoms to complete a (heterocyclic) ring; Z1 = (un)substituted N-attached heterocyclylene; Z2 = bond or (oxo)alkylene; m = 1-3] were prepared Thus, PhCH2CO2Et was arylated by 4-FC6H4NO2 and the cyclized product converted in 3 steps to title compound II. Data for biol.
activity of I were given.
IT 202260-59-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-[2-(4-arylazino)ethyl]-2-indolones and analogs as antiincontinence agents)
RN 202260-59-1 CAPLUS
CN Piperidine, 4-phenyl-1-[2-(1,2,3,4-tetrahydro-1-phenyl-1-naphthalenyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 58 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1998:55616 Document No. 128:1149610 Original Reference No. 128:22541a,22544a
Preparation of tetrahydrobenzindole derivatives for the treatment or prevention of mental diseases. Koyama, Masao; Kikuchi, Chika; Ushiroda, Osamu; Ando, Takashi; Nagaso, Hiroshi; Fuji, Kazuyuki; Okuno, Masayo; Hiranuma, Toyokazu (Meiji Seika Kaisha, Ltd., Japan). PCT Int. Appl. WO 9800400 A1 19980108, 67 pp. DESIGNATED STATES: W: CA, JP, NO, US; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1997-JP2226 19970627. PRIORITY: JP 1996-169702 19960628; JP 1997-96271 19970415; JP 1997-130201 19970521; JP 1997-144376 19970603.
GI



AB The title compds. I [A represents N, CH, C having a double bond or CR5; B and Z independently represent each N, CH or CR1, provided that A is N when
B and/or Z is N; R1 represents hydrogen, halogeno, lower alkyl, cyano, trihalomethyl, hydroxy, alkoxy, alkylthio, alkylsulfenyl, alkylsulfonyl, alkoxycarbonyl, sulfamoyl, optionally substituted amino, optionally alkylated carbamoyl, acyl or carboxy; R2 represents hydrogen or lower alkyl; R3 represents hydrogen, lower alkyl; R3 represents hydrogen, lower alkyl or aralkyl; R4 represents hydrogen, halogeno, lower alkyl, hydroxyl,
alkoxy, acyl, alkoxycarbonyl, nitro, optionally substituted amino, optionally alkylated carbamoyl or acyloxy; R5 represents lower alkyl, cyano, carbamoyl, carboxy, acyl, acyloxy, alkoxy, alkoxycarbonyl, trihalomethyl or hydroxy; and n is an integer of from 2 to 6] are prepared
I strongly inhibit [3H]-serotonin and [3H]-5-CT binding to the human serotonin 5-HT7 receptor subtype expressed in a cultured cell line and are
useful for treating or preventing mental diseases. 2A-[4-[4-(2-Methoxyphenyl)piperazinyl]butyl]-2a,3,4,5-tetrahydrobenz[cd]indol-2-(1H)-one was prepared from 2a,3,4,5-tetrahydrobenz[cd]indol-2-(1H)-one. In tests for affinity for the 5-HT7 receptors, compds. of this invention showed Ki values of 8.9 nM to 27 nM. The title compds. showed selective affinity for 5-HT7 receptors.
IT 201608-38-0P 201608-39-1P 201608-42-6P
201608-43-7P 201608-44-8P 201608-45-9P
201608-46-0P 201608-47-1P 201608-48-2P
201608-49-3P 201608-50-6P 201608-51-7P
201608-52-8P 201608-53-9P 201608-54-0P
201608-55-1P 201608-56-2P 201608-57-3P
201608-58-4P 201608-59-5P 201608-60-8P
201608-61-9P 201608-64-2P 201608-65-3P

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
201608-68-6P 201608-69-7P 201608-70-0P
201608-75-5P 201608-76-6P 201608-77-7P
201608-78-8P 201608-79-9P 201608-80-2P
201608-81-3P 201608-82-4P 201608-83-5P
201608-84-6P 201608-85-7P 201608-86-8P
201608-87-9P 201608-88-0P 201608-89-1P
201608-90-4P 201608-91-5P 201608-92-6P
201608-93-7P 201608-94-8P 201608-95-9P
201608-96-0P 201608-97-1P 201608-98-2P
201608-99-3P 201609-01-0P 201609-03-2P
201609-06-5P 201609-07-6P 201609-11-2P
201609-14-5P 201609-16-7P 201609-18-9P
201609-20-3P 201609-21-4P 201609-22-5P
201609-23-6P 201609-24-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydrobenzindole derivs. for treatment or prevention of
mental diseases)

RN 201608-38-0 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-
piperazinyl]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-39-1 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-
piperazinyl]butyl]- (CA INDEX NAME)



L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
piperazinyl)butyl]- (CA INDEX NAME)



RN 201608-46-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-
piperidinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-47-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-
piperidinyl)butyl]- (CA INDEX NAME)



RN 201608-48-2 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[4-[4-(4-methoxyphenyl)-1-
piperazinyl]butyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 201608-42-6 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2-ethoxyphenyl)-1-piperazinyl]butyl]-
2a,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-43-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2-ethoxyphenyl)-1-piperazinyl]butyl]-
2a,3,4,5-tetrahydro- (CA INDEX NAME)



RN 201608-44-8 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-
piperazinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-45-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-phenyl-1-

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 201608-49-3 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[4-[4-(4-methoxyphenyl)-1-
piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-50-6 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methylphenyl)-1-
piperazinyl]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-51-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methylphenyl)-1-
piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-52-8 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[4-[4-(3-methoxyphenyl)-1-
piperazinyl]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 201608-53-9 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[4-[4-(3-methoxyphenyl)-1-
piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-54-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-[3-
(trifluoromethyl)phenyl]-1-piperazinyl]butyl]-, hydrochloride (1:1) (CA
INDEX NAME)



RN 201608-58-4 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[3-methyl-4-(3-
methylphenyl)-1-piperazinyl]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 201608-59-5 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[3-methyl-4-(3-
methylphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-60-8 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[3-[4-(2-methoxyphenyl)-1-
piperazinyl]propyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 201608-55-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-[3-
(trifluoromethyl)phenyl]-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-56-2 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2-chlorophenyl)-1-piperazinyl]butyl]-
2a,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



RN 201608-57-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2-chlorophenyl)-1-piperazinyl]butyl]-
2a,3,4,5-tetrahydro- (CA INDEX NAME)



RN 201608-61-9 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[3-[4-(2-methoxyphenyl)-1-
piperazinyl]propyl]- (CA INDEX NAME)



RN 201608-64-2 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[5-[4-(2-methoxyphenyl)-1-
piperazinyl]pentyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 201608-65-3 CAPLUS
CN Benz[cd]indol-2(1H)-one,
2a,3,4,5-tetrahydro-2a-[5-[4-(2-methoxyphenyl)-1-
piperazinyl]pentyl]- (CA INDEX NAME)



RN 201608-68-6 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2,6-dimethylphenyl)-1-piperazinyl]butyl]-2a,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-69-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(2,6-dimethylphenyl)-1-piperazinyl]butyl]-2a,3,4,5-tetrahydro- (CA INDEX NAME)



RN 201608-70-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperidinyl]butyl]- (CA INDEX NAME)



● HCl

RN 201608-78-8 CAPLUS
CN Benzonitrile, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



RN 201608-79-9 CAPLUS
CN Benzamide, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



RN 201608-80-2 CAPLUS
CN Benzamide, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 201608-75-5 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(3-methyl-4-phenyl-1-piperazinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-76-6 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(3-methyl-4-phenyl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 201608-77-7 CAPLUS
CN Benzonitrile, 2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-81-3 CAPLUS
CN Benzamide, N,N-dimethyl-2-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



RN 201608-82-4 CAPLUS
CN Benzonitrile, 3-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



RN 201608-83-5 CAPLUS
CN Benzamide, 3-[4-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 201608-84-6 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-hydroxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201608-85-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-86-8 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 201608-90-4 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]butyl]-2a,3,4,5-tetrahydro- (CA INDEX NAME)



RN 201608-91-5 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-hydroxy-4-phenyl-1-piperidinyl)butyl]- (CA INDEX NAME)



RN 201608-92-6 CAPLUS
CN 4-Piperidinecarbonitrile, 4-phenyl-1-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 201608-87-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 201608-88-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[3-(4-phenyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 201608-89-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]butyl]-2a,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 201608-93-7 CAPLUS
CN 4-Piperidinecarbonitrile, 4-phenyl-1-[4-(1,2,4,5-tetrahydro-2-oxobenz[cd]indol-2a(3H)-yl)butyl]- (CA INDEX NAME)



RN 201608-94-8 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-methoxy-4-phenyl-1-piperidinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 201608-95-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-methoxy-4-phenyl-1-piperidinyl)butyl]- (CA INDEX NAME)



RN 201608-96-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-methyl-4-phenyl-1-piperidinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 201608-97-1 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-methyl-4-phenyl-1-piperidinyl)butyl]- (CA INDEX NAME)



RN 201608-98-2 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-hydroxy-4-phenyl-1-piperidinyl)butyl]-1-methyl- (CA INDEX NAME)



RN 201608-99-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(4-methoxy-4-phenyl-1-piperidinyl)butyl]-1-methyl- (CA INDEX NAME)

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 201609-01-0 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a-[4-(4-acetyl-4-phenyl-1-piperidinyl)butyl]-2a,3,4,5-tetrahydro- (CA INDEX NAME)



RN 201609-03-2 CAPLUS
CN Benz[cd]indol-2(1H)-one, 6-acetyl-2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201609-06-5 CAPLUS
CN Benz[cd]indol-2-one, 6-(acetyloxy)-1,2,2a,3,4,5-hexahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 201609-07-6 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-6-hydroxy-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201609-11-2 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-6-methoxy-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201609-14-5 CAPLUS
CN Benz[cd]indole-6-carboxylic acid, 1,2,2a,3,4,5-hexahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-2-oxo-, methyl ester (CA INDEX NAME)

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 201609-16-7 CAPLUS
CN Benz[cd]indole-6-carboxamide, 1,2,2a,3,4,5-hexahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-2-oxo- (CA INDEX NAME)



RN 201609-18-9 CAPLUS
CN Benz[cd]indol-2(1H)-one, 6-bromo-2a,3,4,5-tetrahydro-2a-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201609-20-3 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-pyridinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 201609-21-4 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201609-22-5 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 201609-23-6 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-[6-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]butyl]- (CA INDEX NAME)



L25 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 201609-24-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-[4-[6-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L25 ANSWER 60 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

1998:42309 Document No. 128:1019570 Original Reference No. 128:19973a,19976a

Preparation of fluoro-substituted anthracyclines for use as [19F]-MRI probes for monitoring amyloidotic diseases. Bandiera, Tiziano; Fancelli, Daniele; Caruso, Michele; Lansen, Jacqueline; Suarato, Antonio (Pharmacia & Upjohn S.P.A., Italy). PCT Int. Appl. WO 9749433 A1 19971231, 42 pp. DESIGNATED STATES: W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, SG, SI, UA, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1997-EP3234 19970618. PRIORITY: GB 1996-13433 19960626.

GI



I



II

AB Fluorine substituted anthracyclines I [R1 = H, OH, halogen, alkoxy, amino, alkylsulfonyloxy, arylsulfonyloxy; R2 = H, OH; R3 = H, OH, amino, saccharide, heterocyclyl such as morpholino or piperazino; Y = H, OH, alkoxy, amino, heterocyclyl; Z = CO, CH(OH), CH2] were prepared for use as NMR imaging probes which are useful in the diagnosis of amyloidosis. Thus, anthracycline II was prepared starting from 14-bromodaunomycinone, piperazine and triflic acid anhydride and gave an EC50 value of 8.16 ± 1.32 μM when tested for binding with fibrils from Aβ(25-35) peptide as compared with 52.04 ± 10.66 μM for iododoxorubicin.

IT 201344-98-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fluoro-substituted anthracyclines for use as [19F]-MRI probes for monitoring amyloidotic diseases)

RN 201344-98-1 CAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-1-methoxy-8-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]acetyl]-, (8S,10S)- (CA INDEX NAME)

L25 ANSWER 60 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

Absolute stereochemistry.



IT 201344-89-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fluoro-substituted anthracyclines for use as [19F]-MRI probes for monitoring amyloidotic diseases)

RN 201344-89-0 CAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-1-methoxy-8-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]acetyl]-, hydrochloride (1:1), (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L25 ANSWER 61 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1997:390206 Document No. 127:90128 Original Reference No. 127:17157a,17160a
1-(2-Methoxyphenyl)-4-alkylpiperazines: effect of the N-4 substituent on the affinity and selectivity for dopamine D4 receptor. Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Leopoldo, Marcello; Tortorella, Vincenzo (Dip. Farm.-Chim., Bari, 70126, Italy). Bioorganic & Medicinal Chemistry Letters, 7(10), 1327-1330 (English) 1997. CODEN: BMCLE8.
ISSN:
0960-894X. Publisher: Elsevier.
AB Binding data on dopaminergic D2 and D4 and adrenergic α1 receptors of nine 1-(2-methoxyphenyl)piperazine derivs. are reported. The benzamide
derivative 11 and ketone 12 displayed the highest affinity for human cloned D4
receptor (Ki = 1.3 nM and 1.7 nM, resp.). The former showed to be also selective vs. D2 and α1 receptors.
IT 154744-87-3P 178452-24-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(1-(2-methoxyphenyl)piperazine derivs binding to dopaminergic D2 and D4
and adrenergic α1 receptors)
RN 154744-87-3 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 178452-24-9 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[4-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)butyl]- (CA INDEX NAME)

L25 ANSWER 61 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 62 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1997:67168 Document No. 126:893960 Original Reference No. 126:17267a
Preparation of piperazine, piperidine, and 1,2,5,6-tetrahydropyridine derivatives and pharmaceutical compositions containing them. Peglion, Jean-Louis; Dessinges, Aimee; Goument, Bertrand; Millan, Mark; Newman-Tancredi, Adrian; Gobert, Alain (Adir Et Compagnie, Fr.). Eur. Pat. Appl. EP 745598 A1 19961204, 29 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE. (French). CODEN: EPXXDW. APPLICATION: EP 1996-401156 19960530. PRIORITY: FR 1995-6436 19950531.
GI



I

AB I (AB = CH2CH, CH:C, CH2N; n = 0-6; D = bicyclic ring system; E = heterocyclyl) were prepared E.g., coupling of 2-indancarboxylic acid with
4-(2,3-dihydrobenzo-1,4-dioxin-6-yl)piperazine in the presence of carbonyldiimidazole gave an intermediate amide, which was reduced to give the dihydrochloride of 4-(2,3-dihydrobenzo-1,4-dioxin-6-yl)-1-(indan-2-ylmethyl)piperazine (II). The affinity of II for dopaminergic D4 receptors was determined
IT 185514-59-4P 185514-80-1P 185514-82-3P
185515-26-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacol. study of piperazine, piperidine, and 1,2,5,6-tetrahydropyridine derivs.)
RN 185514-59-4 CAPLUS
CN Piperazine, 1-(2,3-dihydro-5-methoxy-6-benzofuranyl)-4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 185514-58-3
CMF C25 H32 N2 O2



CM 2

L25 ANSWER 62 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 185514-80-1 CAPLUS
CN Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 185514-82-3 CAPLUS
CN Piperazine, 1-(2,3-dihydro-5-methoxy-6-benzofuranyl)-4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 185514-81-2
CMF C24 H30 N2 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 185515-26-8 CAPLUS
CN Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(1,2,3,4-tetrahydro-2-

L25 ANSWER 62 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
naphthalenyl)methyl]- (CA INDEX NAME)



L25 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1996:681311 Document No. 126:14313 Original Reference No. 126:2869a,2872a
Structure-Activity Relationship Studies on the 5-HT1A Receptor Affinity of
1-Phenyl-4-[ω-(α- or β-tetralinyl)alkyl]piperazines. 4.
Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Leopoldo, Marcello; Tortorella, Vincenzo; Fornaretto, Maria Gioia; Caccia, Carla; McArthur, Robert A. (Dipartimento Farmaco-chimico, Universita di Bari, Bari, 70126, Italy). Journal of Medicinal Chemistry, 39(25), 4928-4934 (English) 1996. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.
AB The synthesis of 1-phenylpiperazines, linked in the α or β position of the tetralin moiety on the terminal part of the N-4 alkyl chain, and their radioligand binding affinities for 5-HT1A, 5-HT2A, D-1, D-2, α1, and α2 receptors along with SAR studies on the 5-HT1A receptor are reported. Several changes have been carried out on previous structures of type 2, by inserting the alkyl chain with variable length in the α or β position of the tetralin moiety and by changing the position of the methoxy group on the aromatic ring of the tetralin nucleus.
The highest affinity (IC50 = 0.50 nM) and selectivity for the 5-HT1A receptor were showed by the 1-phenylpiperazine derivative with a three-membered alkyl chain bearing a 1-(5-methoxytetralin-1-yl) ring in the ω position.
IT 154744-86-2 154744-87-3 154744-88-4
184346-64-3
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(preparation and structure-activity relationship studies on serotonin S1A
receptor affinity of phenyl[ω-(α- or β-tetralinyl)alkyl]piperazines)
RN 154744-86-2 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 154744-87-3 CAPLUS

L25 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 154744-88-4 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 184346-64-3 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 184347-24-8P 184347-26-0P 184347-28-2P
184347-33-9P 184347-43-1P 184347-45-3P
184347-47-5P
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(preparation and structure-activity relationship studies on serotonin S1A
receptor affinity of phenyl[ω-(α- or β-tetralinyl)alkyl]piperazines)
RN 184347-24-8 CAPLUS
CN Piperazine, 1-phenyl-4-[2-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 184347-26-0 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-6-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 184347-28-2 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-8-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 184347-33-9 CAPLUS
CN Piperazine, 1-phenyl-4-[4-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)butyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 184347-43-1 CAPLUS
CN Piperazine, 1-phenyl-4-[2-(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 184347-45-3 CAPLUS
CN Piperazine, 1-phenyl-4-[2-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L25 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 184347-47-5 CAPLUS
CN Piperazine, 1-phenyl-4-[2-(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

IT 184346-68-7P 184346-70-1P 184346-72-3P
184346-77-8P 184346-86-9P 184346-89-2P
184346-91-6P
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation and structure-activity relationship studies on serotonin S1A
receptor affinity of phenyl[ω-(α- or β-tetralinyl)alkyl]piperazines)

RN 184346-68-7 CAPLUS
CN Piperazine, 1-phenyl-4-[2-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)ethyl]- (CA INDEX NAME)



RN 184346-70-1 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-6-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 184346-72-3 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-8-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 184346-77-8 CAPLUS
CN Piperazine, 1-phenyl-4-[4-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)butyl]- (CA INDEX NAME)

L25 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 184346-86-9 CAPLUS
CN Piperazine, 1-phenyl-4-[2-(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)ethyl]- (CA INDEX NAME)



RN 184346-89-2 CAPLUS
CN Piperazine, 1-phenyl-4-[2-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)ethyl]- (CA INDEX NAME)



RN 184346-91-6 CAPLUS
CN Piperazine, 1-phenyl-4-[2-(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 64 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1996:522872 Document No. 125:211514 Original Reference No. 125:39263a,39266a

Dopamine and serotonin receptor antagonists. Synthesis of aminoalkyl cyclanones as atypical antipsychotics. Ravina Rubira, E. (Departmento de Quimica Organica, Facultad de Farmacia, Santiago de Compostela, 15706, Spain). Ars Pharmaceutica, 36(3), 337-376 (Spanish) 1995. CODEN: APHRAN.

ISSN: 0004-2927. Publisher: Universidad de Granada, Facultad de Farmacia.

AB A review with 48 refs. A series of 3-aminomethyl tetralones and 2-aminoethyl cycloalkanones carrying o-methoxy phenylpiperazine, p-fluoro butyrophenone and p-fluorobenzoyl piperidine fragments have been prepared The new compds. have been evaluated as potential antipsychotic agents in receptor binding assays for dopamine D1 and D2 receptors and 5-HT2A serotonin receptors and in functional and behavioral screens. The ratios of pKi's for 5-HT2A/D2 receptors may be useful for rapid screening of new compds. and its potential induction of extrapyramidal symptoms (ratio values > 1.12 are predictive of an atypical antipsychotic profile). With the exception of QF 0100B, QF 0102B and QF 0309B, the new compds. had a ratio value in the range 1.08-1.20, while haloperidol showed a ratio of 0.93. In the catalepsy test (predictive test for induction of extrapyramidal symptoms) the values obtained were in accordance with atypical antipsychotic drug profiles. Likewise, a few 2-methyl-3-ethyl-5-aminomethyl-4-oxo-4, 5, 6, 7-tetrahydroindoles (QF 0400B, QF 0402B, QF 0403B, QF 0404B) analogous of neuroleptic molindone receptors. Their affinities for D2 and 5-HT2A receptors are lower than haloperidol and comparable to those of molindone.

IT 133496-60-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(dopamine and serotonin receptor antagonists: synthesis of aminoalkyl cyclanones as atypical antipsychotics)

RN 133496-60-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



L25 ANSWER 65 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1996:422514 Document No. 125:76102 Original Reference No. 125:14243a,14246a

1-Aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3. Perrone, Roberto; Berardi, Francesco; Leopoldo, Marcello; Tortorella, Vincenzo; Fornaretto, Maria Gioia; Caccia, Carla; McArthur, Robert A. (Dipartimento Farmaco-chimico, Universita di Bari, Bari, 70126, Italy). Journal of Medicinal Chemistry, 39(16), 3195-3202 (English) 1996. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

GI



I

AB The synthesis and binding profile on 5-HT1A, 5-HT2, D-1, D-2, α1, and α2 receptors of the N-4 long-chain arylpiperazines 22-40 are reported, where an amino or amido function is inserted into the intermediate chain linked to the α position of the tetralin nucleus, as in I. Unlike the buspirone analogs, for the amido derivs. studied in this paper, the terminal amide function of long-chain piperazines is not important for 5-HT1A receptor affinity binding, and its removal yields high-affinity 5-HT1A receptor agents.

IT 154744-86-2 154744-87-3 154744-88-4
178452-24-9
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent)
(preparation, 5-HT1A receptor affinity, and selectivity of 1-aryl-4-[(1-tetralinyl)alkyl]piperazine alkylamido and alkylamino derivs.)

RN 154744-86-2 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 65 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 154744-87-3 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 154744-88-4 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 65 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 178452-24-9 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[4-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)butyl]- (CA INDEX NAME)



L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1995:951193 Document No. 124:88450 Original Reference No. 124:1873a,1876a
Preparation of heterocyclic compounds for the treatment of CNS and cardiovascular disorders. Ten Brink, Ruth E.; Ennis, Michael D.; Lin, Chiu-Hong; Lahti, Robert A.; Romero, Arthur G.; Sih, John C. (Upjohn Co., USA). PCT Int. Appl. WO 9518118 A1 19950706, 197 pp. DESIGNATED STATES: W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.
APPLICATION: WO 1994-US13284 19941130. PRIORITY: US 1993-175218 19931228;
US 1994-279974 19940725.
GI



I

AB The title compds. (I; R1 = H, alkyl, etc.; R3 = O, S; R4 = H, alkyl, Ph, OH, etc.; R5 = H, alkyl, Ph, OH, alkoxy; R6-R9 = F, Cl, Br, I, H, etc.; m,
n = 0, 1), useful as CNS (no data) and cardiovascular (no data) agents, are prepared Thus, 1-(2-chloroethyl)isochroman was reacted with 1-(2-chlorophenyl)piperazine dihydrochloride, producing 1-(2-chlorophenyl)-4-[2-(isochroman-1-yl)ethyl]piperazine hydrochloride, m.p. 197-198°.
IT 170856-48-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. for the treatment of CNS and cardiovascular disorders)
RN 170856-48-1 CAPLUS
CN Phenol, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 170857-41-7P 170857-43-9P 170857-55-3P
170857-76-8P 170857-78-0P 170857-79-1P
170857-80-4P 170857-82-6P 170857-83-7P
170857-84-8P 170857-85-9P 170857-86-0P
170857-87-1P 170858-80-7P 170858-81-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. for the treatment of CNS and cardiovascular disorders)
RN 170857-41-7 CAPLUS
CN Ethanone, 1-[4-(4-methoxyphenyl)-1-piperazinyl]-2-(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 170857-43-9 CAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-,

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]phenyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 170857-55-3 CAPLUS
CN Piperazine, 1-(4-methoxyphenyl)-4-[1-methyl-2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 170857-76-8 CAPLUS
CN Benzamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 170857-78-0 CAPLUS
CN Benzamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 170857-77-9
CMF C23 H29 N3 O

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 170857-79-1 CAPLUS
CN Benzamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 170857-77-9
CMF C23 H29 N3 O

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 170857-80-4 CAPLUS
CN Benzamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 170857-77-9
CMF C23 H29 N3 O

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 170857-82-6 CAPLUS
CN Benzenesulfonamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, (R)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 170857-81-5
CMF C22 H29 N3 O2 S

Absolute stereochemistry.

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 170857-83-7 CAPLUS
CN Benzenesulfonamide, 4-[4-[2-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]-1-piperazinyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 170857-81-5
CMF C22 H29 N3 O2 S

Absolute stereochemistry.

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 170857-84-8 CAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with (R)-4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]benzenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 170857-81-5
CMF C22 H29 N3 O2 S

Absolute stereochemistry.

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CRN 50-21-5
CMF C3 H6 O3



RN 170857-85-9 CAPLUS
CN Benzenesulfonamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, (R)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 170857-81-5
CMF C22 H29 N3 O2 S

Absolute stereochemistry.

PAGE 1-A



L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 170857-87-1 CAPLUS
CN Benzenesulfonamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, (R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 170857-86-0 CAPLUS
CN Benzenesulfonamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, (R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 170857-81-5
CMF C22 H29 N3 O2 S

Absolute stereochemistry.

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 1

CRN 170857-81-5
CMF C22 H29 N3 O2 S

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 77-92-9
CMF C6 H8 O7



L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 170858-80-7 CAPLUS
CN Benzenesulfonamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 2-A



RN 170858-81-8 CAPLUS
CN Benzenesulfonamide, 4-[4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-1-piperazinyl]-, (S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 170858-80-7
CMF C22 H29 N3 O2 S

Absolute stereochemistry. Rotation (-).

L25 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 75-75-2
CMF C H4 O3 S

L25 ANSWER 67 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1995:790900 Document No. 124:1347420 Original Reference No. 124:24730h,24731a Characterization of Potent and Selective Antagonists at
Postsynaptic 5-HT1A Receptors in a Series of N4-Substituted Arylpiperazines. Peglion, Jean-Louis; Canton, Herve; Bervoets, Karin; Audinot, Valerie; Brocco, Mauricette; Gobert, Alain; Le Marouille-Girardon, Sylvie; Millan, Mark J. (Institut de Recherches Servier, Suresnes, 92150, Fr.). Journal of Medicinal Chemistry, 38(20), 4044-55 (English) 1995. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 124:134742. Publisher: American Chemical Society.
GI



I

AB Benzocycloalkyl and benzocycloalkenyl moieties linked, directly or via an alkyl chain, to oxygen-bearing heteroarylpiperazines were synthesized, in an attempt to obtain potent and selective antagonists at postsynaptic 5-HT1A receptors. From the numerous arylpiperazines described in the literature, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine was chosen as a
model of an arylpiperazine in view of its selectivity for 5-HT1A receptors
vs. α1-, α2-, and β-adrenergic receptors, as well as dopamine D1 and D2 receptors. Two other closely-related arylpiperazines, 1-(1,5-benzodioxepin-6-yl)piperazine and 1-(benzofuran-7-yl)piperazine, were also examined in this study. All compds. showed high affinity at 5-HT1A sites (8.10 ≤ pKis < 9.35), and the majority behaved as antagonists in vivo in blocking the hypothermia induced by the 5-HT1A agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses.
An in vivo evaluation of dopamine D2 receptor antagonist properties revealed that the majority of compds. was devoid of activity at this site,
in marked contrast to BMY 7378 which displayed virtually no selectivity for 5-HT1A vs. dopamine D2 receptors. Moreover, six compds. of the present series, including I, showed >10-fold selectivity in vitro for 5-HT1A vs. α1-adrenergic receptors. I displayed an optimal compromise between potency (pKi = 8.75), marked antagonist activity, and selectivity toward α1-adrenergic (81-fold) and dopamine D2 195-fold receptors. These characteristics clearly distinguish I from previously-reported ligands such as the postsynaptic 5-HT1A antagonist BMY
7378 and the weak partial agonist NAN 190 which, in contrast to the compds. of this series, belong to the well-exemplified class of imido derivs. of (o-methoxyphenyl)piperazines. The availability of I (S 15535) should facilitate the further elucidation of the functional role and potential therapeutic significance of 5-HT1A receptors.
IT 168329-98-4P

L25 ANSWER 67 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(potent and selective antagonists at postsynaptic 5-HT1A receptors in a
series of N4-substituted arylpiperazines)
RN 168329-98-4 CAPLUS
CN Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

10590585.trn

L25 ANSWER 68 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1995:568500 Document No. 123:1695160 Original Reference No. 123:30259a,30262a Preparation of acylaminopiperidines and piperazines as inhibitors of microsomal triglyceride transfer protein.. Wetterau, John R., II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott A.; Dickson, John K.; Lawrence, Michael R.; Lawson, John E.; Holava, Henry M.; Partyka, Richard A. (Bristol-Myers Squibb Co., USA). Eur. Pat. Appl. EP 643057 A1 19950315, 134 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1994-113800 19940902. PRIORITY: US 1993-117362 19930903; US 1992-847503 19920306.

GI







AB Title compds. [I-III; X = CHR8, CHR9CHR10, CR9:CR10; R8-R10 = H, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl; Y = (CH2)m, CO; m = 2, 3; R1 = (substituted) alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, diarylalkyl, diarylalkenyl, diarylalkynyl, diarylalkylaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, etc.; R2-R4 = H, halo, alkyl, haloalkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylthio, arylthio, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, OH, haloalkyl; R5 = (substituted) alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, cycloalkenyl, cycloalkenylalkyl, heteroarylcarbonyl, etc.; R6 = H, alkyl, alkenyl; R7 = alkyl, aryl, aralkyl, oxoalkyl, aryloxoalkyl], were prepared

L25 ANSWER 68 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
as inhibitors of microsomal triglyceride transfer protein. Thus, tert-Bu 4-piperidinylcarbamate (prepn. given) and 3,3-diphenyl-1-propanol tosylate (prepn. given) were stirred with K2CO3 in Me2CHOH overnight to give 76% tert-Bu [1-(3,3-diphenylpropyl)-4-piperidinyl]carbamate. This was deprotected with 4N HCl in dioxane and the product was treated with PhCOCl and Et3N in CH2Cl2 to give title compd. (IV).

IT 133496-60-3P 133496-73-8P 163266-60-2P
163266-62-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminopiperidines and piperazines as inhibitors of microsomal triglyceride transfer protein)

RN 133496-60-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 133496-73-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 163266-60-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 68 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 163266-62-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]- (CA INDEX NAME)



IT 163268-03-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acylaminopiperidines and piperazines as inhibitors of microsomal triglyceride transfer protein)

RN 163268-03-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



L25 ANSWER 69 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1995:413186 Document No. 122:204546 Original Reference No. 122:37061a,37064a
High Affinity and Selectivity on 5-HT1A Receptor of 1-Aryl-4-[(1-tetralin)alkyl]piperazines. 2. Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Leopoldo, Marcello; Tortorella, Vincenzo; Fiorentini, Francesco; Olgiati, Vincenzo; Ghiglieri, Alberto; Govoni, Stefano (Dipartimento Farmaco-chimico, Universita di Bari, Bari, 70126, Italy). Journal of Medicinal Chemistry, 38(6), 942-9 (English) 1995. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

AB Several 4-alkyl-1-arylpiperazines that present a tetralin moiety on the terminal part of the side chain were synthesized in order to increase the selectivity on the 5-HT1A vs. D-2, α1, σ, and other 5-HT receptors. Many changes have been effected on previous structures of type 3 (1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines). Several synthetic procedures were followed to obtain the final products, depending on the presence or absence of a double bond, as well as of a heteroatom on the side chain. In the first case versatile use of Grignard reaction was made, whereas in the second one usual synthetic ways were applied. Final compds. were evaluated for in vitro activity on dopamine D-1 and D-2, serotonin 5-HT1A, 5-HT1B, 5-HT1C, and 5-HT2, α1 adrenergic, and σ receptors by radioreceptor binding assay. For the 2-MeO-Ph, 2-pyridyl, and unsubstituted Ph N-piperazine derivs., low IC50 values (0.3 nM) on 5-HT1A receptors and high selectivity values were observed

IT 161923-75-7P 161923-76-8P 161923-77-9P
161923-78-0P 161923-79-1P 161923-85-9P
161923-86-0P 161923-87-1P 161923-88-2P
161923-89-3P 161923-90-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(high affinity and selectivity on 5-HT1A receptor of aryl[(tetralin)alkyl]piperazines)

RN 161923-75-7 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 69 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 161923-76-8 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 161923-77-9 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 69 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 161923-85-9 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 161923-86-0 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 69 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 161923-78-0 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[4-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)butyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 161923-79-1 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[4-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)butyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 69 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 161923-87-1 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 161923-88-2 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 69 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 161923-89-3 CAPLUS
CN Piperazine,
1-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-4-[3-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 161923-90-6 CAPLUS
CN Piperazine,
1-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-4-[3-(trifluoromethyl)phenyl]-, hydrochloride (2:3) (CA INDEX NAME)

L25 ANSWER 69 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●3/2 HCl

L25 ANSWER 70 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1995:412830 Document No. 122:1876200 Original Reference No. 122:34375a,34378a Preparation of (benzocyclylethyl)arylpiperidines and -piperazines for treating arrhythmia and tachycardia.. Baumgarth, Manfred; Lues, Inge; Minck, Klaus-Otto; Beier, Norbert (Merck Patent GmbH, Germany). Ger. Offen. DE 4321366 A1 19950105, 10 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1993-4321366 19930626.
GI



I

AB Title compds. [I; R1, R2 = H, alkyl; R3-R5 = H, halo, OH, alkoxy, alkanoyloxy, NO2, NH2, alkanoylamino, alkylsulfonylamino, cyano; R3R4 = O(CH2)mO; n = 0-2; X = O, CH2, NH, alkylimino, alkanoylimino; Y = CH, N; m = 1, 2], were prepared as for treating arrhythmia and tachycardia (no data). Thus, 2-(6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)ethyl bromide (preparation given), 4-(3,4-dimethoxyphenyl)piperidine hydrochloride, K2CO3, and KI were refluxed 3 h in MeCOEt to give 1-[2-(6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)ethyl]-4-(3,4-dimethoxyphenyl)piperidine, which was converted to the fumarate.
IT 161525-18-4P 161525-24-2P 161525-26-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (benzocyclylethyl)arylpiperidines and -piperazines for treating arrhythmia and tachycardia)
RN 161525-18-4 CAPLUS
CN Piperidine, 4-(3,4-dimethoxyphenyl)-1-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 70 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 161525-24-2 CAPLUS
CN Piperidine, 4-(3,4-dimethoxyphenyl)-1-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 161525-18-4
CMF C25 H33 N O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

L25 ANSWER 70 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
Double bond geometry as shown.



RN 161525-26-4 CAPLUS
CN Piperazine,
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-(1,2,3,4-tetrahydro-
1-naphthalenyl)ethyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 161525-25-3
CMF C24 H30 N2 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 161525-32-2 161525-33-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (benzocyclylethyl)arylpiperidines and -piperazines for
treating arrhythmia and tachycardia)
RN 161525-32-2 CAPLUS
CN Ethanone,
1-[4-(3,4-dimethoxyphenyl)-1-piperidinyl]-2-(1,2,3,4-tetrahydro-

L25 ANSWER 70 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
1-naphthalenyl)- (CA INDEX NAME)



RN 161525-33-3 CAPLUS
CN Ethanone, 1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-piperazinyl]-2-
(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1994:298643 Document No. 120:298643 Original Reference No.
120:52637a,52640a N-(hetero)aryl-N-[(hetero)tetralinalkyl]piperazine
having serotoninergic, dopaminergic and adrenergic activity. Perrone,
Roberto; Berardi, Francesco; Fiorentini, Francesco; Govoni, Stefano;
Olgiati, Vincenzo; Vanotti, Ermes; Gobetti, Marino; Tonon, Giancarlo
(Pierrel S.p.A., Italy). PCT Int. Appl. WO 9400441 A1 19940106, 72 pp.
DESIGNATED STATES: W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR,
KZ,
LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN; RW: AT, BE, BF,
BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML,
MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION:
WO 1993-EP1589 19930622. PRIORITY: IT 1992-MI1569 19920626.
GI



I



II

AB N-(aryl)-N'-(tetralinalkyl)piperazine having serotoninergic, dopaminergic
and adrenergic activity, the processes for their preparation and relative
therapeutic compns. for the treatment of anxiety generated by depression,
for the treatment of schizophrenia, cerebral ischemia, opium like and
psycho stimulant substances abuse syndromes consciousness disorders such
as senile dementia, vigilance and memory disorders, Parkinson's and
Alzheimer's diseases and for the treatment of arterial hypertension.
More
narrowly defined compds. are the N-(aryl)-N'-(tetralinalkyl)piperazines I
(R1, R2 = alkyl, alkoxy, etc.; R = aryl; XY = alkanediyl, etc.; n = 1,2;
m
= 2,3). A specific compound is
1-(2-methoxyphenyl)-4-[2-[(5-methoxy-1,2,3,4-
tetrahydronaphthalen-1-yl)amino]ethyl]piperazine (II).
IT 154744-84-0P 154744-85-1P 154744-86-2P
154744-87-3P 154744-88-4P 154744-89-5P
154744-91-9P 154744-93-1P 154744-95-3P
154744-96-4P 154744-97-5P 154745-09-2P
154745-10-5P 154745-11-6P 154745-12-7P
154745-13-8P 154745-14-9P 154745-16-1P
154745-18-3P 154745-20-7P 154745-21-8P
154745-22-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as 5-HT receptor antagonist)
RN 154744-84-0 CAPLUS

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-
naphthalenyl)propyl]- (CA INDEX NAME)



RN 154744-85-1 CAPLUS
CN Piperazine,
1-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-4-[3-
(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 154744-86-2 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-
naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 154744-87-3 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 154744-88-4 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 154744-89-5 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]- (CA INDEX NAME)



RN 154744-91-9 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-1-naphthalenyl)propyl]- (CA INDEX NAME)

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 154744-93-1 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[4-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)butyl]- (CA INDEX NAME)



RN 154744-95-3 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)-2-propen-1-yl]- (CA INDEX NAME)

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 154744-96-4 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)-2-propen-1-yl]- (CA INDEX NAME)



RN 154744-97-5 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-1-naphthalenyl)-2-propen-1-yl]- (CA INDEX NAME)

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 154745-09-2 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 154745-10-5 CAPLUS
CN Piperazine, 1-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-4-[3-(trifluoromethyl)phenyl]-, hydrochloride (1:?) (CA INDEX NAME)

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●x HCl

RN 154745-13-8 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 154745-14-9 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●x HCl

RN 154745-11-6 CAPLUS
CN Piperazine, 1-phenyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 154745-12-7 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●x HCl

RN 154745-16-1 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 154745-18-3 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[4-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)butyl]-, hydrochloride (1:?) (CA INDEX NAME)

L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●x HCl

RN 154745-20-7 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)-2-propen-1-yl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 154745-21-8 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)-2-propen-1-yl]-, hydrochloride (1:?) (CA INDEX NAME)

L25 ANSWER 72 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1993:485437 Document No. 119:85437 Original Reference No. 119:15093a,15096a
Antiserotoninergic activity of 2-aminoethylbenzocyclanones in rat aorta: structure-activity relationships. Loza, M. I.; Ferreiro, T. G.; Sanz, F.;
Lozoya, E.; Rodriguez, J.; Manaut, F.; Verde, I.; Castro, E.; Fontenla, J.
A. (Dep. Pharmacol., Univ. Santiago, Santiago de Compostela, E-15706, Spain). Journal of Pharmaceutical Sciences, 82(5), 513=18 (English) 1993.
CODEN: JPMSAE. ISSN: 0022-3549.
AB The antiserotoninergic activity at the serotonin receptor subtype 2 (5-HT2) of seven new 2-aminoethylbenzocyclanones was determined with respect to
serotonin-induced contractions in rat aorta and compared with that of ketanserin (pA2 = 8.87). Competitive antagonism was observed in six compds.
(6.72 ≤ pA2 ≤ 8.12). Three-dimensional structures and mol. electrostatic potential distributions of ketanserin and 2-aminoethylbenzocyclanones were analyzed. Several mol. features correlated with the rank of antiserotoninergic activity. In the case of the cyclanone fragment, the rank of activity was associated with the degree
of planarity of the bicyclic system. The steric and electrostatic effects
due to the loss of planarity were analyzed. In the case of the amino moiety, activity was associated with a particular spatial pattern defined by
the amino nitrogen, the aromatic system, and mol. electrostatic potential min. generated by the oxygen atom.
IT 149247-12-1
RL: BIOL (Biological study)
(serotoninergic S2-antagonist activity of, in aorta, structure in relation to)
RN 149247-12-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



L25 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●x HCl

RN 154745-22-9 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(1,2,3,4-tetrahydro-1-naphthalenyl)-2-propen-1-yl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

L25 ANSWER 73 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1992:551017 Document No. 117:1510170 Original Reference No. 117:26169a
1,4-Disubstituted piperazines, process for their preparation, and pharmaceutical compositions containing them as 5-HT1A receptor antagonists. Peglion, Jean Louis; Millan, Mark; Rivet, Jean Michel (Adir et Compagnie, Fr.). Eur. Pat. Appl. EP 490772 A1 19920617, 23 pp.
DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL,
SE. (French). CODEN: EPXXDW. APPLICATION: EP 1991-403378 19911213.
PRIORITY: FR 1990-15631 19901214.
GI



I

II

AB Title compds. I [X1-X3 = H, halo, alkyl, OH, alkoxy, alkylthio, CF3, NO2, amino, NHAc; or 2 of X form OCH2O or OCH2CH2O; R1 = H, alkyl; DE = (CH2)nCH2 or CH:CH; m, n = 0-3; m+n ≥ 1; p = 0-6; AB = (CH2)2O, (CH2)3O, CH:CH, CH2CH2, COCH:CH], both racemic and optically active, are prepared for treatment of central nervous and neuroendocrine disorders (anxiety, depression, psychosis, diabetes, etc.). For example, N-alkylation of N-(benzodioxan-5-yl)piperazine by (benzocyclobutan-1-yl)methyl iodide and Na2CO3 in MIBK gave (after crystallization
from iso-Pr2O) 29% racemic title compound II. In an in vitro test for binding to rat hippocampal 5-HT1A receptors (displacement of [3H]-8-OH-DPAT), pKi was 8.74 for II and 7.93 for buspirone. Addnl. data include 28 synthetic examples, and in vivo animal experiment results (tail
flick, body posture, corticosterone secretion, and hypothermia) for selected I.
IT 143355-89-9P 168329-98-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as 5-HT1A antagonist)
RN 143355-89-9 CAPLUS
CN Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]- (CA INDEX NAME)

L25 ANSWER 73 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 168329-98-4 CAPLUS
CN Piperazine,
1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(1,2,3,4-tetrahydro-
1-naphthalenyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 143356-23-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for 5-HT1A antagonist)
RN 143356-23-4 CAPLUS
CN Ethanone, 1-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]-2-
(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L25 ANSWER 74 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1992:51593 Document No. 116:515930 Original Reference No. 116:8751a,8754a
Use of bridged tricyclic amine derivatives for treating neurodegenerative
disorders and neurotoxic injury. Gray, Nancy M.; Contreras, Patricia C.
(G.D. Searle and Co., USA). U.S. US 5055468 A 19911008, 23 pp.
(English). CODEN: USXXAM. APPLICATION: US 1989-428531 19891030.
GI



I

AB A neurodegenerative disorder or neurotoxic injury is treated by
administering a therapeutically effective amount of bridged tricyclic
amine
derivs. I (R1, R2 = H, alkyl, cycloalkyl, aryl, halo, etc.; R3-7 = H,
alkyl, OH, cycloalkyl, aralkyl, alkoxy, halo, etc.; n = 0-5; X = H, OH,
alkyl, halo, CN, etc.; R10-13 = H, alkyl, cycloalkyl, halo, etc.; R1 and
R2, R4 and R5, R10 and R11, R12 and R13 may form oxo; p,q = 1-4; Z = O,
S,
NR18; R18 = H, alkyl, cycloalkyl, etc., or R18 and 1 of R10-13 may form
fused 5-8-membered heterocycle ring) or a pharmaceutically-acceptable
salt. 4-[(9,10-Dihydro-9,10-ethanoanthracenyl)methyl]-1-methylpiperazine
(II) (25 μg) blocked the effect of D-serine (200 μg) on cGMP in mice
cerebellum. Cell loss in gerbils was reduced by 30 mg II/kg in a
forebrain ischemia assay. II was prepared from anthracene and allyl
alc. in
3 steps.
IT 133960-68-6P 133960-71-1P 138142-15-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of neurodegenerative disorder and
neurotoxic
injury)
RN 133960-68-6 CAPLUS
CN Pyrimidine, 2-[4-[(9,10-dihydro-9,10-ethanoanthracen-11-yl)methyl]-1-
piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 73 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 74 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 133960-71-1 CAPLUS
CN Pyrimidine, 2-[4-[(9,10-dihydro-9,10-ethanoanthracen-11-yl)methyl]-1-
piperazinyl]- (CA INDEX NAME)



RN 138142-15-1 CAPLUS
CN Piperidine,
1-[(9,10-dihydro-9,10-ethanoanthracen-11-yl)methyl]-4-phenyl-
(CA INDEX NAME)



10590585.trn

L25 ANSWER 75 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1991:449616 Document No. 115:496160 Original Reference No. 115:8617a,8620a
Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogs of butyrophenone. Cortizo, Lourdes; Santana, Lourdes; Ravina, Enrique; Orallo, Francisco; Fontenla, Jose A.; Castro, Elena; Calleja, Jose M.; De Ceballos, Maria L. (Fac. Pharm., Univ. Santiago de Compostela,
Santiago de Compostela, 15706, Spain). Journal of Medicinal Chemistry, 34(7), 2242-7 (English) 1991. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 115:49616.
GI



I

AB Starting from (β-benzoyl)propionic acid, e.g., 3-(aminomethyl)tetralones,e.g., I [R = F, R1 = 4-(N-piperazinyl)-p-fluorobutyrophenone (II); R = H, R1 = 4-benzoylpiperidin-1-yl (III), 4-hydroxy-4-phenylpiperidin-1-yl, 2-(methoxyphenyl)piperazinyl] were synthesized. The possible dopamine antagonist activity of these compds. was investigated in both in vitro and
in vivo expts. These compds. potently inhibited [3H]spiperone binding to D2 striatal receptors and moderately inhibited [3H]SCH-23390 binding to D1
striatal receptors (Kis in the nanomolar and micromolar ranges, resp.). Apomorphine-induced stereotypies and amphetamine group toxicity were antagonized, to different extents by the compds. under study, with a potency similar to that of haloperidol. Interestingly, no catalepsy was observed after administration of the new compds. (2-8 mg/kg). The most active compds. in vivo, II and III, possessed two butyrophenone pharmacophores. However, the tetralone moiety appeared not critical for their antidopaminergic activity, since all target compds. were less active
than haloperidol.
IT 133496-59-0P 133496-60-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antidopaminergic activity of)
RN 133496-59-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)

L25 ANSWER 75 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

L25 ANSWER 75 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 133496-60-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



IT 133496-72-7P 133496-73-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 133496-72-7 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 133496-73-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 76 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1991:247300 Document No. 114:2473000 Original Reference No. 114:41761a,41764a Preparation of dihetero nitrogen-containing cycloheteroethanoanthracene derivatives as antipsychotic agents. Gray, Nancy M. (G.D. Searle and Co., USA). Eur. Pat. Appl. EP 405436 A2 19910102, 41 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1990-112113 19900626. PRIORITY: US 1989-374318 19890629.
GI



I

AB Title compds. I (R5, R6 = H, alkyl, PhCH2, Ph; R7 - R11 = H, alkyl, HO, PhCH2, Ph, alkoxy, PhO, PhCH2O, halo, haloalkyl; R12 = H, alkyl, C5-7 cycloalkyl, Ph, PhCH2, hydroxyalkyl, C5-7 heterocyclyl; R13 - R20 = H, alkyl, PhCH2, Ph, halo, wherein R12 together with one of R13, R14, R19 or R20 may form a fused heterocyclyl containing 5-6-membered-ring) or a salt thereof, are prepared I are also useful in treatment of convulsive and dystonic disorders. 11-(Bromomethyl)-9,10-dihydro-9,10-ethanoanthracene (preparation given), 1-methylpiperazine, and K2CO3 were combined in HMPA and
heated to 90° for 48 h to give after workup I (R5 - R11, R13 - R20 = Y = H, R12 = Me) (II). In blockade of agonist-induced stereotyped behavior and ataxia II blocked N-allylnormetazocine-induced stereotyped behavior and ataxia at 1 and 5 mg/kg, resp. In test for blockade of apomorphine-induced climbing, the ED50 of II was 1.0 mg/kg.
IT 133960-74-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, preparation of antipsychotics)
RN 133960-74-4 CAPLUS
CN Methanone, (9,10-dihydro-9,10-ethanoanthracen-11-yl)[4-(2-pyrimidinyl)-1-piperazinyl]- (CA INDEX NAME)

L25 ANSWER 76 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 133960-68-6P 133960-71-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antipsychotic)
RN 133960-68-6 CAPLUS
CN Pyrimidine, 2-[4-[(9,10-dihydro-9,10-ethanoanthracen-11-yl)methyl]-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 133960-71-1 CAPLUS
CN Pyrimidine, 2-[4-[(9,10-dihydro-9,10-ethanoanthracen-11-yl)methyl]-1-piperazinyl]- (CA INDEX NAME)

L25 ANSWER 76 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 77 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1990:191384 Document No. 112:191384 Original Reference No. 112:32149a
Synthesis of 2-aminomethyltetralins as α-blocking and antidopaminergic agents. Santana, L.; Ravina, E.; Cortizo, L.; Orallo, F.
(Dep. Quim. Org., Lab. Quim. Farm., Santiago de Compostela, 15706, Spain).
Anales de la Real Academia de Farmacia, 55(4), 461-9 (Spanish) 1989.
CODEN: ARAFAY. ISSN: 0034-0618.
GI



AB Five 2-aminomethyltetralins (I, R = heterocyclic; R1 = H, F) were prepared
by reduction of corresponding 3-aminomethyl-1-tetralones. I were characterized by spectroscopic methods and tested for pharmacol. activity as α1-adrenoblocking and antidopaminergic agents in prepns. of the rat ductus deferens. Agents with the 4-phenylpiperidinyl substituents inhibited smooth muscle contractions induced by dopamine or noradrenaline to the extent similar to the action of haloperidol; the α1-blocking activity was slightly weaker. The other agents had much weaker antidopaminergic effects and potentiated the contraction effects of noradrenaline. Details of structure-activity relations are discussed.
IT 109132-90-3P 126684-48-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antidopaminergic and α1-adrenoblocking effects of, structure in relation to)
RN 109132-90-3 CAPLUS
CN Piperidine, 4-phenyl-1-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (CA INDEX NAME)



RN 126684-48-8 CAPLUS
CN Piperidine, 1-[(7-fluoro-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]-4-phenyl- (CA INDEX NAME)



L25 ANSWER 77 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
IT 126684-43-3 126684-44-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)
RN 126684-43-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



RN 126684-44-4 CAPLUS
CN 1(2H)-Naphthalenone, 6-fluoro-3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



10590585.trn

L25 ANSWER 78 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1987:534201 Document No. 107:1342010 Original Reference No. 107:21677a,21680a Fungicidal benzopyran derivatives. Elliott, Alison Clare; Anthony, Vivienne Magaret (Imperial Chemical Industries PLC, UK). Ger. Offen. DE 3620408 A1 19861218, 49 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1986-3620408 19860618. PRIORITY: GB 1985-15389 19850618.
GI



AB Benzopyrans I [X = CH2, Y = O; X = O, Y = CH2, CHOH; R1, R2 = H, halo, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy; R3, R4 = C1-8 alkyl; NR3R4 = (un)substituted heterocyclyl] and their salts, useful as agrochem. fungicides, were prepared 3,4-Dihydro-1-benzopyran-2-carboxylic acid was converted with SOCl2 to its acid chloride, which acylated 4-phenylpiperidine in CH2Cl2 containing pyridine and dimethylaminopyridine to give 100% N-(4-phenyl-1-piperidinyl)-3,4-dihydro-1-benzopyran-2-carboxamide. Reduction of this with LiAlH4 in THF at 0° gave 80% benzopyran II. Barley inoculated with Erysiphe graminis was completely protected with 25 ppm II, and apple inoculated with Venturia inaequalis developed traces to 5% infection when treated with II. Wheat and peanuts developed 60-100% infection from Puccinia recondita and Cercospora arachidicola, resp., after inoculation and spraying with 25 ppm II.
IT 109132-64-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as agrochem. fungicide)
RN 109132-64-1 CAPLUS
CN Piperidine, 4-phenyl-1-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]- (CA INDEX NAME)



L25 ANSWER 79 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 109132-87-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



RN 109132-88-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



RN 109132-89-0 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 109132-90-3 CAPLUS
CN Piperidine, 4-phenyl-1-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (CA INDEX NAME)



L25 ANSWER 79 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1987:439619 Document No. 107:396190 Original Reference No. 107:6619a,6622a Fungicidal benzocycloalkylmethylamines. Worthington, Paul Anthony; Snell, Brian Kenneth; DeFraine, Paul; Anthony, Vivienne Margaret (Imperial Chemical Industries PLC, UK). Ger. Offen. DE 3620356 A1 19861218, 44 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1986-3620356 19860618. PRIORITY: GB 1985-15390 19850618; GB 1986-5418 19860305.
GI



AB Fungicidal compns. comprised compds. I [R5, R6 = H, alkyl, alkoxy, when 1 of R5 and R6 = H, the other ≠ CMe2R (R = H, Me, Et); X = CO or a derivative thereof, CR3R4, CR3OR4; R3, R4 = H, C1-4 alkyl; R1, R2 = H, C1-4 alkyl; NR1R2 = heterocyclyl; n = 0, 1] and a carrier. I were also prepared 6-Methoxy-1,2,3,4-tetrahydro-1-naphthalenone, 2,6-dimethylmorpholine-HCl, and paraformaldehyde were refluxed 3 h in EtOH containing catalytic HCl to give 33% tetrahydronaphthalenone II (Z = O), which was reduced with Zn-Hg to give 20% II (Z = H2). No infection resulted when wheat was sprayed with 100 ppm II (Z = H2) inoculated later with Puccinia recondita or when barley was inoculated with Puccinia recondita or when barley was inoculated with Erysiphe hordei graminis, then sprayed with II (Z = H2). There was 60-100% infection with Cercospora arachidicola on peanuts and Pyricularia oryzae on rice and 26-59% infection with Venturia inaequalis on apples.
IT 109132-64-1P 109132-87-8P 109132-88-9P
109132-89-0P 109132-90-3P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of, as agrochem. fungicide)
RN 109132-64-1 CAPLUS
CN Piperidine, 4-phenyl-1-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]- (CA INDEX NAME)



L25 ANSWER 80 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1987:196210 Document No. 106:196210 Original Reference No. 106:31801a,31804a
Synthesis of nor-meperidine derivatives with a possible analgetic and neuroleptic action. Kolokouris, N. M.; Lambrou, D. (Lab. Pharm. Chem., Univ. Athens, Athens, Greece). Chimika Chronika, 14(4), 251-5 (French) 1985. CODEN: CMCRCZ. ISSN: 0366-693X.
GI



AB The mannich bases I (X = CH2, O, NMe) were prepared from normeperidine and were reduced to the alcs. The latter, according to P.A.J. Janssen (1970), have the required characteristics for neuroleptic and analgesic activity.
IT 108045-97-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and catalytic reduction of)
RN 108045-97-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-phenyl-1-[(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)methyl]-, ethyl ester (CA INDEX NAME)



IT 108046-00-0P 108046-03-3P 108046-06-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 108046-00-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-phenyl-1-[(1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl)methyl]-, ethyl ester (CA INDEX NAME)



RN 108046-03-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-phenyl-1-[(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)methyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 80 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 108046-06-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-phenyl-1-[(1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl)methyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L25 ANSWER 81 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1986:148763 Document No. 104:148763 Original Reference No. 104:23545a,23548a
Benzo[g]quinoline derivatives. Nakao, Tatsu; Terasawa, Michio; Tawara, Tetsuya (Yoshitomi Pharmaceutical Industries, Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 60237071 A 19851125 Showa, 5 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1984-91615 19840507.

GI



I II

AB Title compds. I (R, R1, R3 = H, lower alkyl; R2 = H, lower alkyl, halo; R4, R5 = H, lower alkyl, aralkyl, alicyclic alkyl; or NR4R5 = heterocyclyl) and their salts, useful as cardiovascular agents, platelet aggregation inhibitors, analgesics, and antiinflammatory agents (no data), were prepared Thus, 7.2 g II (R6 = H) was added to a mixture of N-methylpiperazine.2HCl 7.8 g, 3 mL 37% HCHO, and 30 mL acetic anhydride, then heated at 60-70° for 3 h to give 3.5 g II (R6 = N-methylpiperazino).2HCl.

IT 101237-44-9P 101237-45-0P 101237-46-1P
101237-47-2P 101237-48-3P 101237-49-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cardiovascular agent, platelet aggregation inhibitor, analgesic, and antiinflammatory agent)

RN 101237-44-9 CAPLUS
CN Benzo[g]quinoline-2,9-dione, 1,3,4,6,7,8-hexahydro-8-[(4-phenyl-1-piperazinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L25 ANSWER 81 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 101237-45-0 CAPLUS
CN Benzo[g]quinoline-2,9-dione, 1,3,4,6,7,8-hexahydro-8-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 101237-46-1 CAPLUS
CN Benzo[g]quinoline-2,9-dione, 8-[[4-(3-chlorophenyl)-1-piperazinyl]methyl]-1,3,4,6,7,8-hexahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 101237-47-2 CAPLUS
CN Benzo[g]quinoline-2,9-dione, 8-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-1,3,4,6,7,8-hexahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 101237-48-3 CAPLUS
CN Benzo[g]quinoline-2,9-dione, 1,3,4,6,7,8-hexahydro-8-[[4-(4-methylphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 81 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 101237-49-4 CAPLUS
CN Benzo[g]quinoline-2,9-dione, 1,3,4,6,7,8-hexahydro-8-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L25 ANSWER 82 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1982:509663 Document No. 97:1096630 Original Reference No. 97:18233a,18236a
Studies on the amine exchange reactions in C-Mannich bases. Kulkarni, Y. D.; Agarwal, Vipin Kumar (Dep. Chem., Univ. Lucknow, Lucknow, 226 007, India). Journal of the Indian Chemical Society, 59(3), 380-2 (English) 1982. CODEN: JICSAH. ISSN: 0019-4522. OTHER SOURCES: CASREACT 97:109663.
GI



I

AB I (R = R1 = Me) and its methiodide underwent amine exchange reactions yielding I (RR1N = morpholino, 1-piperidinyl, p-ClC6H4NH, p-MeC6H4NH).
IT 60682-02-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 60682-02-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-6-methoxy- (CA INDEX NAME)



L25 ANSWER 83 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1979:152239 Document No. 90:1522390 Original Reference No. 90:24209a,24212a
1,2,3,4-Tetrahydro-2-((4-(phenyl)-1-piperazinyl)methyl)-1-naphthalenols and derivatives and analogs. Vogt, B. Richard; Cullison, David A. (E. R. Squibb and Sons, Inc., USA). U.S. US 4130646 19781219, 18 pp. (English).
CODEN: USXXAM. APPLICATION: US 1976-679411 19760422.
GI



I



II

AB Piperazine derivs. I (R = OH, acyloxy; R1 = H; RR1 = bond; R2 = H, halogen, OH, acyloxy, alkoxy, alkylthio, alkyl, CF3; m, n = 1, 2) were prepared for use as neuroleptics, sedatives, muscle relaxants, antidepressants, and antianxiety agents (no data). Thus, 1-(2-methoxyphenyl)piperazine was treated with α-tetralone and CH2O and reduced with NaBH4 to give II.
IT 59646-31-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 59646-31-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

L25 ANSWER 83 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
IT 59646-26-3P 62811-21-6P 69644-05-9P
69644-06-0P 69644-07-1P 69644-08-2P
69644-09-3P 69644-10-6P 69644-11-7P
69644-12-8P 69644-15-1P 69644-16-2P
69644-17-3P 69644-19-5P 69644-20-8P
69846-95-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 59646-26-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 62811-21-6 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 69644-05-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 69644-06-0 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 83 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 69644-07-1 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 69644-08-2 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, dihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 69644-09-3 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 83 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 69644-10-6 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, 1-acetate, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 69644-11-7 CAPLUS
CN 1-Naphthalenol, 2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-1,2,3,4-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 69644-12-8 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-methoxy-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 83 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 69644-17-3 CAPLUS
CN Decanoic acid, (1R,2R)-1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-1-naphthalenyl ester, rel-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 69644-15-1
CMF C32 H46 N2 O3

Relative stereochemistry.



CM 2

CRN 110-16-7

L25 ANSWER 83 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 69644-15-1 CAPLUS
CN Decanoic acid, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-1-naphthalenyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 69644-16-2 CAPLUS
CN Decanoic acid, (1R,2R)-1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-1-naphthalenyl ester, rel-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 69644-15-1
CMF C32 H46 N2 O3

Relative stereochemistry.

L25 ANSWER 83 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CMF C4 H4 O4

Double bond geometry as shown.



RN 69644-19-5 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, acetate (ester), dihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 69644-20-8 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, acetate (ester), dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 69846-95-3 CAPLUS
CN 1-Naphthalenol, 2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)

L25 ANSWER 83 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L25 ANSWER 84 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

L25 ANSWER 84 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

1979:151858 Document No. 90:1518580 Original Reference No. 90:24129a,24132a Synthesis of 3-aminomethyl-1-tetralones as potential neuroleptic agents. Eirin, Ana Maria; Santana, Lourdes; Ravina, Enrique; Fernandez, Franco; Sanchez-Abarca, Eladio; Calleja, Jose Maria (Dep. Org. Pharm. Chem., Univ. Santiago de Compostela, Santiago, Spain). European Journal of Medicinal Chemistry, 13(6), 533-7 (English) 1978. CODEN: EJMCA5. ISSN: 0009-4374. OTHER SOURCES: CASREACT 90:151858.

GI



I

AB Tetralones I (R = H, R1 = 1-piperidinyl, 4-morpholinyl, 4-methyl-1-piperidinyl, 4-phenyl-1-piperidinyl; R = F, R1 = 4-phenyl-1-piperidinyl) were prepared by Mannich reaction of m-RC6H4COCH2CH2CO2H with heterocyclic amines, catalytic reduction of the resultant m-RC6H4COCH(CH2R1)CH2CO2H, followed by cyclization of the products with polyphosphoric acid. Neuroleptic activity of I was evaluated in mice by the following tests: variation of spontaneous motor activity, hypothermia, evasion, rotating rod, traction, and chimney test; in the 1st test all I had ED50 superior to 40 mg/kg.

IT 69797-43-9P 69797-44-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and neuroleptic activity of)

RN 69797-43-9 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 69797-44-0 CAPLUS

CN 1(2H)-Naphthalenone, 6-fluoro-3,4-dihydro-3-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 85 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

1977:502172 Document No. 87:102172 Original Reference No. 87:16215a,16218a Tetralone and indanone derivatives. (Merck Patent G.m.b.H., Fed. Rep. Ger.). Neth. Appl. NL 7601762 19760824, 31 pp. (Dutch). CODEN: NAXXAN. APPLICATION: NL 1976-1762 19760220.

GI



I



II

AB Piperidinomethyltetralones I (R = R2 = H, R1 = H, OH, O2CEt, OMe, cyclopentyloxy; R = H, 4-Me, 4-F, 4-Cl, 3-CF3, 3,4-CF3Cl, R1 = R2 = OMe; R = H, R1R2 = OCH2O) and indanone II were prepared by Mannich reaction. I and II are central nervous system depressants, bactericides, and fungicides (no data).

IT 60682-23-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)

RN 60682-23-7 CAPLUS

CN 4-Piperidinol, 4-phenyl-1-[(1,2,3,4-tetrahydro-1-hydroxy-6,7-dimethoxy-2-naphthalenyl)methyl]- (CA INDEX NAME)



IT 60711-69-5P 60711-70-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 60711-69-5 CAPLUS

CN 4-Piperidinol, 1-[(3',4'-dihydro-6',7'-dimethoxyspiro[1,3-dioxolane-2,1'(2'H)-naphthalen]-2'-yl)methyl]-4-phenyl- (CA INDEX NAME)

L25 ANSWER 85 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 60711-70-8 CAPLUS
CN 4-Piperidinol, 1-[(3',4'-dihydro-6',7'-dimethoxyspiro[1,3-dithiane-2,1'(2'H)-naphthalen]-2'-yl)methyl]-4-phenyl- (CA INDEX NAME)



IT 60682-00-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)
RN 60682-00-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 60682-01-1P 60682-02-2P 60682-05-5P
60682-06-6P 60682-08-8P 63579-71-5P
63579-72-6P 63579-73-7P 63579-74-8P
63579-75-9P 63579-76-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 60682-01-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-hydroxy-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)

L25 ANSWER 85 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 60682-02-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-6-methoxy- (CA INDEX NAME)



RN 60682-05-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-hydroxy-4-(3-methylphenyl)-1-piperidinyl]methyl]-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 60682-06-6 CAPLUS
CN 1(2H)-Naphthalenone, 2-[[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]methyl]-3,4-dihydro-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 85 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 60682-08-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]methyl]-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 63579-71-5 CAPLUS
CN 1-Naphthalenone, 1,2,3,4-tetrahydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-6-(1-oxopropoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 63579-72-6 CAPLUS
CN 1(2H)-Naphthalenone, 6-(cyclopentyloxy)-3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 85 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 63579-73-7 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 63579-74-8 CAPLUS
CN Naphtho[2,3-d]-1,3-dioxol-5(6H)-one, 7,8-dihydro-6-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 63579-75-9 CAPLUS
CN 1(2H)-Naphthalenone, 2-[[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]methyl]-3,4-dihydro-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 85 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 63579-76-0 CAPLUS
CN 1(2H)-Naphthalenone,
2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-
1-piperidinyl]methyl]-3,4-dihydro-6,7-dimethoxy-, hydrochloride (1:1)
(CA
INDEX NAME)



● HCl

L25 ANSWER 86 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1977:406020 Document No. 87:6020 Original Reference No. 87:977a,980a
Phenylpiperazines. Vogt, Berthold R.; Cullison, David A. (E. R. Squibb
and Sons, Inc., USA). Ger. Offen. DE 2633214 19770217, 37 pp. (German).
CODEN: GWXXBX. APPLICATION: DE 1976-2633214 19760723.

GI



I

AB Phenylpiperazines [I; Rn, R1, m given: H, 2-MeO, 1; 5,6-(MeO)2, 2-MeO, 0; H, 3-F3C, 1; 5,6-(MeO)2, 3-F3C, 0; H, 2-MeO, 0; H, 2-MeO, 2; 6-HO, H, 1], useful as muscle relaxants and sedatives (no data), are prepared by known methods. Thus, reaction of 170 g 1-(2-methoxyphenyl)piperazine-hydrochloride with 172 g α-tetralone and 186 g 24% aqueous CH2O in presence of concentrated HCl gives after .apprx.1 h 171 g 3,4-dihydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-1(2H)-naphthalenone (II). Reduction of 2.14 g II.2HCl.1/2 H2O with NaBH4 gives 1.54
g 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-1-naphthalenol (III). Dehydration of 6 g III with AcOH-H2SO4 15 min at 100° gives 5.6 g I (Rn = H, R1 = 2-MeO, m = 1).

IT 62811-36-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of)

RN 62811-36-3 CAPLUS
CN 1,6-Naphthalenediol,
1,2,3,4-tetrahydro-2-[(4-phenyl-1-piperazinyl)methyl]-
, 6-acetate (CA INDEX NAME)



IT 62811-21-6P 62811-35-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydration of)

RN 62811-21-6 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)

L25 ANSWER 86 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 62811-35-2 CAPLUS
CN 1,6-Naphthalenediol,
1,2,3,4-tetrahydro-2-[(4-phenyl-1-piperazinyl)methyl]-
(CA INDEX NAME)



IT 59646-26-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 59646-26-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



IT 59646-31-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59646-31-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 86 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

10590585.trn

L25 ANSWER 87 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1977:165067 Document No. 86:1650670 Original Reference No. 86:25852h,25853a
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases. Welch, Willard M.; Harbert, Charles A.; Sarges, Reinhard; Stratten, Wilford P.; Weissman, Albert (Med. Res. Lab., Pfizer Inc., Groton, CT, USA). Journal of Medicinal Chemistry, 20(5), 699-705 (English) 1977. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT
86:165067.
GI



I

AB Forty-nine title compds. (including I: R, R1 = H, Me, Et, allyl, cyclohyxyl; NRR1 = morpholino, piperidino, pyrrolidino, piperazino, azepino; R2 = H, Me, Ph; R3, R4 = H, Me; X = H, Cl, F, Me, OMe; Y = H, OMe, OEt) and 4 indanone analogs were prepared from the corresponding tetralones and indanones by standard Mannich reactions. 8-Chloro-5-methoxy-2-morpholinomethyl-1-tetralone maleate [62491-08-1] was
the most potent neuroleptic agent with activity greater than thiothixene. Of the several compds. with analgesic activity, 8-chloro-5-methoxy-2-pyrrolidinomethyl-1-tetralone-HCl [62491-06-9] had potency in the morphine range and low neuroleptic activity, and gave no indication of tolerance development or cross tolerance to morphine, and was not reversed by naloxone. Structure-activity relations are discussed.
IT 62491-17-2P 62491-18-3P 62491-19-4P
62491-20-7P 62491-21-8P 62491-22-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and analgesic activity of)
RN 62491-17-2 CAPLUS
CN 1(2H)-Naphthalenone, 8-chloro-3,4-dihydro-5-methoxy-2-[(4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 87 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN 1(2H)-Naphthalenone,
2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-8-chloro-3,4-dihydro-5-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 62491-21-8 CAPLUS
CN 1(2H)-Naphthalenone,
8-chloro-3,4-dihydro-5-methoxy-2-[[4-(1-oxopropyl)-4-phenyl-1-piperidinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 62491-22-9 CAPLUS
CN 1(2H)-Naphthalenone, 8-chloro-3,4-dihydro-5-methoxy-2-[[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L25 ANSWER 87 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 62491-18-3 CAPLUS
CN 1(2H)-Naphthalenone, 8-chloro-3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-5-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 62491-19-4 CAPLUS
CN 1(2H)-Naphthalenone,
8-chloro-2-[(4-ethoxy-4-phenyl-1-piperidinyl)methyl]-3,4-dihydro-5-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 62491-20-7 CAPLUS

L25 ANSWER 87 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

L25 ANSWER 88 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1976:559908 Document No. 85:159908 Original Reference No. 85:25593a,25596a
Tetralone and indanone derivatives of 4-piperidinol. Jonas, Rochus; Uhl, Juergen; Mueller-Calgan, Helmut; Irmscher, Klaus (Merck Patent G.m.b.H., Fed. Rep. Ger.). Ger. Offen. DE 2507782 19760902, 42 pp. (German).
CODEN: GWXXBX. APPLICATION: DE 1975-2507782 19750222.
GI



I



II

AB [(Hydroxypiperidino)methyl]tetralones [I; Rn = e.g., H, 6-OH, 6-MeO, 6,7-(MeO)2, 6-NH2, 7-NO2; R1n = e.g., 3-Me, 4-Cl, 4-F, 3,4-(F3C)Cl], useful as central nervous depressants and antiemetics (no data), are prepared by several methods, predominantly by condensation of a tetralone with CH2O and a piperidinol. Thus, reaction of 4-phenyl-4-piperidinol-hydrochloride with 1-tetralone and 37% CH2O in refluxing EtOH gives after 1 hr I.HCl(Rn = R1n = H). II is prepared similarly.
IT 60711-69-5 60711-70-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of)
RN 60711-69-5 CAPLUS
CN 4-Piperidinol, 1-[(3',4'-dihydro-6',7'-dimethoxyspiro[1,3-dioxolane-2,1'(2'H)-naphthalen]-2'-yl)methyl]-4-phenyl- (CA INDEX NAME)



RN 60711-70-8 CAPLUS
CN 4-Piperidinol, 1-[(3',4'-dihydro-6',7'-dimethoxyspiro[1,3-dithiane-2,1'(2'H)-naphthalen]-2'-yl)methyl]-4-phenyl- (CA INDEX NAME)

L25 ANSWER 88 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 60682-02-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-6-methoxy- (CA INDEX NAME)



RN 60682-03-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-5,6-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 60682-04-4 CAPLUS
CN Naphtho[1,2-d]-1,3-dioxol-6(7H)-one, 8,9-dihydro-7-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 88 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 60682-23-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)
RN 60682-23-7 CAPLUS
CN 4-Piperidinol, 4-phenyl-1-[(1,2,3,4-tetrahydro-1-hydroxy-6,7-dimethoxy-2-naphthalenyl)methyl]- (CA INDEX NAME)



IT 60682-00-0P 60682-01-1P 60682-02-2P
60682-03-3P 60682-04-4P 60682-05-5P
60682-06-6P 60682-08-8P 60682-11-3P
60682-12-4P 60682-13-5P 60682-14-6P
60682-15-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 60682-00-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 60682-01-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-hydroxy-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)

L25 ANSWER 88 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 60682-05-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-hydroxy-4-(3-methylphenyl)-1-piperidinyl]methyl]-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 60682-06-6 CAPLUS
CN 1(2H)-Naphthalenone, 2-[[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]methyl]-3,4-dihydro-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 60682-08-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]methyl]-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 88 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 60682-11-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-7-nitro- (CA INDEX NAME)



RN 60682-12-4 CAPLUS
CN 1(2H)-Naphthalenone, 7-amino-3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



RN 60682-13-5 CAPLUS
CN 1(2H)-Naphthalenone, 6-amino-3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



RN 60682-14-6 CAPLUS

L25 ANSWER 88 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

L25 ANSWER 88 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN Acetamide, N-[5,6,7,8-tetrahydro-6-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-5-oxo-2-naphthalenyl]- (CA INDEX NAME)



RN 60682-15-7 CAPLUS
CN 1(2H)-Naphthalenone, 6-fluoro-3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)



IT 60682-16-8 60682-17-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)
RN 60682-16-8 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-7-nitro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 60682-17-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-6-nitro-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 89 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1976:432952 Document No. 85:329520 Original Reference No. 85:5349a,5352a
Synthesis and potential neuroleptic activity of new Mannich bases derived from α-tetralone and N-arylpiperazines. Eirin, Ana M.; Ravina, Enrique; Montanes, Jose M.; Calleja, Jose M. (Fac. Pharm., Univ. Santiago Compostela, Santiago, Spain). European Journal of Medicinal Chemistry, 11(1), 29-32 (English) 1976. CODEN: EJMCA5. ISSN: 0223-5234. OTHER SOURCES: CASREACT 85:32952.
GI



I

AB Five I (R = H, OMe; R1 = H, Cl, Me, OMe) were prepared by treating N-arylpiperazines with α-tetralones under Mannich reaction conditions. I (R = H, R1 = Cl) was reduced to the corresponding tetralol (II) with NaBH4. Neuroleptic activity of I and II was determined in mice; I with OMe or Cl groups had higher activity than others, and reduction of the keto group in I to alc. group in II decreased the activity.
IT 59646-23-0P 59646-24-1P 59646-25-2P
59646-26-3P 59646-27-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and neuroleptic activity)
RN 59646-23-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 59646-24-1 CAPLUS
CN 1(2H)-Naphthalenone, 2-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro- (CA INDEX NAME)

L25 ANSWER 89 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 59646-25-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 59646-26-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 59646-27-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



L25 ANSWER 89 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 59646-30-9 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 59646-31-0 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 59646-32-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 89 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

IT 59646-33-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and neuroleptic activity of)
RN 59646-33-2 CAPLUS
CN 1-Naphthalenol, 2-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)



IT 59646-29-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 59646-29-6 CAPLUS
CN 1(2H)-Naphthalenone, 2-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

IT 59646-28-5P 59646-30-9P 59646-31-0P
59646-32-1P 59646-34-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 59646-28-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)

L25 ANSWER 89 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●2 HCl

RN 59646-34-3 CAPLUS
CN 1-Naphthalenol, 2-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-1,2,3,4-tetrahydro-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

10590585.trn

L25 ANSWER 90 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1972:461675 Document No. 77:61675 Original Reference No. 77:10199a,10202a
1-Phenyl-3-(aminoalkyl)-1,2,3,4-tetrahydronaphthalenes and their salts as anorectic agents or central nervous system stimulants. Holava, Henry Michael; Partyka, Richard Anthony (Bristol-Myers Co.). U.S. US 3663608 19720516, 8 pp. (English). CODEN: USXXAM. APPLICATION: US 1969-883985 19691210.
GI For diagram(s), see printed CA Issue.
AB -Phenyl-3-aminomethyl-1,2,3,4-tetrahydronaphthalenes (I) were prepared and found to have activity as anorectic agents or central nervous system stimulants. Thus, PhMgCl reacted with 3-carboxy-1-tetralone to give, after dehydration, 1-phenyl-3-carboxy-3,4-dihydronaphthalene, which was hydrogenated to II (R = H). II reacted with SOCl2 and NH3 or amines to give the corresponding amides which were treated with LiAlH4 to give I. Among 17 I prepared as their hydrochloride salts were (R, R1 given): H, H; H, Me; H, (CH2)3NMe2; H, CH2C.tplbond.CH; CF3, Me. Also prepared were III and IV.
IT 38046-29-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 38046-29-6 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[(1,2,3,4-tetrahydro-4-phenyl-2-naphthalenyl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

L25 ANSWER 91 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1971:100100 Document No. 74:100100 Original Reference No. 74:16301a,16304a
Antiinflammatory 1-[(N-heterocyclyl)methyl]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalenes and 1-[(N-heterocyclyl)methyl]-1,1a,6,6a-tetrahydrocycloprop[a]indenes. Welstead, Williams J., Jr. (A. H. Robins Co., Inc.). Ger. Offen. DE 2035400 19710204, 38 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1970-2035400 19700716.
GI For diagram(s), see printed CA Issue.
AB The antiinflammatory title compds. (I, R = N-heterocyclyl; n = 1 or 2) were prepared Thus, reduction of trans-II with LiAlH4 gave 67% trans-I [R = 4-(p-chlorophenyl)-1,2,3,6-tetrahydro-1-pyridyl, n = 2; isolated as hydrochloride]. Similarly prepared were I (R, n, isomer, and salt isolated given): 3-phenyl-1-piperazinyl, 2, trans, -; 4-phenyl-1-piperazinyl, 1, trans, hydrochloride hydrate; 4-phenyl-1-piperazinyl, 2, cis, ; 4-benzylpiperidino, 2, trans, hydrochloride,; 4-(p-methoxyphenyl)-1-piperazinyl, 2, trans, hydrochloride; 4-phenyl-1,2,3,6-tetrahydro-1-pyridyl, 2, trans, hydrochloride hemihydrate.
IT 31481-70-6P 31481-75-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31481-70-6 CAPLUS
CN Piperazine, 1-phenyl-4-[(1,1a,6,6a-tetrahydrocycloprop[a]inden-1-yl)carbonyl]-, stereoisomer (8CI) (CA INDEX NAME)



RN 31481-75-1 CAPLUS
CN Piperazine, 1-phenyl-4-[(1,1a,6,6a-tetrahydrocycloprop[a]inden-1-yl)methyl]-, monohydrochloride, stereoisomer (8CI) (CA INDEX NAME)



● HCl

L25 ANSWER 92 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1967:37729 Document No. 66:37729 Original Reference No. 66:7175a,7178a
Derivatives of 1- and 2-tetralones. DeStevens, George; Smolinsky, Barbara (CIBA Pharm Co., Summit, NJ, USA). Journal of Medicinal Chemistry, 9, 954-7 (English) 1966. CODEN: JMCMAR. ISSN: 0022-2623.
GI For diagram(s), see printed CA Issue.
AB cf. CA 59, 2761h. Since 1-tetralone and 4-chromanone are useful in the synthesis of highly potent analgetics, some substituted derivs. are prepared especially with groups known to be responsible for particular boil. effects.
The derivs. are obtained by condensation of the appropriate Grignard or organolithium reagent with the cycloketone. In this way I are prepared None of the compds. has any significant biol. activity. Since 2-tetralone has a tendency to exist predominantly in the tautomeric form favoring enolization toward C-1, although some enolization toward C-3 also exists, 1,1-dimethyl-2-tetralone derivs. were prepared to restrict reactivity to only one reactive center of the ketone. Also prepared are IV and VII.
IT 7314-20-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 7314-20-7 CAPLUS
CN 2(1H)-Naphthalenone, 3,4-dihydro-1,1-dimethyl-3-[(4-phenyl-1-piperazinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L25 ANSWER 93 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1965:410079 Document No. 63:10079 Original Reference No. 63:1772d-h Benzyl piperidyl ketones. Pesson, Marcel (Laboratoire Roger Bellon). GB 979555 19650106, 6 pp. (Unavailable). APPLICATION: GB 19620117. PRIORITY: GB 19620117.
GI For diagram(s), see printed CA Issue.
AB The title compds., which have central nervous system activity, and in addition are either respiratory analeptics or analgesics, were prepared by the condensation, in the presence of a basic catalyst, of a benzyl cyanide of the structure RC6H4CH2CN with an ester of piperidinecarboxylic acid. Thus, a solution of 16 g. p-ethoxybenzyl cyanide and 25.4 g. ethyl N-methylisonipecotate in 40 cc. absolute alc. was added to a solution of EtONa (prepared from 3 g. Na and 60 cc. absolute EtOH) and refluxed 7 hrs. to yield 8.5 g. α-(4-ethoxyphenyl)-α-N-methylisonipecotoylacetonitrile (I), m. 239° (EtOH); HCl salt m. 142-4° (decomposition). A solution of 11.7 g. PhCH2CN in 50 cc. PhMe was added to a suspension of NaNH2 [prepared from 2.3 g. Na and 200 cc. liquid NH3 in the presence of a small quantity of Fe(NO3)3]. The excess NH3 was driven off and 20.3 g. Et N-ethylisonipecotate was added and the mixture heated at 80° for 3 hrs. to yield 21.1 g. α-phenyl-α-N-ethylisonipecotoylacetonitrile, m. 274°; HCl salt m. 194°.
The following acetonitriles were similarly prepared (substituents and m.p. given): α-phenyl-α-N-methylpipecoloyl, -; α-phenyl-α-N-methylnipecotoyl (II), 255° [HCl salt m. 161° (decomposition)]; α-(4-chlorophenyl)-N-methylnipecotoyl, 256°; α-(4-chlorophenyl)-α-N-methylisonipecotoyl, 306-7°; α-(4-chlorophenyl)-α-N-ethylisonipecotoyl, 292°; α-phenyl-α-N-butylnipecotoyl, 197°; α-phenyl-α-N-methylisonipecotoyl, 297-80°. A solution of 6 g. II in 60 cc. 2N NaOH was methylated in the usual manner with 9 cc. Me2SO4 to yield α-phenyl-α-methyl-α-N-methylnipecotoylacetonitrile, m. 277°; HCl salt m. 238°. A suspension of 24.2 g. II in 50 cc. AcOH, 50 cc. H2SO4, and 25 cc. H2O was refluxed 12 hrs., the bulk of the AcOH removed in vacuo on the H2O bath, and the residue poured on to ice to yield 16.1 g. benzyl N-methyl-3-piperidyl ketone, b0.9 135-40°; citrate m. 253° (EtOH). Hydrolysis of the corresponding oxonitriles similarly yielded the following ketones (m.p. given). 4-ClC6H4CH2 N-methyl-3-piperidyl, 71°; 4-ClC6H4CH2 N-ethyl-4-piperidyl, 79°; PhCH2 N-ethyl-4-piperidyl, b0.8 136-7° (HCl salt m. 174°); α-phenethyl N-methyl-3-piperidyl, - (citrate m. 228°); PhCH2 N-butyl-3-piperidyl, b0.8 152-5° (oxalate m. 177°); PhCH2 N-methyl-4-piperidyl, b0.8 140-2° [HCl salt m. 178° (EtOH)].
IT 3036-57-5P, 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-p-tolylpiperidino)methyl]-6,7-dimethyl-, hydrochloride
RL: PREP (Preparation)
(preparation of)
RN 3036-57-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-hydroxy-4-(4-methylphenyl)-1-piperidinyl]methyl]-6,7-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 93 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

L25 ANSWER 94 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1965:410078 Document No. 63:10078 Original Reference No. 63:1772b-d
β-Amino ketone derivatives. Nakanishi, Michio; Mukai, Toshihiko; Inamasu, Shuji (Yoshitomi Pharmaceutical Industries, Ltd.). JP 40006464 19650330 Showa, 2 pp. (Unavailable). APPLICATION: JP 19621130. PRIORITY: JP 19621130.
GI For diagram(s), see printed CA Issue.
AB Manufacture of I, a useful tranquilizer, was described. Thus, a mixture of 4-cyano-4-phenylpiperidine-HCl 2.23, paraformaldehyde 0.3, and 6,7-dimethyl-1-tetralone 1.75 g. is refluxed in 50 ml. EtOH containing small amount of HCl 7 hrs., then refluxed with more 0.15 g. paraformaldehyde 6 hrs., evaporated, the residue washed with dilute HCl, then washed with Et2O, and recrystd. from dioxane-iso-PrOH to give I (R = CN, R' = Ph), m. 187-8°. Similarly is prepared I (R = OH, R' = p-tolyl), m. 167-7.5°.
IT 3036-56-4P, Isonipecotonitrile, 1-phenyl-4-[(1,2,3,4-tetrahydro-6,7-dimethyl-1-oxo-2-naphthyl)methyl]-, hydrochloride 3036-57-5P, 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-p-tolylpiperidino)methyl]-6,7-dimethyl-, hydrochloride
RL: PREP (Preparation)
(preparation of)
RN 3036-56-4 CAPLUS
CN 4-Piperidinecarbonitrile, 4-phenyl-1-[(1,2,3,4-tetrahydro-6,7-dimethyl-1-oxo-2-naphthalenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 3036-57-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-hydroxy-4-(4-methylphenyl)-1-piperidinyl]methyl]-6,7-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

L25 ANSWER 94 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

L25 ANSWER 95 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1963:53341 Document No. 58:53341 Original Reference No. 58:9097g-h
Sulfamoyl-3,4-dihydro-4-quinazolones. Horii, Zenichi JP 37003580 19620606
Showa, 1 p. (Unavailable). APPLICATION: JP 19591125. PRIORITY: JP 19591125.
GI For diagram(s), see printed CA Issue.
AB A mixture of 0.3 g. 4-chloro-5-sulfamoylanthranilic acid and 1 cc. formamide is heated at 160-5° for 1 hr., cooled, and allowed to stand with 5 cc. H2O to give 0.25 g. (77%) 7-chloro-6-sulfamoyl-3,4-dihydro-4-quinazolone (I), microneedles, m. 317-18° (decomposition) (H2O). Also prepared is 7-sulfamoyl-3,4-dihydro-4-quinazolone (m. 293-4°). These are useful as decarboxylase inhibitors.
IT 94879-31-9P, 1(2H)-Naphthalenone, 2-[[4-(p-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro- 99904-89-9P, 1(2H)-Naphthalenone, 2-[[4-(p-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro-, hydrobromide
RL: PREP (Preparation)
(preparation of)
RN 94879-31-9 CAPLUS
CN 1(2H)-Naphthalenone, 2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro- (CA INDEX NAME)



RN 99904-89-9 CAPLUS
CN 1(2H)-Naphthalenone, 2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro-, hydrobromide (1:?) (CA INDEX NAME)



●x HBr

10590585.trn

L25 ANSWER 96 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
1963:53340 Document No. 58:53340 Original Reference No. 58:9097c-g
N,N'-Disubstituted piperazines. Nichols, Gust (Miles Laboratories, Inc.).
BE 614151 19620315, 17 pp. (Unavailable). PRIORITY: US 19610224.
GI For diagram(s), see printed CA Issue.
AB A series of HCl and HBr salts of disubstituted piperazines of the general type I, where Y represents an α-oxocycloalkylmethyt group and R stands for H, a halogen atom, or a lower alkyl or alkoxy group, is described. N-Phenylpiperazine (II) (648 g.) in absolute EtOH treated with 1
equivalent N alc. HBr (total volume of EtOH 3400 cc.), refluxed, treated with 8
cc. concentrated HBr and 490 g. cyclohexanone (III) and then with 198 g. paraformaldehyde in 25-g. portions during 45 min., refluxed 6.5 hrs., filtered hot, and cooled gave 903 g. 4-(2-oxocyclohexylmethyl) derivative (IV)
of II.HBr, m. 168-70° (iso-PrOH). II (81 g.) in absolute EtOH converted to II.HCl with alc. HCl (total volume of EtOH 500 cc.), treated with 0.5 cc. concentrated HCl and 61.25 g. III and then dropwise with 55 cc. 37%
aqueous CH2O in 100 cc. absolute EtOH, and worked up the usual manner yielded 76
g. IV.HCl, m. 167-8° (CHCl3-C6H6). IV.HBr treated with K2CO3, and the resulting IV treated with HCl gave IV.2HCl. In the usual manner were prepared the following compds. (m.p. and starting amine and ketone given):
4-(2-oxo-3-methylcyclohexylmethyl) derivative of II.HBr, 164-6° II, 2-methylcyclohexanone; 4-(2-oxo-5-methylcyclohexylmethyl) derivative of II.HBr, 169-70°, II, 4-methylcyclohexanone;
4-(2-oxo-5-methoxycyclohexylmethyl) derivative of II.HBr, m. 154-5.5° II, 4-methoxycyclohexanone; 1-(o-chlorophenyl)-4-(2-oxocyclohexylmethyl)piperazine-HBr (V HBr), 171-3°,
N-(o-chlorophenyl)piperazine (VI), III; I-(p-ClC6H4) analog of V.HBr, 173-4°, p-isomer of VI, III; 1-(p-MeC6H4) analog of V.HBr, 160-2°, N-(p-methylphenyl)piperazine, III.
N-(p-Chlo-ophenyl)piperazine-HBr (VII.HBr) from 19.65 g. free base in 350 cc. absolute EtOH treated with 10.5 g. cyclopentanone and 0.25 cc. concentrated HBr
and then during 80 min. with 5 g. paraformaldehyde, refluxed 3 hrs., and worked up gave 12 g. 4-(2-oxocyclopentylmethyl) derivative of VII.HBr, m. 159-61°(EtOH). VII.HBr from 19.65 g. free base and 18.25 g. 1-tetralone gave 23 g. [1-(p-chlorophenyl)-4-piperazinylmethyl]-1-tetralone-HBr, m. 192-4° (MeOH). Similarly was prepared 1-phenyl-4-(2-oxocyclopentylmethyl]piperazine-HBr, m. 158-60°. The new piperazine derivs. show analgesic activity.
IT 94879-31-9P, 1(2H)-Naphthalenone, 2-[[4-(p-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro-
99904-89-9P, 1(2H)-Naphthalenone, 2-[[4-(p-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro-, hydrobromide
RL: PREP (Preparation)
(preparation of)
RN 94879-31-9 CAPLUS
CN 1(2H)-Naphthalenone, 2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro- (CA INDEX NAME)

L25 ANSWER 96 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 99904-89-9 CAPLUS
CN 1(2H)-Naphthalenone, 2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-3,4-dihydro-, hydrobromide (1:?) (CA INDEX NAME)



● x HBr

10590585.trn

```
=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 11:36:07 ON 23 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 19, 2010 (20100219/UP).

=>
Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 10   Time limit for inactive STN sessions doubles to 40
                   minutes
 NEWS  3  AUG 18   COMPENDEX indexing changed for the Corporate Source
                   (CS) field
 NEWS  4  AUG 24   ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
 NEWS  5  AUG 24   CA/CAplus enhanced with legal status information for
                   U.S. patents
 NEWS  6  SEP 09   50 Millionth Unique Chemical Substance Recorded in
                   CAS REGISTRY
 NEWS  7  SEP 11   WPIDS, WPINDEX, and WPIX now include Japanese FTERM
                   thesaurus
 NEWS  8  OCT 21   Derwent World Patents Index Coverage of Indian and
                   Taiwanese Content Expanded
 NEWS  9  OCT 21   Derwent World Patents Index enhanced with human
                   translated claims for Chinese Applications and
                   Utility Models
 NEWS 10  NOV 23   Addition of SCAN format to selected STN databases
 NEWS 11  NOV 23   Annual Reload of IFI Databases
 NEWS 12  DEC 01   FRFULL Content and Search Enhancements
 NEWS 13  DEC 01   DGENE, USGENE, and PCTGEN: new percent identity
                   feature for sorting BLAST answer sets
 NEWS 14  DEC 02   Derwent World Patent Index: Japanese FI-TERM
                   thesaurus added
 NEWS 15  DEC 02   PCTGEN enhanced with patent family and legal status
                   display data from INPADOCDB
 NEWS 16  DEC 02   USGENE: Enhanced coverage of bibliographic and
                   sequence information
 NEWS 17  DEC 21   New Indicator Identifies Multiple Basic Patent
                   Records Containing Equivalent Chemical Indexing
                   in CA/CAplus
```

10590585.trn

```
 NEWS 18  JAN 12  Match STN Content and Features to Your Information
                  Needs, Quickly and Conveniently
 NEWS 19  JAN 25  Annual Reload of MEDLINE database
 NEWS 20  FEB 16  STN Express Maintenance Release, Version 8.4.2, Is
                  Now Available for Download
 NEWS 21  FEB 16  Derwent World Patents Index (DWPI) Revises Indexing
                  of Author Abstracts
 NEWS 22  FEB 16  New FASTA Display Formats Added to USGENE and PCTGEN
 NEWS 23  FEB 16  INPADOCDB and INPAFAMDB Enriched with New Content
                  and Features
 NEWS 24  FEB 16  INSPEC Adding Its Own IPC codes and Author's E-mail
                  Addresses

 NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
              AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:51:53 ON 23 FEB 2010

=> file reg
FILE 'REGISTRY' ENTERED AT 16:52:08 ON 23 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 FEB 2010  HIGHEST RN 1207159-36-1
DICTIONARY FILE UPDATES:  22 FEB 2010  HIGHEST RN 1207159-36-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
```

10590585.trn

on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10590585-888.str





chain nodes :
27
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 18 19 20 21 22 23 25 26
ring/chain nodes :
28 29
chain bonds :
9-27 13-27 16-20 27-28 27-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-18 13-14 14-15 15-16
16-19 18-19 20-21 20-22 21-26 22-23 23-25 25-26
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 9-10 9-27 13-18 13-14 13-27 14-15
15-16 16-19 16-20 18-19 20-21 20-22 21-26 22-23 23-25 25-26 27-28 27-29
exact bonds :
7-8 8-9

10590585.trn

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 29:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:52:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 79202 TO ITERATE

2.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1567272 TO 1600808
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:52:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1587402 TO ITERATE

100.0% PROCESSED 1587402 ITERATIONS 265 ANSWERS
SEARCH TIME: 00.00.08

10590585.trn

L3 265 SEA SSS FUL L1

=> d scan

10590585.trn

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-5,6-dimethoxy-
MF C24 H29 N O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 4-Piperidinecarboxylic acid, 4-phenyl-1-[(1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl)methyl]-, ethyl ester
MF C25 H31 N O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-, O-ethyloxime
MF C22 H28 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1(2H)-Naphthalenone, 3,4-dihydro-3-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-
MF C20 H23 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10590585.trn

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1(2H)-Naphthalenone,
2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-
1-piperidinyl]methyl]-3,4-dihydro-6,7-dimethoxy-, hydrochloride (1:1)
MF C25 H27 Cl F3 N O4 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-
piperidinyl]methyl]-5,6,7,8-tetrahydro-, hydrochloride (1:1), (6R,8S)-
MF C21 H24 Cl F N2 O2 . Cl H

Absolute stereochemistry.



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1(2H)-Naphthalenone,
3,4-dihydro-2-methyl-6-(phenylmethoxy)-2-[(4-phenyl-1-
piperidinyl)methyl]-, oxime, (1Z)-
MF C30 H34 N2 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1(2H)-Naphthalenone, 2-[[4-(4-chlorophenyl)-4-hydroxy-1-
piperidinyl]methyl]-3,4-dihydro-6,7-dimethoxy-, hydrochloride (1:1)
MF C24 H28 Cl N O4 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10590585.trn

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzamide, 3-[3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]-
MF C25 H30 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1-Naphthalenol, 1,2,3,4-tetrahydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-
MF C22 H28 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[4-(4-fluoro-2-methylphenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
MF C22 H27 F N2 O2 . C4 H6 O6

CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-6,7-dimethoxy-
MF C24 H29 N O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10590585.trn

L3 265 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzo[g]quinoline-2,9-dione, 1,3,4,6,7,8-hexahydro-8-[(4-phenyl-1-piperazinyl)methyl]-, hydrochloride (1:1)
MF C24 H27 N3 O2 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10590585.trn

```
=> d his

     (FILE 'HOME' ENTERED AT 16:51:53 ON 23 FEB 2010)

     FILE 'REGISTRY' ENTERED AT 16:52:08 ON 23 FEB 2010
L1              STRUCTURE UPLOADED
L2            0 S L1
L3          265 S L1 FULL

=> s l3 and C9N/rf
       1566957 C9N/RF
L4          28 L3 AND C9N/RF

=> d scan
```

10590585.trn

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 3-Quinolinecarboxylic acid,
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-
[[1,2,3,4-tetrahydro-1-(hydroxyimino)-6-methoxy-2-naphthalenyl]methyl]-1-
piperazinyl]-
MF C29 H31 F N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2000

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-
piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-
MF C21 H24 Cl F N2 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[4-(4-fluoro-2-methylphenyl)-3-hydroxy-1-
piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1)
MF C22 H27 F N2 O2 . C4 H6 O6

CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry.



L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 3-Quinolinecarboxylic acid,
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-

[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]-
MF C29 H30 F N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10590585.trn

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[4-(2-chloro-4-fluorophenyl)-3-methoxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI)
MF C22 H26 Cl F N2 O2 . C4 H6 O6

CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry.



L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-
MF C22 H28 N2 O
CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Azabicyclo[3.2.1]octan-2-ol, 3-(2-chloro-4-fluorophenyl)-8-[[(6R,8S)-5,6,7,8-tetrahydro-8-hydroxy-6-quinolinyl]methyl]-, hydrochloride (1:1)
MF C23 H26 Cl F N2 O2 . Cl H

Absolute stereochemistry.





● HCl

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 5(6H)-Quinolinone, 7,8-dihydro-7-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-
MF C21 H25 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10590585.trn

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]-
MF C30 H32 F N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 2-chloro-5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-rel-
MF C22 H27 Cl N2 O

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
MF C22 H28 N2 O . C4 H6 O6

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry.



L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Azabicyclo[3.2.1]octan-2-ol, 3-(2-chloro-4-fluorophenyl)-8-[[(6R,8S)-5,6,7,8-tetrahydro-8-hydroxy-6-quinolinyl]methyl]-
MF C23 H26 Cl F N2 O2
CI COM

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10590585.trn

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[4-(2-chlorophenyl)-4-fluoro-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-
MF C21 H24 Cl F N2 O
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]-
MF C29 H28 F3 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 3-chloro-5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-rel-
MF C22 H27 Cl N2 O
CI COM

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 5,6,7,8-tetrahydro-6-[[3-hydroxy-4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-
MF C22 H28 N2 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10590585.trn

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 3-Piperidinol,
4-(2-chloro-4-fluorophenyl)-1-[[(6R,8S)-5,6,7,8-tetrahydro-
8-[(triethylsilyl)oxy]-6-quinolinyl]methyl]-, (3R,4R)-
MF C27 H38 Cl F N2 O2 Si

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[4-(2-chlorophenyl)-4-fluoro-1-piperidinyl]methyl]-
5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
(salt) (9CI)
MF C21 H24 Cl F N2 O . C4 H6 O6

CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry.



L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 3-Quinolinecarboxylic acid,
1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-

[3-methyl-4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-
piperazinyl]-4-oxo-
MF C31 H34 F N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 3-chloro-5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-
piperidinyl]methyl]-, (6R,8S)-rel-, (2R,3R)-2,3-dihydroxybutanedioate
(1:1) (salt) (9CI)
MF C22 H27 Cl N2 O . C4 H6 O6

CM 1

Relative stereochemistry.



CM 2

Absolute stereochemistry.



10590585.trn

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 5,6,7,8-tetrahydro-6-[[3-hydroxy-4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
MF C22 H28 N2 O2 . C4 H6 O6

CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry.



L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8(5H)-Quinolinone, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-6,7-dihydro-, (6R)-
MF C21 H22 Cl F N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, hydrochloride (1:1), (6R,8S)-
MF C21 H24 Cl F N2 O2 . Cl H

Absolute stereochemistry.



● HCl

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]-
MF C28 H30 F N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10590585.trn

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 5,6,7,8-tetrahydro-2-methyl-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-rel-
MF C23 H30 N2 O

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[4-(4-fluoro-2-methylphenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-
MF C22 H27 F N2 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-6-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-
MF C21 H24 Cl F N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 28 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[4-(2-chloro-4-fluorophenyl)-3-methoxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-
MF C22 H26 Cl F N2 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10590585.trn

=>
Uploading C:\Program Files\Stnexp\Queries\11580585-0000.str





10590585.trn

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l5

10590585.trn

L6 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[(4-methoxyphenyl)methyl]-
MF C19 H20 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10590585.trn

=>
Uploading C:\Program Files\Stnexp\Queries\11580585-0000.str





chain nodes :
20
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 18 19
ring/chain nodes :
21 22
chain bonds :
9-20 13-20 20-21 20-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-18 13-14 14-15 15-16
16-19 18-19
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 9-10 9-20 13-18 13-14 13-20 14-15
15-16 16-19 18-19 20-21 20-22
exact bonds :
7-8 8-9

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 18:Atom 19:Atom 20:CLASS 21:CLASS 22:CLASS

10590585.trn

L7 STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l7
SAMPLE SEARCH INITIATED 16:55:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 79202 TO ITERATE

2.5% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1567272 TO 1600808
PROJECTED ANSWERS: 1723 TO 3029

L8 3 SEA SSS SAM L7

=> d scan

10590585.trn

L8 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Morphinan-3,6-diol, 17-(cyclopropylmethyl)-4,5-epoxy-14-(phenylmethyl)-, (5α,6α)- (9CI)
MF C27 H31 N O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1(2H)-Naphthalenone, 3,4-dihydro-6-methoxy-2-[(4-methoxyphenyl)methyl]-
MF C19 H20 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 2(1H)-Naphthalenone, 3,4-dihydro-3-[(3-methoxyphenyl)methyl]-
MF C18 H18 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10590585.trn

=>
Uploading C:\Program Files\Stnexp\Queries\10590585-narro.str





10590585.trn

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l9
SAMPLE SEARCH INITIATED 16:57:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 59389 TO ITERATE

10590585.trn

L12 45 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[(1R,5S)-6'-fluoro-1',1'-dimethylspiro[8-azabicyclo[3.2.1]octane-3,3'(1'H)-furo[3,4-c]pyridin]-8-yl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI)
MF C25 H30 F N3 O2 . C4 H6 O6

CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 45 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
MF C22 H28 N2 O . C4 H6 O6

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 45 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[(3,3-dimethylspiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl)methyl]-5,6,7,8-tetrahydro-, (6S,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI)
MF C24 H30 N2 O2 . C4 H6 O6

CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 45 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 3-Piperidinol, 4-(2-chloro-4-fluorophenyl)-1-[[(6R,8S)-5,6,7,8-tetrahydro-8-[(triethylsilyl)oxy]-6-quinolinyl]methyl]-, (3R,4R)-
MF C27 H38 Cl F N2 O2 Si

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10590585.trn

L12 45 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[4-(4-fluoro-2-methylphenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-
MF C22 H27 F N2 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 45 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, hydrochloride (1:1), (6R,8S)-
MF C21 H24 Cl F N2 O2 . Cl H

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 45 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 8(5H)-Quinolinone, 6-[(6-fluoro-1,1-dimethylspiro[furo[3,4-c]pyridine-3(1H),4'-piperidin]-1'-yl)methyl]-6,7-dihydro-, (6R)-
MF C23 H26 F N3 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10590585.trn

=> file caplus
FILE 'CAPLUS' ENTERED AT 16:57:53 ON 23 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Feb 2010 VOL 152 ISS 9
FILE LAST UPDATED: 22 Feb 2010 (20100222/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

10590585.trn

```
=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y
```

10590585.trn

L13 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
2009:753543 Document No. 151:1632230 Identification of an Orally Active Opioid Receptor-like 1 (ORL1) Receptor Antagonist

4-{3-[(2R)-2,3-Dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as Clinical Candidate. Satoh, Atsushi; Sagara, Takeshi; Sakoh, Hiroki; Hashimoto, Masaya; Nakashima, Hiroshi; Kato, Tetsuya; Goto, Yasuhiro; Mizutani, Sayaka; Azuma-Kanoh, Tomoko; Tani, Takeshi; Okuda, Shoki; Okamoto, Osamu; Ozaki, Satoshi; Iwasawa, Yoshikazu;
Ohta, Hisashi; Kawamoto, Hiroshi (Tsukuba Research Institute, Banyu Pharmaceutical Co. Ltd., Okubo-3, Tsukuba 300-2611, Ibaraki, 300-2611, Japan). Journal of Medicinal Chemistry, 52(14), 4091-4094 (English) 2009.
CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 151:163223.
Publisher: American Chemical Society.

AB Our efforts to optimize prototype opioid receptor-like 1 (ORL1) antagonist
1 led to the discovery of 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine 10. 10 Showed potent ORL1 antagonistic activity, excellent selectivity over other opioid receptors, and in vivo efficacy after oral dosing. Currently clin. trials of 10 are underway.

IT 864830-99-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally active ORL1 antagonists preparation)

RN 864830-99-9 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
2008:1368162 Document No. 149:5566000 Substituted heterocyclic derivatives as antimicrobial agents and their preparation, pharmaceutical compositions
and use in the treatment of bacterial infection. Brickner, Steven Jospeh;
Chen, Jinshan Michael; Li, Zhengong Bryan; Marfat, Anthony; Mitton-Fry, Mark Joseph; Plotkin, Micheal A.; Reilly, Usa Datta; Subramanyam, Chakrapani; Zhang, Zhijun; Robinson, Shaughnessy (Pfizer Inc., USA). U.S.
Pat. Appl. Publ. US 20080280879 A1 20081113, 54pp. (English). CODEN: USXXCO. APPLICATION: US 2008-117071 20080508. PRIORITY: US 2007-916906P 20070509.

GI



I



II

AB Compds. of the general formula I, their preparation and their use as antimicrobial agents are disclosed. Compds. of formula I wherein at least
one of X1 - X6 is N or N-oxide and the remaining is N and CR1; each R1 is independently H, halo, CN, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is H, OH, halo, NH2, C1-6 alkyl, C1-6 alkylthio, etc.; X7 is O, NH and derivs., CH2,
S, SO, SO2, etc.; R4 is H, OH, C1-6 alkoxy, F, NH2, CN, etc.; D is (un)substituted azacyclyl and (un)substituted azacyclylalkyl; C is (un)substituted cycloalkyl and (un)substituted azacycle; and pharmaceutically acceptable salts, prodrugs, hydrates, and solvates thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for

L13 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
their antimicrobial activity (data given).

IT 1080635-89-7P 1080635-90-0P 1080635-91-1P
1080635-92-2P 1080635-93-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic derivs. as antimicrobial agents
useful in the treatment of bacterial infection)

RN 1080635-89-7 CAPLUS
CN 3-Piperidinecarboxylic acid, 4-[3-hydroxy-3-(6-methoxy-4-quinolinyl)propyl]-1-[[5,6,7,8-tetrahydro-2-(1-methylethyl)-6-quinazolinyl]methyl]-, (3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1080635-90-0 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[[2-(cyclopropylmethyl)-5,6,7,8-tetrahydro-6-quinazolinyl]methyl]-4-[3-hydroxy-3-(6-methoxy-4-quinolinyl)propyl]-, (3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1080635-91-1 CAPLUS
CN 3-Piperidinecarboxylic acid, 4-[3-hydroxy-3-(6-methoxy-4-
quinolinyl)propyl]-1-[(5,6,7,8-tetrahydro-2-phenyl-6-quinazolinyl)methyl]-, (3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1080635-92-2 CAPLUS
CN 3-Piperidinecarboxylic acid, 4-[3-hydroxy-3-(6-methoxy-4-quinolinyl)propyl]-1-[[5,6,7,8-tetrahydro-2-(2-pyrazinyl)-6-quinazolinyl]methyl]-, (3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1080635-93-3 CAPLUS
CN 3-Piperidinecarboxylic acid, 4-[3-hydroxy-3-(6-methoxy-4-quinolinyl)propyl]-1-[[5,6,7,8-tetrahydro-2-(1-piperidinyl)-6-quinazolinyl]methyl]-, (3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



10590585.trn

L13 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
2008:685859 Document No. 149:1761540 A Novel Class of Cycloalkano[b]pyridines as Potent and Orally Active Opioid Receptor-like 1
Antagonists with Minimal Binding Affinity to the hERG K+ Channel.
Yoshizumi, Takashi; Takahashi, Hirobumi; Miyazoe, Hiroshi; Sugimoto, Yuichi; Tsujita, Tomohiro; Kato, Tetsuya; Ito, Hirokatsu; Kawamoto, Hiroshi; Hirayama, Mioko; Ichikawa, Daisuke; Azuma-Kanoh, Tomoko; Ozaki, Satoshi; Shibata, Yoshihiro; Tani, Takeshi; Chiba, Masato; Ishii, Yasuyuki; Okuda, Shoki; Tadano, Kiyoshi; Fukuroda, Takahiro; Okamoto, Osamu; Ohta, Hisashi (Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd, Okubo-3, Tsukuba, Ibaraki, 300-2611, Japan). Journal of Medicinal Chemistry, 51(13), 4021-4029 (English) 2008. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 149:176154. Publisher: American Chemical Society.
GI



I



II

AB A series of compds. based on 7-{[4-(2-methylphenyl)piperidin-1-yl]methyl}-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol ((-)-I), a potent and selective opioid receptor-like 1 (ORL1) antagonist, was prepared and evaluated using structure-activity relationship studies with the aim of removing its affinity to human ether-a-go-go related gene (hERG) K+ channel. From these studies, II was identified as an optimized structure with respect to ORL1 antagonist activity, and affinity to the hERG K+channel. Furthermore, II showed good in vivo antagonism with a wide therapeutic index in regards to adverse cardiovascular effects.
IT 864828-68-2P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal structure; synthesis and biol. evaluation of

L13 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT 1039359-51-7P 1039359-53-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(lipophilicity; synthesis and biol. evaluation of arylpiperidinylmethyl-substituted cycloalkano[b]pyridines as orally active opioid receptor-like 1 antagonists with minimal binding affinity
to the hERG K+ channel)
RN 1039359-51-7 CAPLUS
CN 8-Quinolinol, 5,6,7,8-tetrahydro-6-[[3-hydroxy-4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1039359-50-6
CMF C22 H28 N2 O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

L13 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
arylpiperidinylmethyl-substituted cycloalkano[b]pyridines as orally active opioid receptor-like 1 antagonists with minimal binding affinity
to the hERG K+ channel)
RN 864828-68-2 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, hydrochloride (1:1), (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 1039359-49-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(lipophilicity and acidity; synthesis and biol. evaluation of arylpiperidinylmethyl-substituted cycloalkano[b]pyridines as orally active opioid receptor-like 1 antagonists with minimal binding affinity
to the hERG K+ channel)
RN 1039359-49-3 CAPLUS
CN 8-Quinolinol, 5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1039359-48-2
CMF C22 H28 N2 O

Absolute stereochemistry. Rotation (-).



L13 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1039359-53-9 CAPLUS
CN 8-Quinolinol, 6-[[4-(4-fluoro-2-methylphenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1039359-52-8
CMF C22 H27 F N2 O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



10590585.trn

L13 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
2008:670939 Document No. 149:100450 Synthesis of quinoline derivatives with antibacterial activity. Srivastava, Brijesh K.; Jain, Mukul R.; Patel, Pankaj R. (Cadila Healthcare Limited, India). Eur. Pat. Appl. EP 1927589 A1 20080604, 19pp. DESIGNATED STATES: R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS. (English). CODEN: EPXXDW. APPLICATION: EP 2007-254643 20071130. PRIORITY: IN 2006-MU1967 20061130.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to a process for preparing quinoline compds. I [R1 = H, (C1-C12)alkyl, (C3-C12)cycloalkyl; R2, R3 = H, OH, halo, alkoxy, NO2, cyano; R8, R9, R10, R11 = H, alkyl; R4, R5, R6, R7 = H, halo, haloalkyl, OH, alkoxy, thio NO2, cyano, amino, (C1-C12)alkyl, (C1-C12)alkoxy derivative of sulfenyl or sulfonyl group, sulfonic acid and derivs.; Z = O, S, NR, R = H, OH , (C1-C3)alkyl; X = absent or CH2, O, S, SO, SO2; Y = (CH2)n, n = 0-3], their tautomeric forms, their pharmaceutically acceptable salts and pharmaceutical compns. containing them. For example, reacting 6-methoxy-α-tetralone with quinolinecarboxylic acid II gave piperazinyl quinoline III in 75% yield. Compound III and analog IV were tested for antibacterial activity; their pharmacokinetic profile was also explored.

IT 1029844-02-7P, 1-Cyclopropyl-6-fluoro-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (oxoquinolinyl)piperazine derivs. and their antibacterial activity)

RN 1029844-02-7 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)

L13 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1029844-06-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-methyl-4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]-4-oxo- (CA INDEX NAME)



RN 1029844-07-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 1029844-18-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-[[1,2,3,4-tetrahydro-1-(hydroxyimino)-6-methoxy-2-naphthalenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)

L13 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 1029844-04-9P, 1-Cyclopropyl-6-fluoro-8-methoxy-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 1029844-05-0P, 1-Cyclopropyl-5,6,8-trifluoro-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 1029844-06-1P, 1-Cyclopropyl-6-fluoro-8-methoxy-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]-3-methylpiperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 1029844-07-2P, 1-Ethyl-6-fluoro-7-[4-[(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 1029844-18-5P, 1-Cyclopropyl-6-fluoro-7-[4-[(1-hydroxyimino-6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (oxoquinolinyl)piperazine derivs. and their antibacterial activity)

RN 1029844-04-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 1029844-05-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-4-oxo-7-[4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)

L13 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L13 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
2007:655407 Document No. 147:2498640 Multistructure 3D-QSAR Studies on a Series of Conformationally Constrained Butyrophenones Docked into a New Homology Model of the 5-HT2A Receptor. Dezi, Cristina; Brea, Jose; Alvarado, Mario; Ravina, Enrique; Masaguer, Christian F.; Loza, Maria Isabel; Sanz, Ferran; Pastor, Manuel (Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Barcelona, E-08003, Spain). Journal of Medicinal Chemistry, 50(14), 3242-3255 (English) 2007.
CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 147:249864.
Publisher: American Chemical Society.

AB The present study is part of a long-term research project aiming to gain insight into the mechanism of action of atypical antipsychotics. Here we describe a 3D-QSAR study carried out on a series of butyrophenones with affinity for the serotonin-2A receptor, aligned by docking into the binding site of a receptor model. The series studied has two peculiarities: (i) all the compds. have a chiral center and can be represented by two enantiomeric structures, and (ii) many of the structures can bind the receptor in two alternative orientations, posing the problem of how to select a single representative structure for every compound We have used an original solution consisting of the simultaneous use of multiple structures, representing different configurations, binding conformations, and positions. The final model showed good statistical quality (n = 426, r2 = 0.84, q2LOO = 0.81) and its interpretation provided useful information, not obtainable from the simple inspection of the ligand-receptor complexes.

IT 325489-07-4 325489-08-5 325489-09-6
RL: PAC (Pharmacological activity); BIOL (Biological study)
(multistructure QSAR studies on conformationally constrained butyrophenones docked into homol. model of 5-HT2A receptor)

RN 325489-07-4 CAPLUS
CN 5(6H)-Quinolinone, 7,8-dihydro-7-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 325489-08-5 CAPLUS
CN 5(6H)-Quinolinone, 7-[[4-(4-fluorobenzoyl)-1-piperidinyl]methyl]-7,8-dihydro- (CA INDEX NAME)

L13 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 325489-09-6 CAPLUS
CN 5(6H)-Quinolinone, 7-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]methyl]-7,8-dihydro- (CA INDEX NAME)



L13 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
2007:201033 Document No. 146:2743470 Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus. Zhou, Yuanxi; Bourque, Elyse; Zhu, Yongbao; McEachern, Ernest J.; Harwig, Curtis; Skerlj, Renato T.; Bridger, Gary J.; Li, Tong-Shuang; Metz, Markus (Anormed Inc., Can.). PCT Int. Appl. WO 2007022371 A2 20070222, 363 pp.
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-US32170 20060816. PRIORITY: US 2005-708471P 20050816.

GI



I



II

AB The invention relates to chemokine receptor binding compds. of formula I, pharmaceutical comps. and their use. Compds. of formula I wherein V and W are independently N and CR; X is O, S, NH and derivs., NOH and derivs., N-acyl, etc.; Y is O, S, N and CR; Z is absent, (un)substituted alkyl, OH and derivs., CO2H and derivs., CONH2 and derivs., carbocycle, heterocycle, and (hetero)aryl; Ar is (un)substituted carbocycle, (un)substituted heterocycle, and (un)substituted (hetero)aryl; L is absent id Z is absent; L is linker between Ar and Z, wherein L is a bond, O, S, NH and derivs., SO, SO2, SO2NH and derivs., co, etc.; R2 is (un)substituted alkyl,

L13 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

(un)substituted alkenyl, (un)substituted alkynyl, carbocycle, heterocycle, and (hetero)aryl; R3 is absent when Y is O and S; when Y is N or CR, R3 is H, NH2 and derivs., CONHOH and derivs., CONH2 and derivs., acyl, CO2H and derivs., OH and derivs., etc.; each R and R4 are independently H and C1-6 alkyl; n is 1 - 3; and their pharmaceutically acceptable salts thereof, are claimed. More specifically, the invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compds. demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Example compd. II was prepd. by cross-coupling of 5-bromopyrimidine with 4-formylbenzeneboronic acid; the resulting 4-(pyrimidin-5-yl)benzaldehyde underwent reductive amination with (R)-1-cyclohexyl-4-phenyl-3-(piperidin-4-yl)imidazolidin-2-one to give compd. II. All the invention compds. were evaluated for their chemokine receptor binding affinity (data given).

IT 926636-86-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)

RN 926636-86-4 CAPLUS
CN Benzoic acid, 3-[[(4R)-2-oxo-4-phenyl-3-[1-[(5,6,7,8-tetrahydro-6-quinolinyl)methyl]-4-piperidinyl]-1-imidazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



10590585.trn

L13 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
2006:941104 Document No. 145:335937 Preparation of A-form crystals of tetrahydroquinoline derivative and their medical compositions and pharmaceuticals. Sugimoto, Yuichi; Miyazoe, Hiroshi; Tsujita, Tomohiro (Banyu Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2006241096 A 20060914, 16pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2005-60632 20050304.
GI



I

AB A-form crystals of I.HCl are useful for prophylactic or therapeutic treatment of nociceptin receptor-associated diseases, e.g., pain, obesity, impaired learning, dementia, schizophrenia, depression, etc. Thus, trimethylsilylated I was deprotected, converted into HCl salt in MeOH, the solvent evaporated, dissolved in EtOH and treated with n-heptane to give A-form crystals of I.HCl, which inhibited the binding of [125I]-Tyr14-nociceptin to its receptor with IC50 value of 9.00 nM. The X ray powder diffraction pattern of the crystals is also described.
IT 864828-68-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of A-form crystals of tetrahydroquinoline derivative as nociceptin receptor antagonist)
RN 864828-68-2 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, hydrochloride (1:1), (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L13 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

IT 864830-99-9P 909781-64-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of A-form crystals of tetrahydroquinoline derivative as nociceptin receptor antagonist)
RN 864830-99-9 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 909781-64-2 CAPLUS
CN 3-Piperidinol, 4-(2-chloro-4-fluorophenyl)-1-[[(6R,8S)-5,6,7,8-tetrahydro-8-[(triethylsilyl)oxy]-6-quinolinyl]methyl]-, (3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
2005:1004733 Document No. 143:3061610 Preparation of cycloalkanopyridine derivatives as antagonists of nociceptin receptor. Takahashi, Hirobumi; Sugimoto, Yuichi; Yoshizumi, Takashi; Kato, Tetsuya; Asai, Masanori; Miyazoe, Hiroshi (Banyu Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 2005085228 A1 20050915, 205 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2005-JP4264 20050304. PRIORITY: JP 2004-62405 20040305.
GI



I



II

AB Cycloalkanopyridine derivs. represented by the general formula (I) [A1-A8 = (un)substituted CH or N, provided that at least one of A1-A4 is N; R1, R1' = H, halo, OH, cyano, C1-6 alkyloxy, C1-6 alkyloxyalkyloxy, C1-6 alkyloxycarbonyl, C1-6 alkyloxycarbonylamino, C1-6 alkylcarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, etc.; or R1 and R1' together form oxo or C1-3 alkylene ketal; R2, R2'= H, C1-6 alkyl, C1-6 hydroxyalkyl or R2 and R2' or R3' together form C1-3 alkylene or oxy-C1-3 alkylene; R2' and R2 or R3 together form C1-3 alkylene or oxy-C1-3 alkylene; R3, R3'= H, HO, halo, C1-6 alkyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylsulfonyl, C1-6 alkylsulfonylamino, C1-6 alkylsulfonylalkylamino, cyano, (un)substituted C1-6 alkyl; or R3 and R3' or R2' form C1-3 alkylene or oxy-C1-3 alkylene; or R3' and R3 or R2 together form C1-3 alkylene or oxy-C1-3 alkylene; R4 = H, halo, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 alkyloxy-C1-6 alkyl, C1-6 alkylcarbonyl, cyano, CHO, C1-6 alkyloxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkyloxycarbonyl, etc.; X = CH2, CH(OH),

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
(un)substituted NH, O, S, SO2; Y = CH2, (un)substituted NH; Z = (un)substituted CH, N; N = 0,1] or pharmaceutically acceptable salts thereof are prepd. These compds. are nociceptin receptor antagonists and useful for treatment or prevention of diseases in which a nociceptin receptor participates, e.g. (1) as drugs for overcoming resistance to narcotic analgesics, (2) as analgesic enhancers, antiobesity agents, and appetite regulators, (3) as drugs for improving or preventing learning or memory decline or dementia in aging, cerebral vascular disorders, or Alzheimer's disease, (4) as cognition enhancers in attention deficit hyperactivity disorder or learning disorder during developmental stage, (5) as drugs for treatment of schizophrenia, (6) as drugs for treatment of
regressive neurodegenerative diseases such as Parkinson's disease and chorea, (6) as antidepressants or mood regulators, (7) as preventives or remedies for diabetes insipidus or polyuria, and (8) as remedies for hypotension. Thus, a soln. of 70 mg toluene-4-sulfonic acid [(7R,9S)-9-(tert-butyldimethylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-7-yl]methyl ester and 33 mg spiro[8-azabicyclo[3.2.1]octane-3,1'-3'H-isobenzofuran] hydrochloride in 1.0 mL N-methylpyrrolidone were treated with 124 mg NaI and 0.21 mL Et3N and heated at 90° for 5 h with stirring, followed by treatment of the product with 1 M Bu4NF/THF at 50° for 4 h and sepn. of the resulting racemate using chiral column (CHRALPAC AD column), to give (7R,9S)- and (7S,9R)-7-[spiro[8-azabicyclo[3.2.1]octane-3,1'-3'H-isobenzofuran]-8-ylmethyl]-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol (II) and its (7R,9S)-stereoisomer. II inhibited the binding of [125I]Tyr14-nociceptin to human nociceptin receptor by 50% at 0.39 nM.
IT 864828-44-4P 864828-45-5P 864828-56-8P
864828-57-9P 864828-63-7P 864828-68-2P
864828-72-8P 864829-28-7P 864829-30-1P
864829-31-2P 864830-99-9P 864861-83-6P
864861-84-7P 864861-85-8P 864861-86-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cycloalkanopyridine derivs. as antagonists of nociceptin
receptor for treating or preventing nociceptin receptor-associated diseases)
RN 864828-44-4 CAPLUS
CN 8-Quinolinol, 5,6,7,8-tetrahydro-6-(spiro[isobenzofuran-1(3H),4'-piperidin]-1'-ylmethyl)-, (6S,8S)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 864828-45-5 CAPLUS
CN 8-Quinolinol, 5,6,7,8-tetrahydro-6-(spiro[isobenzofuran-1(3H),4'-piperidin]-1'-ylmethyl)-, (6S,8S)-,(2R,3R)-2,3-dihydroxybutanedioate (1:1)
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864828-44-4
CMF C22 H26 N2 O2

Absolute stereochemistry.



CM 2

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864828-56-8 CAPLUS
CN 8-Quinolinol, 6-[(3,3-dimethylspiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl)methyl]-5,6,7,8-tetrahydro-, (6S,8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864828-57-9 CAPLUS
CN 8-Quinolinol, 6-[(3,3-dimethylspiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl)methyl]-5,6,7,8-tetrahydro-, (6S,8S)-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864828-56-8
CMF C24 H30 N2 O2

Absolute stereochemistry.

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864828-63-7 CAPLUS
CN 8-Quinolinol, 6-[[4-(2-chlorophenyl)-4-fluoro-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864828-62-6
CMF C21 H24 Cl F N2 O

Absolute stereochemistry.



L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864828-68-2 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, hydrochloride (1:1), (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 864828-72-8 CAPLUS
CN 8-Quinolinol, 6-[[4-(2-chloro-4-fluorophenyl)-3-methoxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864828-71-7
CMF C22 H26 Cl F N2 O2

Absolute stereochemistry.

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864829-31-2 CAPLUS
CN 8-Quinolinol, 5,6,7,8-tetrahydro-2-methyl-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 864830-99-9 CAPLUS
CN 8-Quinolinol, 6-[[(3R,4R)-4-(2-chloro-4-fluorophenyl)-3-hydroxy-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864829-28-7 CAPLUS
CN 8-Quinolinol, 2-chloro-5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 864829-30-1 CAPLUS
CN 8-Quinolinol, 3-chloro-5,6,7,8-tetrahydro-6-[[4-(2-methylphenyl)-1-piperidinyl]methyl]-, (6R,8S)-rel-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864829-29-8
CMF C22 H27 Cl N2 O

Relative stereochemistry.

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 864861-83-6 CAPLUS
CN 8-Quinolinol, 6-[[1',1'-dimethylspiro[(3-endo)-8-azabicyclo[3.2.1]octane-3,3'(1'H)-furo[3,4-c]pyridin]-8-yl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864861-84-7 CAPLUS
CN 8-Quinolinol, 6-[[6'-fluoro-1',1'-dimethylspiro[(3-endo)-8-azabicyclo[3.2.1]octane-3,3'(1'H)-furo[3,4-c]pyridin]-8-yl]methyl]-5,6,7,8-tetrahydro-, (6R,8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864861-85-8 CAPLUS
CN 8-Quinolinol, 6-[[(1R,5S)-6'-fluoro-1',1'-dimethylspiro[8-azabicyclo[3.2.1]octane-3,3'(1'H)-furo[3,4-c]pyridin]-8-yl]methyl]-5,6,7,8-

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
tetrahydro-, (6R,8S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864861-84-7
CMF C25 H30 F N3 O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864861-86-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-2-ol, 3-(2-chloro-4-fluorophenyl)-8-[[(6R,8S)-5,6,7,8-tetrahydro-8-hydroxy-6-quinolinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)





● HCl

L13 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
2000:855012 Document No. 134:1629040 A simple, efficient method for regioselective synthesis of 7-aminomethyl-7,8-dihydro-6H-quinolin-5-ones, new potential CNS agents. Pita, B.; Masaguer, C. F.; Ravina, E. (Facultad de Farmacia, Laboratorio de Quimica Farmaceutica, Departamento de Quimica Organica, Universidad de Santiago de Compostela, Santiago de Compostela, 15706, Spain). Tetrahedron Letters, 41(50), 9829-9833 (English) 2000. CODEN: TELEAY. ISSN: 0040-4039. OTHER SOURCES: CASREACT 134:162904. Publisher: Elsevier Science Ltd..

AB An efficient and convenient strategy for the regioselective synthesis of new conformationally restricted butyrophenones of the quinoline series is presented. 7-(Aminomethyl)-7,8-dihydro-6H-quinolin-5-ones were obtained from 7-(methoxymethyl)-7,8-dihydro-6H-quinolin-5-one via the tosylate, and also in a 1-pot reaction via 7-(bromomethyl)-7,8-dihydro-6H-quinolin-5-one, with moderate-to-good overall yields in both cases.

IT 325489-07-4P 325489-08-5P 325489-09-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (aminomethyl)dihydroquinolinones)

RN 325489-07-4 CAPLUS
CN 5(6H)-Quinolinone, 7,8-dihydro-7-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 325489-08-5 CAPLUS
CN 5(6H)-Quinolinone, 7-[[4-(4-fluorobenzoyl)-1-piperidinyl]methyl]-7,8-dihydro- (CA INDEX NAME)



RN 325489-09-6 CAPLUS
CN 5(6H)-Quinolinone, 7-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]methyl]-7,8-dihydro- (CA INDEX NAME)



L13 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

10590585.trn

=>